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CHAPTER 1 
BIOPHYSICAL METHODS FOR STUDYING PROTEIN-MEDIATED 
INTERACTIONS 
Understanding biological processes in living organisms ultimately means 
understanding the atomic-level molecular recognition events between the primary 
biomolecules—proteins, nucleic acids, carbohydrates and lipids—that take place 
at the cellular level. To these participants can also be added the endogenous 
array of organic metabolites, inorganic salts and metals, and—last but certainly 
not least—water, which not only serves as universal host for all the binding 
interactions among all the aforementioned, but can be an explicit participant as 
well. The presence of these naturally occurring molecular components, in both 
static and dynamic roles, results in all the structures and process we associate 
with cellular function. 
Although all the biomolecular classes are involved in generating and 
maintaining higher-level molecular organization on the cellular level, the 
formation of macromolecular complexes is predominately the responsibility of 
proteins. To elucidate the function of this diverse group of biomolecules, it is of 
central importance to reveal their structure. Empirically solving the three-
dimensional structure of a protein represents a key step in the determination of 
its structure-activity relationship (SAR). X-ray crystallography and nuclear 
magnetic resonance (NMR) spectroscopy are the methods of choice to 
accomplish this. To these can be added other methods that aid in characterizing 
protein structures, circular dichroism (CD) and mass spectrometry (MS). In 
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combination, all these techniques contribute to assembling a more complete 
picture of a protein structure, as well as the protein-drug, protein-inhibitor, and 
protein-protein complexes that it can engage in. Computer-aided visualization 
and manipulation (e.g., molecular modeling and dynamics), while not strictly 
empirical techniques, are often invaluable additions to the study of protein 
structure and behavior. 
Despite the enormous amount of knowledge gained from the use of these 
experimental approaches regarding the structure of a protein (either alone or in a 
complex), they do not ensure accurate prediction of its function and, by 
extension, its biological activity. The first step to functional analysis is in fact the 
understanding of a protein's binding behavior, since the binding of a protein to 
one or more ligands (broadly defined from small metals and organic molecules all 
the way to other large proteins) is what will immediately or eventually result in a 
'biological activity'. The first rigorous step towards this understanding is to then 
examine the biomolecular associations themselves, and this at the level of 
thermodynamic binding parameters. Thermodynamics provides information on 
the forces that drive biomolecular interactions, providing a detailed energetic 
foundation to the analysis of the basic behavior of a protein. 
In brief, then, a complete understanding of a protein's cellular role means 
that both structural and thermodynamic properties need to be characterized. In 
this dissertation, I present research based on both approaches, directed towards 
two different proteins: the peptide-binding PDZ domains of PSD-95, and iron-
binding frataxin. Specifically, the two primary methods utilized in the in vitro 
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characterization of the protein complexes presented here are isothermal titration 
calorimetry (ITC) and X-ray crystallography. What follows is a brief overview of 
the techniques themselves and their theoretical foundations, beginning first with 
thermodynamic binding parameters and their measurements by ITC, followed by 
structural analysis as determined by X-ray crystallography. 
1.1 Isothermal Titration Calorimetry (ITC) as a Method for Measuring 
Thermodynamic Parameters.  
1.1.1 Basic thermodynamic parameters. There are four basic thermodynamic 
parameters that govern all biomolecular interactions; these are (1) change in 
Gibbs free energy (ΔG); (2) change in enthalpy (ΔH); change in entropy (ΔS); 
and (4) change in heat capacity (ΔCp). 
1.1.1.1 Gibbs free energy change (ΔG). By definition, the Gibbs free energy of 
a system is the enthalpy of the system (all molecular participants, including 
solvents) minus the product of the temperature times the entropy of the system 
(1). Therefore, the change in free energy that occurs during a chemical process 
(such as a binding interaction or an actual transformation or reaction) is equal to 
the difference in enthalpy change and the change in entropy at the given 
temperature (2). 
€ 
G = H −TS   (1)  
€ 
ΔG = ΔH −TΔS  (2) 
The change in free energy in a chemical process is also related to the 
association or dissociation equilibrium constants through equation (3). 
€ 
ΔG = −RT lnKa = RT lnKd  (3) 
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Thus, by combining equations 2 and 3, it is clear that there is a direct correlation 
between the key thermodynamic parameters of enthalpy and entropy, and the 
affinity of a binding interaction as represented by the equilibrium constant.  
1.1.1.2 Enthalpy change (ΔH). Enthalpy change of a chemical process can be 
assessed in a single ITC experiment. By definition, change in enthalpy between 
products and reactants for a chemical transformation represents heat released or 
absorbed during the reaction. Exothermic reactions, in which the heat of the 
system is emitted, have negative ΔH whereas the reactions in which heat is 
absorbed (i.e. endothermic) have a positive ΔH. Regarding the relations in 
equation (2), a negative value of ΔH is favorable for the interaction and a positive 
ΔH is unfavorable. In terms of molecular interactions, changes in enthalpy are 
most closely linked with actual atomic-level interactions, such as those based on 
hydrogen bonds, electrostatic (charged, ionic, or dipole) forces, or Van der Waals 
forces. To a first approximation, the changes in enthalpy are often attributed to 
the making and breaking of specific interactions, between the binding molecules 
themselves as well as with (and between) solvent (i.e., buffered water, in both 
cellular and ITC environments). 
1.1.1.3 Entropy change (ΔS). The change in entropy between the products and 
the reactants for a chemical process is defined as a change of degree of freedom 
at a molecular level. Theoretically, this can be expressed as the difference in the 
number of accessible energetic states, before and after a binding interaction. 
Specifically, this is associated with several processes, such as the net increase 
or decrease in conformational mobility, as dictated by the changes in rotatable 
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bonds. Also, the restriction or immobilization (or release) or water molecules is 
also a major biomolecular process that is linked to changes in entropy. 
Spontaneous changes occur with an increase in entropy and negative values of 
ΔS indicate decrease in the number of accessible states during the 
transformation.  In regards to the free energy change given in equation (2), a 
positive ΔS is favorable for the association and negative ΔS has an opposite 
effect. 
1.1.1.4 Heat capacity change (ΔCp). The net change in heat capacity between 
chemical transformation reaction products and reactants, at constant pressure, 
can be calculated using equations (4) and (5).  
€ 
ΔCp =
d(ΔH)
dT             (4)  
€ 
ΔCp = T
d(ΔS)
dT  (5) 
In many regards ΔCp is considered a subtler and more complex parameter than 
enthalpy and entropy, since it is not as easy to assign to it specific molecular 
processes. But it is considered by some even more fundamental than the other 
parameters, since it places limits on what the values of enthalpy and entropy can 
be at a given temperature, as equations 3 and 4 demonstrate. Nonetheless, 
there are processes, such as the extent of burial of polar or nonpolar surface 
area when a ligand binds a protein, that have been correlated to the sign and 
magnitude of ΔCp. 
1.1.2 ITC as a biophysical technique. 
1.1.2.1 General aspects of ITC. Calorimetry, derived from the Latin word calor 
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(heat) and the Greek word metria (a measure), is, as the combination implies, a 
method that quantitatively determines the heat absorbed or released during 
physicochemical transformations. Calorimetric methods have proven very useful 
in characterizing biomolecular interactions. However, only recently with technical 
improvements in instrumentation that have given rise to several highly sensitive 
titration calorimeters that are increasingly accessible to researchers, has the 
method became highly valued and widely used. The increased popularity of ITC 
as a tool for studying biomolecular interactions in vitro has been addressed in 
many review articles lately [1-9]. In order to summarize the wide landscape of 
applications of the method, Ladbury and coworkers have published yearly 
surveys on calorimetry from 2002-2005 [10-13]. 
1.1.2.2 Advantages of ITC. Compared to other methods applied in 
thermodynamic studies of biomolecular systems, the ITC technique offers some 
important and unique advantages. The particular aspects involving the interaction 
of proteins with peptides and metal ions is addressed in Chapter 2 of this 
dissertation, and the following is a broader survey of ITC as pertaining to five 
basic attributes of ITC.  
1. ITC is the only technique that directly provides the thermodynamic binding 
constants. van't Hoff analysis of temperature-dependent affinity values from 
other assay methods has been used to provide ΔH and ΔS parameters (see 
1.1.2.4), but there is concern that this does not yield optimal or valid results. 
In addition, ITC provides those values in the course of a single experiment. 
2. ITC relies on the 'universal' signal of heat transfer, which is not restricted to 
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molecular class or type, and consequently can be used to study almost any 
type of biomolecular binding process. A detailed list of all the possible 
applications is given on the official MicroCal website [14]. Further, reliance 
on a heat signal avoids the need to prepare chemically-modified versions of 
one or more participants in the process (e.g., as with fluorescently-labeled 
ligands). All the reagents are used in their ‘native’ form. 
3. Experimental conditions can be easily varied without adversely affecting the 
binding analysis. Typical perturbations of interest for a particular biological 
interaction include, but are not limited to, component concentration; 
temperature, ionic strength, pH and buffer composition. As part of a 
systematic and thorough study of a particular protein-ligand system, 
conditions like the nature and concentration of salts used can be altered as 
well as mutational changes in the protein itself (site-specific or group 
mutagenesis). [2, 15] 
4. ITC is a true solution method, and unaffected by artifacts that can arise in 
other assays that involve chemical modification (e.g., affects of fluorescent 
spectral labels) or when heterogeneous surface immobilization (e.g., as with 
surface plasmon resonance (SPR), such as Biacore) of interacting species 
is required. This is an important property, since attachment of different 
reporting groups can alter the binding properties of the system. In addition, 
unlike the ELISA (enzyme-linked immunosorbent assay) and related 
methods, the equilibrium state of the interaction is not perturbed since it is 
not necessary to separate bound from free species.  
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5. Assuming the appropriate fitting model is used, ITC can also generate the 
binding stoichiometry (n, the number of equivalents of ligand per protein) in 
a single experiment. This is also a particularly important factor in this 
dissertation research, as the issue of multivalency is central to the reported 
PDZ domain and frataxin studies. The reproducibility of ITC measurements 
regarding molar binding ratios (i.e., n) is claimed to be within 1% [16].  
1.1.2.3 Limitations of ITC. No experimental method is perfect, and like any 
other analytical technique, ITC has its own set of disadvantages. But as noted 
below in the four challenges that can be encountered, most of them can be 
overcome in one way or another. 
1. A large sample requirement still remains the principal limitation of the ITC 
technique. The actual differences are highly case- and volume-dependent, 
but ITC may require, for example, hundreds of micrograms of a protein, 
whereas a fluorescence method or SPR might consume material in the 
nanogram range [2]. Thus, as currently practiced ITC requires upwards of 
102-103 more material than the most sensitive methods currently available. 
It is possible, however, to recover the protein sample used, since ITC is a 
non-destructive method. Also, the next generation of microcalorimeter from 
MicroCal is reported to use considerable less material (only 200 µL of 
protein sample) than the current series.  
2. A primary requirement for all ITC experiments is that there should be a 
measurable heat signal. Although noncovalent macromolecular interactions 
are associated with intrinsically small heat changes (typically 5 to 10 
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kcal/mol), experimental conditions can be manipulated in order to obtain 
valid data. However, it is occasionally possible to encounter an entropically-
driven high affinity interaction with an insignificant ΔH contribution [17]. For 
example, a case where ΔG = -8 kcal/mol can be due to TΔS ≈ +8 kcal/mol, 
and ΔH ≈ 0 kcal/mol (see equation 2). In such a case, it is possible to 
perform the same experiment using a different buffer system with a higher 
heat of ionization, or at a higher temperature (if stability of macromolecule is 
not jeopardized). Such changes can often move the enthalpy change further 
from zero. 
3. ITC experiences a relatively narrow range for the direct determination of 
binding affinity (Kd), from 10 mM to 0.1 µM. However, a common 
workaround solution is to conduct a competitive titration experiment with a 
known binding agent of differing affinity. [1, 18, 19] 
4. The buffer system might also be a restriction for some proteins that have a 
requirement for a specific buffer. Protonation and deprotonation reactions 
result in change of the overall enthalpy, and therefore corrections need to 
be made [2, 20]. This requires that ITC titrations be performed in buffers 
with different ionization enthalpies (at least three for reliable data analysis), 
and if there is any change in the enthalpy values due to proton exchange, 
these should be adjusted. Otherwise, the observed ΔH values may not be 
interpretable in terms of only the protein-ligand interactions involved. 
1.1.2.4 Indirect estimation of ΔH without ITC: the van’t Hoff analysis. In the 
van’t Hoff method, temperature dependence of the equilibrium constant is used 
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for calculations of ΔH and ΔS; lnKa is plotted against 1/T, multiplied by (-R) and 
used to determine ΔH. This method is potentially valuable since it does not 
require a calorimeter, and can rely upon much less material, and that of lower 
purity. This latter aspect alone makes the method attractive for analysis of 
membrane proteins, such as receptors, which are difficult to access in large 
quantities in pure form [21]. However, there are significant differences amongst 
authors as to the accuracy of this approach. There are three major points that 
van’t Hoff omits: (1) the assumption is made that ΔH is constant over the entire 
experimental temperature range; (2) enthalpy-entropy compensation is not taken 
into account; and (3) the thermodynamic parameters cannot be determined 
independently. The matter is not fully resolved. Based on the specific 
experimental setup, some researchers obtained good agreement in enthalpy 
values determined by by both ITC and van’t Hoff analysis [22, 23], while others 
that demonstrated significant differences [16, 24]. 
1.1.3 ITC instrumentation. Not long ago, investigators conducting 
biocalorimetric analyses did so on custom-made instrumentation specifically built 
for the purpose in their respective laboratories. Few calorimeters were 
commercially available with the required sensitivity. The breakthrough period in 
the field came with the commercial availability of newly developed 
microcalorimeters (both ITC and DSC (differential scanning calorimetry)) in the 
beginning of the 1980s. Today, two companies, MicroCal (acquired in 2008 by 
GE Healthcare) [14] and Calorimetry Sciences Corporation (acquired in 2007 by 
TA Instruments) [25] dominate the field of ultra-sensitive microcalorimeters 
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suitable for biomolecular analysis. 
The most common type of differential power compensation isothermal 
titration calorimeters consists of twin coin-shaped cells composed of a highly 
efficient conducting material (Hastelloy® Alloy C 276 in the case of the VP-ITC, 
which is the calorimeter used for all measurements reported in this dissertation) 
surrounded by an adiabatic jacket. [6, 8] A schematic diagram of the VP-ITC is 
shown in Figure 1.1. Sample cell volumes vary with instrument type; in the case 
of the VP-ITC the cell volume is exactly 1.4154 mL [26]. Operationally, this 
requires a (bio)macromolecule sample of approximately 1.8 mL ,even though the 
working volume of the cell is only 1.4 mL [26]. In addition to the sample cell filled 
with the macromolecule solution, a reference cell is also present that contains 
either water or buffer, and plays no direct role in the titration. The titrating agent 
or ligand is loaded into an injection syringe with a volume of 290 µL. 
A thermoelectric device measures the temperature difference between the 
sample and reference cells, and a second device measures the temperature 
difference between the cells and the adiabatic jacket. During the experiment, 
very low constant power is applied to the reference cell and a variable power to 
the sample cell in order to preserve the temperature difference. The power added 
to the sample cell to maintain this fixed difference is the experimentally measured 
quantity related to the heat of reaction [27]. A constant power (< 1mW) is applied 
before the injections start and represents the baseline signal [6]. The noise level 
of the VP-ITC instrument is 1 ncal/sec (4 nW) and the baseline constancy is ± 5 
ncal/sec (± 20 nW) [26]. 
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In an ITC experiment, the signal actually presents time dependence of the 
electric power (µcal/sec) necessary to maintain constant the temperature 
difference between the reaction in the sample cell and the reference cell, after 
each injection of reactant [8]. The area under each peak is the area associated 
with the process. Depending on the reaction type, exothermic or endothermic, 
heat is released or absorbed. For an exothermic reaction, with the temperature 
increase, feedback power will be deactivated in order to preserve equal 
temperatures between the cells, resulting in a negative signal. The situation is 
reversed for the endothermic reaction, where the recorded signal is positive [6].  
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Figure 1.1 A schematic diagram of the ITC instrument. Reproduced from the VP-
ITC MicroCalorimeter user’s manual [26]. 
1.1.4 Designing the ITC experiment. There are many different aspects that 
need to be taken into account before performing an ITC experiment. A critical 
factor is correct sample preparation, both in terms of purity and concentration 
determination of both the macromolecule and the ligand. The solutions of the two 
interacting species must be prepared carefully using the same exact buffer in 
order to avoid a false heat signal that such solution mismatch can generate. In 
the experiments described in this dissertation two different techniques were 
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employed in order to achieve this. For the PDZ domain protein-peptide 
interactions, both solutions were prepared in the same buffer, and the ligand 
solution was usually titrated to adjust the pH value to within acceptable limits. A 
difference of ±0.02 pH units was considered acceptable [1, 2]. For frataxin 
protein-iron interactions, that procedure was impossible since all sample 
preparation had to be conducted anaerobically. It was determined in a separate 
study that dissolving iron salt in the buffer that the protein was dialyzed in did not 
change the pH significantly. 
Accurate concentration estimation of both macromolecule and the ligand 
is important since it directly affects the calculation of all thermodynamic 
parameters. Protein concentration can be determined using different assays: UV 
reading at 280 nm wavelength; Coomassie Plus Assay (modified Bradford 
assay); and the Advanced Protein Assay, among others. Ligand concentration 
need also be precisely determined. For both PDZ domain -peptide and frataxin-
iron studies, ligand was in the solid form: lyophilized peptide powder or inorganic 
iron salt, respectively. In both cases, careful weighing of the compound yielded 
sufficient accuracy for the concentration determination. Ligand concentration 
affects all the thermodynamic parameters (stoichiometry, Ka, ΔH) obtained from 
ITC experiments, while the concentration of the macromolecule affects the 
stoichiometry (n) of the reaction [26]. 
For the PDZ domain-peptide interactions, thorough degassing along with 
thermo stating was needed. The thermovac is an ITC accessory device used for 
this purpose, prior to loading protein and peptide samples into the sample cell 
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and injector [26]. Degassing of the solutions is also important, since the presence 
of released air bubbles can interfere with the signal that is recorded during the 
ITC run. In order to accelerate the degassing process stirring the macromolecular 
sample can also be employed. However, stirring can lead to protein denaturation 
and precipitation, and therefore it was avoided in all the experiments described in 
this dissertation. During thermo stating the temperature species is usually kept at 
few degrees lower than the actual working temperature. This is preferred since 
the time required for the instrument to heat up is much less than the time 
required to cool down. For frataxin-iron interactions all these preparations were 
avoided, due to the anaerobic preparation of samples. 
In a typical ITC experiment, the macromolecule solution is added to the 
sample cell using a long needle glass syringe with a blunt end [6]. Slowly 
releasing liquid is followed by two or three rapid spurts of at least 2.3 mL solution 
to ensure the removal of air bubbles from the bottom of the cell. Any excess 
solution remaining in the reservoir is removed.  
ITC experiments are fully automated, and can be designed in several 
different ways. One key parameter that can be changed easily is the 
temperature, which is kept fixed throughout the duration of a single experiment. 
The range of temperatures available with the VP-ITC varies from 2 °C to 80 °C 
[26]. This is fairly broad, and the very low and high ends assume that the protein 
remains stable (either avoiding precipitation or denaturation), which is of course 
case dependent. Other adjustable parameters include injection volume, injection 
number, spacing between the injections, stirring speed, baseline position, and 
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feedback mode. At the outset of a study with a new protein, several pilot 
experiments are performed in which these settings are systematically varied. 
Once optimal conditions are found, they are employed for all future experiments.  
Control ITC experiments are another necessary factor in characterizing 
the system under study. Usually referred to as blank experiments or blank 
titrations, they can be designed in different manners. Titrating ligand solution into 
the matching buffer in the sample cell is a control experiment with the most 
pronounced impact. Highly concentrated ligand solution (volume = 290 µL) is 
diluted several fold when added to the sample cell (volume = 1.41 mL) and can 
lead to the release or absorption of a considerable amount of heat. This effect 
must be separated from the heat of the macromolecular interaction by running 
this control experiment and correcting for the ligand dilution effect. 
Another variant of the dilution effect involves that of the protein. Buffer 
from the injector is added to the protein solution in the sample cell. The heat 
change is usually insignificant, since during the course of the experiment the 
sample solution is only diluted ca. 10-20%. This type of blank titration is usually 
only needed when starting a new protein study, or switching to a new buffer 
system. Finally, the last type of blank titration is buffer into buffer. Assuming care 
is taken to prepare the protein and ligand in matched buffers to begin with, this is 
not a required control, as the heat associated is usually negligible under normal 
circumstances. it may be important, though, if the experiment is performed at 
more than ±10°C of the environment temperature (since the ligand is in the 
external syringe at ambient temperature) [26].  
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Another control experiment that can be useful in investigating errors or 
artifacts in ITC experiments is reverse titration. Here the interacting species 
switch places: protein is used as a titrating agent, and ligand is placed in the 
sample cell. The concentration of both components needs to be adjusted 
accordingly (since the titration typically proceeds to saturation), while keeping all 
other parameters the same as in the standard “direct titration”. Theoretically, in 
case of 1:1binding, if the correct model is used for data fitting, the same values 
for the thermodynamic parameters should be obtained from both experiments.  
If desired, ITC experiments can also be designed to obtain the enthalpy 
change (ΔH) alone, or the complete set of binding parameters (n, Ka, ΔH, ΔS). In 
the first case, introducing ligand in a single injection into the protein sample is 
sufficient. Enthalpy change can be determined at concentrations when the 
binding partners are fully associated and the saturation is still low, i.e. full 
saturation at partial saturation [28]. In order to obtain all binding parameters, a 
complete isotherm needs to be recorded.  Usually, ligand is added in ca. 3-4 
molar excess to ensure complete saturation of the macromolecule at the end of 
titration. Another important point is the limiting sensitivity of 0.1 µcal/s of the VP-
ITC instrument [26]. Therefore, experiment should be designed in such a way 
that in each injection at least 1-2 µcal/s heat change is produced [9]. The most 
recent version of the software for VP-ITC has an option for Single Injection 
Method (SIM) [29] as a separate, innovative ITC technique. 
1.1.5 Data analysis. The method of data analysis depends on the system under 
study. Detailed explanations about the data treatment are given in Appendix A. 
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ORIGIN software supplied by MicroCal comes preloaded with different models of 
curve fitting; they include: “One Set of Binding Sites”, “Two Sets of Binding Sites” 
and “Sequential Binding Sites” models. The latest version of the ORIGIN 
software offers additional data fitting equations that include 
“Enzyme/Substrate/Inhibitor Assay”, “Dissociation Model” and “Competitive 
Binding Model”. 
Before peak integration, the heats of binding are normalized as a function 
of ligand concentration. Additionally, a volume correction is also performed due 
to the dilution of the macromolecule during each injection (also explained in 
Appendix A). The area of each peak is then automatically integrated using the 
routines of the ORIGIN software. Experimentally obtained data is normalized as 
kilocalories per mole of ligand injected, and plotted against the ratio of the ligand 
to macromolecule concentration. The derived sigmoidal titration curve is further 
fitted to yield the final binding isotherm. The final figure obtained characterizes 
the interaction of the macromolecule and the ligand, and includes the 
thermodynamic parameters of binding, i.e. n, K and ΔH. 
The quality of the experimental data fitting procedure is usually judged by 
the value of the χ2 (chi squared) parameter [30]. The standard manner of defining 
the best fit is to choose the parameters so that the sum of the squares of the 
deviations of the theoretical curve from the experimental points for a range of 
independent variables is at a minimum. The χ2 parameter is equal to the sum of 
the squares of the deviations of the theoretical curve from the experimental 
points, divided by the number of degrees of freedom.  
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If a set of experimental data is treated with different models, the most 
meaningful thermodynamic parameters are obtained from the model that results 
in the minimum χ2 value—provided, of course, that they do not violate what is 
biochemically known about, or reasonable for, the protein under study. 
1.1.6 of the ITC c value. The critical parameter that determines the shape of the 
binding isotherm is the unitless constant c. The value c is defined as product of 
the binding constant Ka and the total starting macromolecule concentration of the 
macromolecule in the sample cell, Mtot, times the stoichiometry n, as shown in 
the equation (6).  
c = KaMtotn  (6) 
Tight binding (i.e., small Kd) as a consequence has a  very large c value 
and lower values are signature for weak binding (high Kd). Figure 2.2 depicts 
shape variants of the binding isotherm as a function of the c value.  
 
Figure 1.2 Schematic diagram of simulated binding isotherm for different values 
of c. Picture reproduced from VP-ITC user’s manual [26]. 
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Close inspection of these isotherms reveals that their shape is reasonably 
sensitive to the binding constant only when the c value is between 1 and 1000 
[26]. Often times this range is referred to as the “experimental K window”. Curve 
fitting of the experimental data should allow reliable determination of all 
thermodynamic parameters (n, Ka, ΔH,). Therefore, the binding isotherm should 
have at least a few data points corresponding to the initial phase of the 
experiment, additional points for the transition from the unsaturated to the 
saturated state of the macromolecule, and finally, a few points towards the end of 
the experiment that demonstrates complete saturation. Each of these parts of the 
experiment is valuable, and the absence of any makes data interpretation 
difficult. 
 Values for binding affinity (i.e., Kd) that can be reliably measured by ITC 
are typically between 10-3 and 10-8 M. Very tight binding cannot be determined, 
since in order to satisfy the c value and generate a continuous, fittable curve with 
all the regions discussed above, the concentration of the macromolecule should 
be very small, which will result in a very low heat signal. Even with the most 
recent ITC instrumentation these measurements cannot be accurately made. 
Similarly, very weak binding cannot be studied. For the good data fitting and an 
acceptable c value, macromolecular concentration would need to be so high that 
sample aggregation and other effects would preclude the accurate determination 
of the thermodynamic parameters. However, there is a way to extend the range 
of such applications by designing appropriate competitive experiments [18, 19]. 
The most recent version (2004) of the ORIGIN software tutorial [31] includes 
21 
 
complete descriptions of this method, based on the contributions of Sigurskjold 
[19].  
In brief, a competitive displacement experiment can be executed by 
titrating a very tight binding ligand into a solution of macromolecule already 
saturated with a weak binder of known affinity [3]. Obtaining thermodynamic 
parameters is possible only if two ligands have significant differences in binding 
enthalpy [18, 32-35]. Detailed calculations and fitting routine are provided in 
Appendix B. Another approach to overcoming this problem in the case of a weak 
affinity system is to saturate the macromolecule in a single injection of ligand. 
The obtained enthalpy change is fixed during data fitting in ORIGIN.  
1.1.7 Calculating thermodynamic binding parameters in ITC experiments. 
ITC records the heat signal during a biochemical interaction. The heat released 
or absorbed during each injection is proportional to the change in concentration 
of the bound species. The overall heat content during the experiment is related to 
the total macromolecule concentration, and used to calculate the enthalpy 
change of binding. Utilizing the volume change in the course of the titration, the 
software calculates the heat released or absorbed in each injection. Calculated 
values from the model and experimental values for data fitting are then compared 
by standard Marquardt methods. Iterations are performed until no further 
improvement in the data fitting finally gives values for the stoichiometry (n), 
association constant (Ka), and enthalpy (ΔH). From this ΔG is calculated. The 
change in entropy (ΔS) is obtained using ΔG and ΔH from the standard 
thermodynamic equation (equation 2). It is in this manner that ITC provides all 
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the thermodynamic parameters from a single experiment [7]. Detailed 
calculations are given in the Appendix D. 
1.1.8 Thermodynamic data interpretation. Binding affinity is an exponential 
function of the energy of association, as shown in equation 7. 
€ 
Ka = e −
ΔG
RT    (7) 
Therefore, ΔG is considered the most important thermodynamic parameter of 
binding that determines the stability of a biomolecular complex. Free energy is 
often used to characterize structure-function relationships [9]. In various studies it 
was noted that, compared to thermodynamic parameters measured by ITC, ΔG 
has the lowest signal to noise ratio (values close to one another) [7]. Enthalpy-
entropy compensation (explained in section 1.1.8) is the reason why free energy 
change is relatively insensitive to the change in molecular details of interactions 
[36-38]. Since two different parameter contribute to the value of ΔG, many 
combinations of ΔH and ΔS can result in the same binding affinity [8].  
The enthalpy change measured by ITC is a property of the net change of 
the whole system. Therefore, the total heat released or absorbed in the cell upon 
adding the ligand represents the cumulative effect of many components. These 
include, for example, the enthalpy of association of molecules, the heat due to 
mixing and the heat of dilution (especially that of the ligand). Due to contributions 
from nonspecific effects, what is measured is actually the apparent enthalpy 
change [3]. For these reasons it is important to correct the calculated heat and 
accurately determine the intrinsic ΔH of the reaction.  
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The enthalpy change has the highest signal-to-noise ratio in an ITC 
experiment [7]. This parameter reflects the formation of discrete noncovalent 
interactions [9]. During the binding of the ligand to the macromolecule, old 
interactions are broken while new ones are formed. The interactions that are lost 
include hydrogen bonding and van der Waals interactions between the protein 
and the solvent (water in most cases) and ligand and the solvent. New bonds 
formed are protein-ligand interactions that also typically involve hydrogen 
bonding and van der Waals forces, but can also include hydrophobic interactions 
and salt bridges, and solvent reorganization near protein surfaces. All these 
interactions can be favorable or unfavorable, but since ITC measures the net 
change, the overall effect is usually smaller than the individual specific 
contributions [17]. Specific interactions, however, can be evaluated through 
alanine scanning [39] and mutational studies [40], by removing specific amino 
acid functionality from the binding site of the macromolecule. 
The entropy change is calculated indirectly from ΔG and ΔH based on 
equation (2). Entropy change is less precisely determined than these other two 
thermodynamic parameters because of error propagation [7]. Several factors 
contribute to ΔS, but the main one is generally considered the solvation 
(hydration) effect. Complex formation is often coupled with the release of ordered 
water from the binding regions of the protein surface and the ligand, which enters 
into the bulk water phase, which is less ordered (higher entropy). The net result 
for this specific process is a large and positive entropy change upon binding. The 
factors that affect unfavorably the entropy change of binding are any reductions 
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of rotational, translational and conformational entropy when free protein and 
ligand associate. Standard errors within experiments for the ΔH, ΔS and ΔG 
parameters are typically around 1 kcal/mol [7]. 
Stoichiometry is calculated from the molar ratio of the interacting species 
at the equivalence point of the titration curve. In order to obtain an accurate value 
for n, the concentration of the interacting species should be known very precisely 
[2]. The potential factors that can affect the n value are experimental errors in the 
concentration measurement. For example, if a solid ligand is weighed out in 
order to prepare the desired concentration solution, any error in weight 
measurement will be transferred to the error in concentration. If the concentration 
of the macromolecule (in the sample cell) is lower than what is determined as a 
result of misfolding, inactivation, or degradation, then the n value will be smaller 
than expected, and vice versa. Similarly, the presence of an impurity in the ligand 
will cause the n value to be larger than expected. For this same reason ITC can 
be applied as a quality control tool for analyzing the protein stability where the 
stoichiometry is already known [2]. 
1.1.9 Enthalpy-entropy compensation. As mentioned earlier (section 1.1.8) 
compensation between ΔH and ΔS is a common phenomenon observed in many 
biological systems [37, 38]. This is a result of a linear relationship between the 
two parameters (i.e. any increase in favorable enthalpy is often matched by an 
unfavorable entropy and vice versa), resulting in no noticeable improvement in 
affinity. In such a case, any increase in the bonding that produces a highly 
favorable enthalpy will be at the expense of freezing rotations and increasing 
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order, leading to more unfavorable entropy. Enthalpy-entropy compensation has 
been considered a general consequence of weak intermolecular interactions [41]. 
1.1.10 Heat capacity change. Since the working temperature range for the VP-
ITC is quite wide (2-80 ºC), it  is suitable for the experimental calculation of ΔCp 
during complex formation. Heat capacity change can be calculated from a plot of 
ΔH versus temperature (T) using equation (3). The correlation between ΔCp and 
the change in surface area buried upon binding of the macromolecular complex, 
has been very well studied, and forms a link between structural and 
thermodynamic information. 
1.2 X-ray Crystallography as a Method for Structural Determination. Proteins 
are defined as amino acid heteropolymers, whose exact sequence is defined by 
their corresponding gene sequence. The amino acid sequence determines its 
three-dimensional tertiary structure, which dictates its function [42]. Structural 
information reveals design principles of the molecular foundations of living 
systems. It not only answers basic mechanistic questions of protein function, but 
it can also provide insight into evolutionary relationships between cellular 
components [43]. 
There are several methods used to determine structural information: X-ray 
crystallography; electron microscopy (EM); small-angle X-ray scattering (SAXS); 
and nuclear magnetic resonance (NMR). Among them, X-ray crystallography has 
historically proven to be the preferred method, judging by the more than 40,000 
structures deposited in the official protein structure repository, the Protein Data 
Bank (PDB; http://www.rcsb.org). Although protein NMR methods have increased 
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in popularity, X-ray crystallography is still the major source of protein structures 
since it routinely yields the highest resolution data, and can solve structures that 
are considerably larger than those solvable by any other current technique. The 
number of structures in the PDB has increased exponentially over the last few 
years [44], a trend that will certainly continue with the development of "structural 
proteomics" as a field of research [45-47]. 
X–ray crystallography is a powerful technique in resolving the three-
dimensional structure of biological macromolecules [48-50]. Details of covalent 
and noncovalent interactions during protein-ligand complex formation are 
frequently revealed by this type of analysis [51]. Thus far, it is the only method 
that can routinely reach atomic resolution, and in addition to providing information 
to basic questions about protein behavior, it has proven invaluable in the applied 
biomedical sciences. Data obtained using this method has been instrumental in 
structure-based design efforts [52, 53] that ultimately led to the discovery and 
development of many drugs, including HIV protease inhibitors, neuramidase 
inhibitors, rennin inhibitors [53] and anticancer agents [54], to cite only a few 
examples. 
X-ray crystallography was first used as a method in structural biology in 
1934, when Bernal and Crowfoot (later Hodgkin) [55] produced the first diffraction 
pattern of a protein, pepsin. The real breakthrough in the field came with the work 
of Perutz [56] and Kendrew [57] on the structures of hemoglobin and myoglobin, 
respectively, in the 1950’s. Technological advances brought many improvements 
to instrumentation, sample preparation, data collection and processing. However, 
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the methods and mathematical approaches that were developed to solve those 
first protein structures represent the core of the methodology that is used even 
today.  
In the process of solving a protein structure by X-ray crystallography, a 
series of steps, each with its own difficulties, is required. In brief, these include 
(1) crystal formation; (2) data collection; (3) solving the structure. Each of these 
steps is summarized below. 
1.2.1 Crystal formation. The first requirement is a reliable method for producing 
a good supply of protein crystals. Protein crystals are, unlike mineral or small 
molecule crystals, mostly made of water (30%-80%), and as a result are 
extremely fragile due to the relatively weak interactions that hold the lattice 
together. For determining crystallization conditions and effecting subsequent 
growth of crystals of suitable quality for structure determination, at least 2 mg of 
pure protein is needed, in a highly concentrated form of 5–30 mg/mL [43]. 
Although this amounts is considered high for certain proteins, only a few 
microliters (1 – 3 µL) of this concentration sample is required for a 'screening set 
up'; thus, a 1 mL sample can be used to screen for hundreds of different 
crystallization conditions [58]. In the early days of protein crystallography, 
experiments were carried out on proteins obtained from natural sources (usually 
cow and pig organs or blood). Recent advances in recombinant DNA technology 
[59] and newly developed bacterial expression systems, principally those based 
on E. coli [60, 61], routinely allow overproduction of properly folded target protein 
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[62]. A wide array of bacterial expression plasmids is nowadays available from 
commercial vendors (e.g., Novagen and Invitrogen).  
However, not only protein quantity, but also quality is important for 
crystallization [63]. Protein samples need to be chemically pure; that is, having 
only one type of macromolecule or complex in the tube. It should be folded into 
its native conformation and not contain covalently heterogeneous features (such 
as partial glycosylation or phosphorylation, or mixtures of truncation products). 
Methods like gel electrophoresis, protein chromatography, and mass 
spectrometry should be employed in order to provide and confirm a chemically 
pure sample [63, 64]. The sample must also be conformationally pure, which is 
usually assessed with size exclusion chromatography or with light scattering 
measurements [65-67].  
Protein crystallization is a phase transition that consists of nucleation and 
crystal growth [63, 68]. The basic idea is to transfer the concentrated protein of 
interest into a solution of precipitants that will trigger crystal formation. 
Precipitants act by promoting the formation of intermolecular interactions by 
affecting macromolecular hydration, molecular crowding, solubility, hydrophobic 
interactions, and electrostatics. Unfortunately, the same components that push 
proteins towards crystallization can also promote the common (and undesired) 
phenomenon of amorphous precipitation. It is impossible to predict in advance 
which conditions, if any, will cause a protein or protein complex to crystallize. The 
list of possible factors is a long one: precipitant type; pH; salt concentration; 
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detergents; temperature; and the inclusion of cofactors and ligands are the most 
common variables. The variables are endless.  
A prudent route to take involves screening sets of already established 
'good' protein crystallization agents. Crystallization screens often focus on a 
limited set of concentrations of various sizes of polyethylene glycols (PEGs), 
salts, and alcohols that have been successful for protein crystallization in the 
past [68-71].  Commercially available crystallization screening kits (e.g., those of 
Hampton Research, Wizard, and Nextal), especially if the experimental set up is 
performed utilizing microcrystallization robotics, makes it possible to test 
thousands of initial conditions. The newest trend that appears to be emerging in 
the field is to have screenings conducted in a dedicated 'crystallization centers'.  
Although there are other techniques available, vapor diffusion is the most 
frequently used method of setting up crystallization experiments. Protein and 
precipitant are usually mixed in a 1:1 proportion, in volumes from 50 nL to 1 µL, 
depending on the type of instrumentation used. A solution drop that is formed in 
such a way is then placed in a sealed chamber that contains a large volume 
relative to the drop of precipitant, also termed the mother liquor solution. The 
imbalance in vapor pressure slowly draws water from the protein/precipitant drop 
into the mother liquor, and gradually concentrates the protein solution. Crystals 
can be formed if the process proceeds through a supersaturated protein solution. 
Crystal formation time is highly variable. They may form within a few hours 
(sometimes even only minutes), or, quite commonly, they may require weeks or 
months, depending on the protein and the particular conditions used. 
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Vapor-diffusion can be performed in two modes: the hanging-drop method 
and the sitting-drop method. In the hanging-drop method, each drop is prepared 
by mixing the protein sample with the buffer. A small slide with the droplet is 
inverted over a prepared well with the buffer. The drop is kept on the slide by the 
surface tension forces. This kind of setup is usually performed in a multiwell plate 
format, with 4 x 6 wells per plate. The sitting drop method utilizes the same 
principle, only in this case the drop sits on a microbridge over the precipitant 
reservoir, in the same well. 
Another interesting method used for crystallization of proteins is known as 
the microbatch method. Using this technique a small drop of concentrated protein 
solution, combined with the crystallization reagent of choice, is pipetted under a 
layer of oil. All of the reagents involved in the crystallization are present at a 
specific concentration and no significant concentration of the protein or the 
reagents occurs in the drop. This method is simple and efficient for screening for 
crystallization conditions, but not for obtaining good quality crystals. 
A new advancement in crystal preparation methods is the use of robotic 
systems that are able to prepare and evaluate up to 40,000 crystallization 
experiments per day, using this microbatch technique, or 60,000 micro-vapor 
diffusion experiments per day. These technological advancements are very 
important in the new field of high-throughput crystallization and structure 
determination, which is expected to have a large impact in the drug discovery 
process. 
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1.2.2 Data collection. Unfortunately, having crystals form does not necessarily 
mean that they will be suitable for obtaining a good structure. Crystals can only 
diffract X-rays if they are well ordered. Since weak interactions hold the lattices 
together, fragile crystals might, in some cases, have internal disorder and 
therefore diffract poorly. This is impossible to determine in advance just by 
visually judging the crystal appearance, The only way to be certain is to actually 
expose a crystal to  the X-ray beam and measure the diffraction pattern. 
The question is then why some crystals lead to solvable structures and 
others do not. A more detailed discussion of the nature of crystals is required. 
Crystals represent an “orderly three-dimensional array of molecules, held 
together by noncovalent interactions [55]"; that is, built in space from multiple 
copies of the same repetitive element. These building blocks are called unit cells 
and are related to each other by simple translations. There are fourteen types of 
unit cells (cubes, prisms, hexagons).  
The unit cell may contain a single copy of the protein or complex of 
interest, but often it contains many copies, and they are related to each other by 
a set of rotations and translations defined by crystallographic symmetry. The 
symmetry of the unit cell is indicated by its space group. Theoretically, 230 
different space groups exist, but luckily for researchers, only 65 different types of 
symmetry are actually known. In the unit cell the “largest aggregate of molecules 
that possesses no symmetry elements, but can be juxtaposed on other identical 
entities by symmetry operations, is called the asymmetric unit [55].” The 
asymmetric unit and its dimensions (coordinates) are determined in solving the 
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structure. Often times this can be a biological unit, but it can also be built from 
symmetrically positioned protein chains such as homodimer or homoteteramer. 
These symmetry elements are depicted in Figure 1.3.  
 
 
Figure 1.3 Anatomy of a protein crystal. Reproduced from Minor, DL[43] by 
permission of Elsevier 
 
1.2.3 Data collection. Actual determination of a structure begins with measuring 
the X-ray diffraction from the crystal. X-rays are electromagnetic waves that have 
short wavelengths, and the best range for crystallography involves wavelengths 
between 0.5 Å–1.6 Å. These X-rays are able to penetrate samples of up to 1 mm 
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thickness. They are also able to discern between features that have magnitudes 
on the order of angstroms (1-2 Å covalent distance between atoms, and 
hydrogen bonds at 2.5 Å – 3.5 Å).  
X-rays can be produced by exciting a metal (usually copper or 
molybdenum) with high energy electrons produced by a heated filament, and 
accelerated by an electric field. X-rays are emitted by excited copper electrons, 
making a L→ K transition at λ = 1.54 Å. In order to produce monochromatic 
radiation, usually a nickel filter of 0.015 mm thickness is used.  
In an X-ray diffraction experiment the intensity of the coherently scattered 
X-rays is measured. The diffraction pattern is an array of “reflections” in which 
the pattern and spacing is set by the unit cell parameters (Figure 1.4).  
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Figure 1.4 Scheme of diffraction experiment. Reproduced from Minor, 
DL[43] by permission of Elsevier 
Each reflection carries information about the entire asymmetric unit. There 
is an inverse relationship between the position of a reflection in a diffraction 
pattern and the resolution of the information. Near the center of the diffraction 
image, close to the position of the incident beam, are where the low-resolution 
reflections found, while high-resolution data are found at larger scattering angles 
(Figure 1.4B). High-resolution reflections determine the resolution limits of a 
given experiment. These limits are a result of the quality of the internal order of 
the crystal. Once the crystal parameters (i.e., space group and unit cell size) are 
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determined from the diffraction pattern, the crystallographer knows exactly where 
all the reflections at any resolution should be. 
For data collection either a diffractometer or synchrotron radiation is used. 
Diffractometers have three main components: X-ray source, goniometer and 
detectors. The goniometer is able to rotate a crystal by a 40° angle in each of two 
perpendicular planes during data collection. The steps in diffraction experiments 
are described in Figure 1.4. Presently, most data collection is done at the 
synchrotron radiation sources, although for the studies reported in this 
dissertation, an in-house Rigaku instrument was used. The main advantage of 
synchrotron radiation is that the intensity of X-rays generated is much higher, so 
the crystal exposure time can reduced. This is very important since most 
molecular crystals lose the ability to diffract X-rays within a few seconds of 
exposure, due to the high energy imparted by X-rays. In order to preserve 
crystals, they have to be flash frozen before the exposure, usually using liquid 
nitrogen [72]. As already explained, this is important for crystal lifetime and 
quality of data [73, 74]. Nearly 90% of all crystallographic data is performed at  a 
temperature of 100 K or lower [73]. During the whole expose time, the crystal is 
placed in a cryostream of nitrogen gas, which keeps it frozen throughout the 
experiment.  
The X-ray crystal reflections are recorded by detectors. These can be of 
different types depending on their specific design. Image plate detectors  and 
area detectors are most commonly used for X-ray crystallography. Image plates 
are plastic sheets with a coating of small crystals of phosphor material, like 
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BaF:Eu2+. By hitting the detector surface, X-ray photons excite the electrons in 
the material. Laser is then used to scan the detector surface and record the 
signal. The pixel size depends mainly on the reading system and varies from 
100x100 to 200x200 µm. The image plate detectors have a wide dynamic range 
and can be used indefinitely. 
Area detectors are based on either a gas filled ionization chamber or an 
image intensifier coupled to a video system. The X-ray photons cause ionization 
of gas atoms. The disadvantage of this type of detector is the limitation of 
counting rate due to the build up of charges in the chamber and the processing 
electronics. The maximum counting rate is about 105 Hz. Another disadvantage is 
the lower sensitivity at shorter wavelengths due to poor absorption, if used in 
combination with synchrotron radiation.  
1.2.4 From diffraction data to electron density. In order to obtain an atomic-
scale image from crystallographic data, a computer simulates the action of a lens 
[55]. Electron density is computed from the list of indexed intensities obtained, 
which is the final outcome of the X-ray data collection. Each intensity has an 
index hkl assigned corresponding to its position in the reciprocal lattice. This 
diffraction pattern can be mathematically related, very precisely, to the object 
using a Fourier transform [55]. A Fourier-series description of the reflections is 
converted into Fourier-series description of electron density. A reflection can be 
described by a structure-factor equation, containing one term for each atom in 
the unit cell. 
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Crystallographers use Fourier transforms to convert structure factors to an 
electron density equation. However, one necessary piece of information is 
missing. A description of a diffracted wave includes knowing its amplitude, 
frequency and phase. For each reflection, we can only measure its intensity, Ihkl 
not the complete structure factor Fhkl. The amplitude of structure factor Fhkl is 
actually proportional to square root of the measured intensity. Unfortunately, its 
phase still remains unknown. In an analogy that was mentioned before, in 
focusing reflected light from the object, a lens maintains all phase relationships 
among the rays constructing an image accurately. Recorded diffraction 
intensities do not carry that necessary information. This is often referred to as the 
phase problem of X-ray crystallography. This problem can be overcome, 
however, and phases can be obtained using different indirect approaches, as 
explained in the following sections. 
1.2.4.1 Heavy atom derivative. This method was developed when solving the 
first protein structures in the 1960s. It is based on modifying the protein in the 
crystal with a “heavy atom”, such as in the form of a mercury or platinum 
complex. Because proteins are made of “light atoms” (C, H, O, N, S), the 
selective addition of a heavy atom or atoms with a large number of electrons 
(e.g., 80 electrons in Hg) to precise binding sites on the protein causes 
perturbations to the intensities of the reflections in the diffraction pattern. The key 
objective is to produce modified crystals in a way that the unit cell is not altered, 
and possessing the same dimensions and crystal symmetry group. This condition 
is also known as isomorphism. Obtaining phases from only one crystal derivative 
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is called the single isomorphous replacement (SIR) method; if two or more 
derivatives are required then the method is termed multiple isomorphous 
replacement (MIR). 
At the same time, the presence of heavy-atom should result in detectable 
changes in the reflection intensities. If that is the case, than these atoms can be 
easily located and the phases can be calculated by different computational 
programs that are available. Phase estimates are further used for refinement and 
structure solution. For producing the right crystals two methods are employed: 
soaking of native crystals with heavy atom derivatives solutions, and 
cocrystallization of the protein and heavy atoms. 
MIR requires a lot of material, since many crystals often need to be 
screened to yield the appropriate derivatives. Just like the search for 
crystallization conditions, it cannot be known a priori which derivatives will be 
useful. Often derivatization alters the unit cell parameters in such a way that the 
isomorphism is not maintained 
1.2.4.2 Anomalous Scattering Method. This second method of solving the 
phase problem takes advantage of having a heavy atom incorporated into the 
protein. Three very important technical developments make this method possible: 
variable wavelength of synchrotron radiation, cryocrystallography, and the 
production of proteins that contain selenomethionine instead of sulfur-containing 
methionine [55]. For proteins that naturally contain a heavy atom, such as the 
iron in globin or cytochtrome, the native heavy atom provides the source of 
anomalous dispersion. 
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Proteins lacking functional heavy atoms, but which naturally (or through 
introduced point mutations) encode for methionine, can be expressed in E. coli 
containing exclusively selenomethionine. Selenium atoms serve as heavy atoms 
in a protein that is essentially identical to the “native” form. Isomorphism does not 
represent a problem since same protein serves as both native and derivative 
form. This method requires a tunable X-ray source, generally provided by a 
synchrotron X-ray beamline. The incorporation of selenium allows a special type 
of experiment to be done in which data are collected at the wavelength at which 
the selenium atoms absorb X-rays as well as at wavelengths at which they do 
not. This sort of experiment is known as a multiwavelength anomalous dispersion 
or single wavelength anomalous dispersion (MAD and SAD, respectively) [75-
77]. Selenium atoms are located based on differences in the intensities of the 
reflections, just as similar differences allow the determination of heavy atom 
positions. The advantage over MIR, which requires multiple crystals, is that in 
this case the experiment can be conducted with a single crystal. Also, for MIR the 
treatment of the crystals with the heavy atoms frequently causes serious 
degradation in the diffraction quality. This issue is completely avoided with the 
MAD or SAD experiments. The quantity of selenomethionine residues allowed in 
a single protein or protein complex can vary, but the largest number in a structure 
solved by MAD was six per protein subunit, in the dimeric enzyme DsbA [55]. 
1.2.4.3 Molecular replacement: related proteins as phasing models. The 
third method of solving structures is by molecular replacement. This technique, 
developed by Rossman and Blow [78], takes advantage of the fact that the basic 
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backbone architecture of many proteins of interest is similar to other proteins or 
protein domains for which there are already solved, high resolution structures. In 
this case the known structure of the macromolecule is referred to as the phasing 
model. The model and the molecule of interest should share at least 40% 
homology. This method is extremely useful in examining a series of mutations to 
see how they perturb a structure or to see how drugs might bind and interact with 
a target. In general, the target and the model backbone atoms must be within 
~2.0 Å root mean squared deviation (RMSD). 
If the model and the new protein are isomorphous, then the phases for the 
new protein can be calculated directly, after which they are improved during an 
iterative process. If they are not isomorphous the problem is more complicated, 
and the position and the orientation of the phasing model in the unit cell are 
searched [55]. One of the best ways to do this is through calculating the 
Patterson map. The Patterson function P(u,v,w) is a Fourier series used to 
calculate ρ(x,y,z) from structure factors. The coordinates (u,v,w) locate a point in 
the Patterson map in the same way that coordinates (x,y,z) locate a point in an 
electron density map. A Patterson map shows peaks at locations corresponding 
to vectors between atoms, and is independent of the position of the structure in 
the unit cell. But if the structure is rotated in the unit cell, the “Patterson map 
rotates around the origin, changing the position of Patterson atoms in a single 
Patterson unit cell”[55]. This has important implications for the use of the 
Patterson map in determining the best orientation of the model in the unit cell of 
the new protein. 
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Different programs are available that perform a combination of rotational 
and translational searches, or both. For the orientation search, which is also 
known as rotational search, the program is looking for large values of the model 
Patterson function Pmodel(u,v,w) at locations corresponding to peaks in the 
Patterson map of the desired protein. The resolution range used for rotational 
searches is usually within 10–3.5 Å, with 8–4 Å being the most common. For the 
location search, which is also known as translational search, the program is 
looking for the “correspondence between the expected structure-factor 
amplitudes from the model in a given trial location and the actual amplitudes 
derived from the native data on the desired protein.” 
The parameter used to determine the success of the search procedure is 
the R-value [55]. For proteins, R-values of 0.3 to 0.4 for the best orientation of 
the phasing model have proven successful in providing initial estimates of 
phases. If they are superimposed, then the phases of the model can be used as 
initial estimates and improved via an iterative process. 
1.2.5. Solving and refining a structure. Once the phase problem has been 
solved, than the electron density function ρ(x,y,z) can be calculated from the 
measured intensities. This is only the beginning of an iterative process that 
attempts to improve the quality of the initial map by different methods, which 
inlcude solvent flattening, noncrystallographic symmetry averaging, or 
introducing a partial atomic model (which is building the structure into electron 
density maps). If the initial electron density maps are good, protein structural 
features such as α-helices, β-sheets, side chains, and cofactors can be 
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recognized. The procedure involves matching the covalent structure of the 
molecule (i.e., the protein sequence) with the density. 
How easy or how hard this step is depends on the resolution to which the 
crystals yield good data. Different protein structural features require different 
resolutions. The definition of individual atoms requires data at 1.5 Å resolution or 
better. At ≤ 2.0 Å resolution, the electron density of individual side chains will be 
sufficiently resolved to define specific conformers. At 3.0 Å resolution or lower, 
major structural features such as α helices and β sheets are clearly 
distinguishable, but many side chains may not be resolved. Another problem is 
that the electron density map may not be of uniform quality, and some parts of 
the protein may be poorly ordered and not visible at all. 
With high-resolution data (≤ 2.0 Å) interpretation is fairly straightforward. 
At lower resolutions, ambiguities may exist that require multiple rounds of model 
building and refinement. In both cases the basic procedure of map fitting employs 
placement of atoms for the interpretable density in the map (i.e., given 3-D 
coordinates within the asymmetric unit); the positions are then refined against the 
data, new maps are calculated using the new phase information from the model, 
and the procedure is repeated. This iterative building and refinement process 
gradually improves the phases and the quality of the maps such that features 
that may not have been visible at the outset become visible. In cases where the 
data are ≤ 2.3 Å, automated building and refinement programs can do much of 
the work. At lower resolutions, the work still requires building and map 
interpretation to be done manually. It should be noted that the precision of the 
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placement of the atoms in a macromolecular structure is typically much greater 
than the resolution of the data. The positional errors in the core regions (i.e., 
those that are best defined) range from 0.1–0.2 Å at 1.5 Å resolution to ~0.5 Å at 
3.0 Å resolution. Why is this precision better than the diffraction limit? The 
answer is chemistry. We know the average lengths and angles for all of the types 
of covalent bonds that hold together a protein. These values are included as 
restraints in the refinement procedure and ensure that the final structural model 
makes good chemical sense.  
Another important parameter that defines data quality is the R factor. It 
shows how well a final model fits the experimental data. Fortunately, the data 
from an X-ray diffraction experiment are redundant to some degree. Thus, 5%–
10% of the data can be actually excluded from the entire refinement procedure 
and this set used (known as the Rfree set) as an unbiased metric of how correct 
the structure refinement is. During the structure refinement, the crystallographer 
compares how well the structural model predicts the Rfree dataset. 
It is now routine to report the R and Rfree values for a crystal structure. 
These two numbers serve as one metric for how correctly things have been 
done. R and Rfree should be similar (Rfree is always higher by ~2%–6% for well-
refined structures). During the refinement process, the value of R may decrease, 
but Rfree will stay the same (or increase). If the R values are already low, this is 
one way for crystallographers to know when to stop refining. Large differences 
between R and Rfree indicate that some portion of the model is incorrect and that 
something needs to be corrected before the refinement can be completed. 
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Examination of stereochemistry and Ramachandran analysis provide two other 
good measures of the quality of a structure. In good structures, one should see 
RMSD for bond lengths of < 0.02 Å and bond angles of < 2°; curiously, lower 
values than these do not necessary indicate higher quality structures but may 
reflect the use of too-tight constraints during refinement. Ramachandran analysis 
examines which parts of conformational space the protein is in. 
Although the final refined model represents the average positions of the 
atoms, the structures do contain information about the mobility of different parts. 
One indicator is a parameter known as the B-factor. Each atom in the structure 
has a B-factor value that describes the average mean displacement from the 
position seen in the structure. Low B-factors show areas of low mobility and high 
B-factors show regions of higher mobility. This simple interpretation can break 
down in low-resolution structures (> 2.7 Å), as these generally have higher 
average B-factors that also reflect the general disorder in the lattice. 
1.2.4 Finale and future: integrated studies. The methods outlined in this 
chapter, which have been utilized in the research presented in this dissertation, 
offer a powerful way to gain valuable molecular insight into the fine anatomy that 
underlies how macromolecules look and behave. Besides the explanatory power 
that such approaches offer for understanding the native structure and function 
itself, they are often the first step in protein design, allowing the engineering of 
variant proteins with novel function, and they also provide guidance for drug 
discovery and development, as commonly employed in “structure-based design” 
(or “rational design”) methodologies. Although each method offers complimentary 
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information, integrated studies that use various methods to get at different levels 
of structural questions offer a great advantage for exploring large 
macromolecular complexes in different functional states. 
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CHAPTER 2 
PDZ PROTEIN INTERACTION DOMAINS 
The central theme of the thesis project is multivalency of biological 
systems and the core study was done on the dual PDZ domain of PSD-95 
protein. Special focus was on utilizing ITC technique for analyzing affinity of 
protein–protein interactions. This lead us to design of potent molecular probes to 
target these interactions. Ligand design and subsequent in vivo studies are also 
described in this chapter. 
Different cellular processes are regulated by proteins through their various 
interactions with other polypeptides, small molecules, phospholipids or nucleic 
acids [79]. Many of the associated regulatory proteins are constructed of different 
protein interaction domains, or PIDs [80]. In structural biology or biochemistry the 
definition of a ‘domain’ is somewhat broad, although usually they are described 
as relatively independent (structurally and/or functionally) structures of 35-150 
amino acids that retain their fold and binding characteristics even when they are 
expressed separately. A striking but not unusual structural feature is that the N- 
and C- termini are often located very close, on the opposite side of the ligand-
binding site. This arrangement enables the assembly of PIDs into different host 
proteins while keeping their binding affinity very similar. Utilizing such “building 
blocks” introduces diversity in complex proteins with a limited number of 
components.  
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Many protein domains are known to bind to different sequences in their 
target molecules. Another interesting feature is that different interaction domains 
are present in the same host molecule (single or multiple copies) thus forming a 
complex protein that can mediate multiple protein-protein or protein-ligand 
interactions. Based on their sequence homology or their ligand-binding 
properties, domains are organized into different groups; for example, SH2 (Src 
Homology 2) [81], SH3 (Src Homology 3) [82], WW (two conserved tryptophan 
residues) [83], PTB (Phosphotyrosine binding domain) [84], PDZ (PSD-95, Discs-
large, ZO-1), LIM (Lin11, Isl-1, Mec-3) domain, etc [80].  
2.1. The PDZ Domain. PDZ domains are members of the same PID family of 
proteins, and likewise are relatively small, independently folded 'modules' that 
occur in longer polypeptides [85-87]. As with the other members of the PID 
family, PDZ domains are largely responsible for promoting transient non-covalent 
protein-protein interactions. These occur primarily within the intracellular space of 
a cell, and represent a number of different signaling pathways that affect all 
manner of cellular functions, from growth to death. 
The PDZ domains themselves are among the youngest of the identified 
PIDs. They were discovered on the basis of sequence repeats first found in three 
different proteins: postsynaptic density 95 (PSD-95); Disc Large (DLG) and 
zonula occludens 1 (ZO-1) [88]. Initially these regions of polypeptide were 
referred to as GLGF domains [85], because of the highly conserved Gly-Leu-Gly-
Phe motif found within the amino-terminal sequence, or DHR domain for discs 
large homology region. Later, the acronym “PDZ” rose to dominance (from PSD-
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95, Dlg and ZO-1, the initial letters of the first three proteins in which they were 
identified), and was widely adopted by the scientific community. Since the 
sequences of several genomes have been determined, it has been shown that 
PDZ domains occur in hundreds of proteins, and are among the most abundant 
protein domains in multicellular eukaryotic genomes, Caerohabitis elegans (89), 
Drosophila (128) and Homo sapiens (320). 
2.2 PDZ Domain Specificity and Nomenclature. PDZ domains consist of 
approximately 100 amino acid residues and bind in a sequence-specific manner 
to the carboxyl terminus of their protein-binding partners [85, 86]. While almost 
exclusively recognizing peptides with free carboxyl termini, some PDZ domains 
can also interact with internal peptide sequences, and in at least one case, with a 
non-C terminal cyclic peptide [89]. PDZ domains are predominantly found in 
cytoplasmic proteins, in which they occur in one or multiple copies. These protein 
domains are widespread in organisms, ranging from simple bacteria to complex 
eukaryotes, including humans, indicating that “they are either hyper adaptable or 
that they are essential or fundamental to cellular processes” [90]. Their high 
conservation level throughout the species indicates that their molecular function 
has been retained since the beginning of cellular life. These modular protein 
domains show no catalytic activity and preferentially bind to C-terminal 
sequences of the target protein, like cytoplasmic tails of transmembrane 
receptors and ion channels [91, 92]. However, it has been observed that PDZs 
can bind in non-canonical fashion as well to internal sequences, cyclic peptides 
or even lipid molecules [89, 93]. As stated before, PDZ domains are found in 
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multiple copies in complex proteins, often in combination with other domains like 
SH3, WW, LIM [94], etc. A recent search in the SMART (Simple Modular 
Architecture Research Tool) database found 20,072 in 12,617 proteins. PDZ 
proteins can be classified into three principal families based on their modular 
organization (Figure 2.1).  
 
Figure 2.1 Examples of PDZ domain classification according to modular 
organization. Reprinted by permission [94]  
 
The first family contains proteins consisting entirely of PDZ domains, 
though their number may vary from two to more than ten in certain proteins. The 
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second family is the MAGUK (membrane-associated guanylate kinase) proteins. 
These are a well studied family of PDZ containing proteins, particularly the 
mammalian MAGUK proteins that include PSD-95/SAP-90, PSD-93/chapsyn-
110, SAP-97/hdlg, and SAP-102 [94]. They are found at synapses and behave 
as protein-protein interaction modules that target and cluster ion channels, 
receptors, and cell adhesion proteins. MAGUKs all share a common domain 
organization, consisting of (one or three) PDZ domains at the N-terminus, 
followed by an SH3 domain, and at the C-terminus a guanylate kinase-like (GK) 
domain. PSD-95, the focal protein of the PDZ domain research presented in this 
dissertation, belongs to this family [95]. Overall it is probably one of the best 
studied PDZ domain-containing proteins to date, if not the best studied. The third 
family encompasses proteins that, in addition to PDZ domains, contain other 
domains, such as LIM, L27, C2, PH, WW, DEP and LRR [96]. 
2.3 The Significance of PDZ domains 
PDZ domains have been found to perform a wide variety of functions on different 
cell and tissue types, and many of those occurrences are associated with 
disease states. Thus, the importance of these domains spans from their basic 
endogenous functions all the way to disorders that are associated with protein-
protein interactions that involve binding (or disruption thereof) of PDZ domains. A 
brief overview is provided here that exemplifies the range and significance of 
these domains, especially as it applies to human health. 
2.3.1 PDZ domains as scaffolding proteins. A well documented property of 
PDZ domain-bearing proteins is their ability to serve as scaffolding elements for 
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the assembly of macromolecular complexes at specific subcellular locations, 
particularly at the cell surface [97, 98]. PDZ domains have a specific fold and 
interact with their binding partner proteins through the latter’s variable C-terminal 
region. Along with their often being accompanied in their host protein by one or 
more different PIDs, such as SH2, SH3, WW and PTB, PDZ domains are usually 
present in multiple copies. This enables them to assemble and anchor large 
multimeric protein complexes. A primary role of such protein assemblies is to 
maintain signal transduction specificity and efficiency. Sheng et al. have 
described some of the best known systems where PDZ domains are involved 
[96]. A representative example of a PDZ domain protein acting as such a scaffold 
in the cell is INAD (inactivation-no-afterpotential D), which contains five domains 
that interact in the phototransduction network [99].  
2.3.2 PDZ domains and their roles in cancer development.  Numerous PDZ 
domain-containing proteins have been shown recently to play a role in cancer 
progression, and thus emerge as potential drug targets [100]. Syntenin, a 
structurally well characterized protein that contains two PDZ domains, represents 
one such example [100]. Syntenin is overexpressed in many metastatic breast 
and gastric cell lines. Since syntenin is localized in the area of cell-cell contacts 
that act as cell adhesion sites, it might be involved in tumor cell invasion. In 
support of this mechanism, forced in vitro overexpression in MCF7 (non-
metastatic breast cancer cell line) or poorly metastatic AZ-521 gastric cancer 
cells increases the invasion and migration properties of those cell lines [100].  As 
shown in work by Boukerche et al [101], altering syntenin expression leads to 
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modifications in phenotype and alters the metastatic capabilities of melanoma 
cells. 
Another PDZ domain-bearing protein, PCD1 (pancreatic cancer derived), 
is found to be highly overexpressed in different types of tumor tissues, such as 
colon, breast, liver, pancreas, stomach and prostate [102]. Rarely is PCD1 
expressed in normal tissues. Further studies have shown that the PCD1 gene 
may play a role in colorectal cancer development from adenomas [103]. The 
same group has shown that PCD1 is implicated in breast cancer progression and 
nodal metastasis [104]. Therefore, this protein is a potential candidate for 
diagnosis and treatment of these types of cancer. 
Activated in prostate cancer (AIPC) is another PDZ domain protein 
containing six such domains, and is highly expressed in prostate tumor tissues 
The initial immunohistochemical studies have linked accumulation of this protein 
with the promotion of prostate tumorigenesis [105]. 
Finally, another cancer-associated protein is MAGI-3, a member of the 
MAGI family of PDZ domain-containing proteins that interact with proteins from 
viruses like human T-cell leukemia virus type 1 (HTLV-1) and high-risk human 
papilloma-virus (HPV) types. MAGIs can be viewed as a distinct subgroup of the 
MAGUK family. They have three PDZ domains, but instead of an SH3 domain 
there is a WW domain and guanylate kinase (GK) is found at the N-terminus. 
MAGI-3 has been shown to interact through its PDZ domain with Tax1 viral 
protein in HTLV-1 infected cells. This binding event alters the cellular localization 
of these proteins and might have implications for their biological activity, leading 
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to continuous infection of HTVL-1 in T-cells. Therefore, MAGI-3 is a very 
interesting target for understanding the mechanism of these dangerous 
infections, and ultimately for the design of inhibitors that could control them.  
2.3.3 PDZ domain proteins in cystic fibrosis. Cystic fibrosis (CF) is the most 
common lethal genetic disease in Caucasians [106].  The CF conductance 
regulator (CFTR) is a low conductance chloride channel that mediates cAMP 
dependent chloride secretion [107]. Changes in CFTR function are associated 
with CF, secretory diarrhea and pancreatitis. Mutation of the gene encoding 
CFTR reduces its chloride transport capacity and/or its level of cell surface 
expression. Another disease caused by the overstimulation of CFTR activity 
through bacterial enterotoxins is secretory diarrhea, the second largest cause of 
infant mortality in developing countries [106].  
The mechanism of action is mediated through the C-terminal tail of CFTR 
that directly binds to the PDZ domain proteins NHERF (Na+/H+ exchanger 
regulatory factor) [108] and EBP50 (ezrin-binding protein) [109]. It has been 
shown that binding of tandem PDZ domains to the C-terminal of CFTRs has a 
modulatory effect on the channel activity, revealing a new function of PDZ 
domains, which might not be limited only to this complex. It has been reported 
that regulation of CFTR with the PDZ domains of NHERF involves 
phosphorylation of one PDZ domain. This mechanism is under control of protein 
kinase C (PKC) [110]. PKC phosphorylates PDZ2 of NHERF, which triggers a 
conformational change that results in loss of affinity for CFTR and inability to 
activate the channel [110].  
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2.3.4 PDZ domain involvement in neurodegenerative diseases. Early studies 
of PDZ domains were especially interested in a single such repeat in CASK 
protein (calcium/calmoudlin-dependent serin protein kinase, a mammalian 
homologue of Lin2) [111]. Through its PDZ domain, CASK is shown to interact 
with parkin, a protein involved in progression of Parkinson's disease [111, 112]. 
Parkin is an E3 ligase responsible for the ubiquitination of protein substrates as a 
tag or marker, a critical step in the protein degradation pathway. It is believed 
that CASK acts as a scaffold enabling cellular trafficking and localization of 
parkin. However, it remains unclear what the consequence is when this 
interaction is lost. Designing ligands to selectively disrupt the interaction would 
be one possible way to study the associated complex functional properties, and 
subsequently might lead to developing therapeutics for this neurodegenerative 
disorder. 
Another very interesting example is GRIP1 (glutamate receptor-interacting 
protein 1), which is shown to have a direct functional link with the Fraser 
syndrome protein Fras1 [113]. GRIP1 contains seven PDZ domains, and through 
them it can form a diverse network of protein-protein interactions. This adaptor 
protein has been implicated in the regulation of neuronal synaptic function, but its 
physiological roles have not been defined in vivo. Thus far studies in mouse 
model have shown that loss of GRIP1 leads to epidermal blistering, renal 
agenesis and defects in the brain, a condition similar to human Fraser syndrome 
[113, 114].  
55 
 
A novel protein, human like X11-like (hX11L), contains a phosphotyrosine 
interaction (PI) domain and two PDZ domains [115]. Through the PI domain, 
hX11-L interacts with a sequence containing the same motif found in the 
cytoplasmic domain of Alzheimer’s (amyloid precursor protein APP). Further 
analysis of binding to APP of different hX11-L constructs indicates that PDZ 
domains at the carboxy-terminal region are essential for modulating APP 
degradation [115]. These observations should contribute in the current 
understanding of the molecular mechanism of APP in Alzheimer’s disease. 
After reviewing all these therapeutic areas that have been summarized, it 
is evident that the PDZ domain is a critical player in a variety of protein binding 
interactions. What unites these incidents is a molecular recognition event 
between the partner protein and the PDZ domain itself. Focusing attention on 
this, what is revealed is that there is both a conformity and diversity in the peptide 
sequences that different PDZ domains bind, and which gives rise to how these 
structures are classified. 
2.4 Classification of PDZ domains. PDZ domains predominantly bind to C-
terminal sequences of their binding partners [116]. The mode of recognition 
represents the basis for their derived nomenclature, describing residue position 
away from the carboxy end, and which was adopted for their binding targets. C-
terminal residue is referred to as the “0“ position with the subsequent residues 
labeled “-1“, “-2“, “-3“, etc. Classification by Songyang et al. showed that PDZ 
domains can be classified based on the preference for certain amino acid 
residues at key positions “0“ and “-2“ in their sequence (Figure 2.2). Class I PDZ 
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domains prefer peptides with small hydrophobic residues at the “0” position and a 
β-hydroxyl group (Ser or Thr) at the “-2” position, while class II PDZ domains 
prefer hydrophobic or aromatic residues at this position. Most of the PDZs fall 
into these two classes, but later on novel domains were discovered that have 
different preferences and that led to establishing class III and class IV categories 
as well (Table 2.1).   
 
 
Figure 2.2 Schematic diagram of peptide orientation in the PDZ binding site. P“0” 
and P”-2” point toward PDZ binding pocket while P”-1” and P”-3” are solvent 
exposed. 
 
Class III PDZ domains bind to their partner ligands with Cys at position “0” and 
any amino acid residue at the “-2” position. According to the latest classification 
class IV PDZs recognize Val at the “0” position and a negatively-charged residue 
(Asp or Glu) at “-2”. However, there are quite a few PDZ domains that cannot be 
listed in any of these classes, since they show unique binding patters. 
A different study has taken into account the nature of amino acids in two 
critical positions. First would be the position that immediately follows the second 
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β-strand (βB5) and another would be the first position in the second alpha helix 
(αB1) of the binding pocket [117]. This method was successful for classification 
for the limited number of PDZ domains, however not for all, since the criterion 
based on nature of amino acids at these two positions was insufficient to classify 
all PDZs. 
 
 
 Position “-3” Position “-2” Position “-1” Position “0” 
Class I X Ser/Thr X Val/Leu/Ile 
Class II X Phe/Tyr X Phe/Tyr 
Class III X X X Cys 
Class IV X Asp/Glu X Val 
 
Table 2.1 Classification of PDZ domains based on the preference in amino acid 
sequence of their binding partners; X stands for multiple possible standard amino 
acids. 
 
The idea of Bezprozvanny’s work [117] can be utilized by expanding the 
number of residues in the binding pocket of the domain that are taken into 
consideration. Thus proposed classification of PDZ domains by Bezprozvanny 
and Maximov was listed in SMART website (yielding 25 groups overall) [118].  
Insight into structure of both class I and II PDZ domains reveals that they 
have a very similar fold of six β-sheets and two α-helices despite their differences 
in amino acid sequence. Protein domain structure is the property that is 
conserved, not its sequence [90].  
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2.4.1 Class I PDZ domains. The majority of studies on PDZ domains was done 
on class I PDZs. Doyle et al. [88] pioneered the work by solving the crystal 
structure of PDZ3 of PSD-95 bound with the peptide derived from C-terminal of 
CRIPT (cysteine rich interactor of PDZ domain).  
 
Figure 2.3 Structure of the PDZ3 domain (blue) from PSD-95 
complexed with peptide TKNYKQTSV (golden) derived from C-
terminal of CRIPT. Only four C-terminal residues (QTSV) were 
resolved in the crystal structure. The picture is reprinted from Doyle 
et al. with the permission from Elsevier. 
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Published crystal structure of PDZ3 (Figure 2.2) is comprised of six β 
strands (βA- βF) and two α-helices (αA and αB), which fold in an overall six-
stranded β sandwich.  
Four residues of the ligand’s C-terminal region have been shown to 
interact with the peptide binding groove between the βB strand and αB helix as 
an antiparallel β strand extending one of the β sheet. The C-terminal hydrophobic 
residue valine at the “0” position of the peptide binds to the hydrophobic pocket 
created in the PDZ domain by several hydrophobic residues, which are Leu 323, 
Phe 325, Ile 327, and Leu 379. Since this pocket is the only one present on the 
binding surface of the domain, authors hypothesize that selection of biding 
parthner is done based on the volume of this pocket. The tight contact of the side 
chain of valine with the hydrophobic pocket explains the preference for the 
sequence having a hydrophobic residue at the “0” position [88]. Another critical 
interaction is the hydrogen-bonding interaction of the hydroxyl group of the “-2” 
position Thr with N3 of His 372 (first residue of the αB helix). The side chain of 
the “-1” Ser residue is shown pointing away from the interacting surface. 
The general feature of PDZ domains to bind to C-terminal sequences is 
supported by the stabilization of carboxylate through the series of H-bonds to the 
so called carboxylate binding loop formed by the conserved Gly-Leu-Gly-Phe 
(GLGF) and an Arg 318 through a highly ordered water molecule.  
Superposition of crystal structures of the peptide-free and peptide-bound 
PDZ3 domain of PSD-95 showed very little conformation change leading to 
peptide binding event 
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Figure 2.4 Mechanism of peptide recognition by PDZ domain. 
Reprinted figure from Harris et al.[119] 
 
2.4.2 Class II PDZ domains The class II recognition mechanism was first 
studied on crystal structure of hCASK/LIN-2 PDZ domain [120]. The structure of 
hCASK/Lin-2 PDZ domain is consistent with the typical PDZ fold formed by six 
β–strands and two α-helices shown also for class I PDZ domains, even though 
these classes only share a low percentage (20%) of sequence identity. An 
unexpected feature of this structure is that the peptide binding pocket of this 
domain is occupied by the C-terminal sequence of a neighboring non-
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crystallographically related molecule. Peptide binding site consists of two 
hydrophobic pockets for residues at positions “0” and “-2” which is consistent with 
the class II binding sequence: X-φ-X-φ (where X is any amino acid and φ is a 
hydrophobic residue). Binding pocket can accommodate smaller and larger 
hydrophobic groups.  
After closely examining the binding pocket, it is noted that “-2” position is 
formed by residues Met 507, Val 549 (at position αB1) and Leu 552. Among 
these, Val 549 is highly conserved in the class II PDZ domains. This residue is 
replaced by histidine in class I PDZ domains and forms an important H-bond with 
the Ser/Thr residue at “-2” position of their binding partner. Another interesting 
feature of this domain is that the carboxylate binding loop is structurally very 
similar with that of class I, although sequences are very different (Pro-Met-Gly-Ile 
in the hCASK instead of Gly-Leu_Gly-Phe). Despite these sequence differences, 
both class I and II PDZ domains are structurally similar and form H-bonding 
through an ordered water molecule.; yet, they bind to completely different target 
sequences. 
2.4.3 Non-C-terminal PDZ domain-peptide binding Non-canonical binding of 
PDZs to cyclic peptides was first discovered through the phage dislay library 
containing peptides cyclized via an intramolecular disulfide bond [89]. Later 
reports have shown that PDZ domains can bind to internal sequences in other 
PDZ domains [121, 122]. Both these complexes are characterized by interactions 
of PDZ domains with “pre-organized β-finger motifs” in their partners. This β-
finger motif is formed by an extension of the canonical PDZ sequence that 
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contains around 30 amino acids. The β-finger motif binds into the traditional 
peptide binding site of the PDZ domain and its first strand mimics a C-terminal 
peptide binding. The terminal carboxylate of a peptide ligand is replaced by the 
sharp β turn at the tip of the nNOS β-finger. The loss of the important interaction 
of the C-terminal carboxylate with the GLGF motif in the PDZ domain is most 
probably compensated by the tertiary interactions between these two PDZ 
domains. Evidence that supports this hypothesis is the calculation of the surface 
area buried upon binding of the β-finger motif of nNOS PDZ domain to the PDZ 
domain of syntrophin, which comes to 800 Å2. This value is twice as much as the 
burial of the surface area for binding of a C-terminal peptide ligand. This type of 
interaction might be typical for other PDZ domains than PDZ of nNOS if they 
fulfill the requirements for the β-finger motif in their structure. 
2.5 Ligand recognition by PDZ domain. As previously stated positions “0” [116, 
123] and “-2” [88, 124] are the critical residues for the recognition of the peptide 
sequence by PDZ domains. Evidence is emerging that other residues play role in 
the specificity of the peptide recognition [116]. Structural data of PDZ domains 
complexed with peptides [88, 120, 121] reveals the key components for the 
molecular interaction event; (1) stabilization of C-terminal carboxylate group, (2) 
binding of the “0” residue at a hydrophobic pocket, (3) hydrogen bonding of 
peptide backbone with the side chain of different residues in the PDZ domain, 
and (4) binding of the “-2” residue with the conserved His residue (the first 
residue in the αB helix) in PDZ domain. 
PDZ domains have a unique ability to stabilize the C-terminal carboxylate 
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group. They do so due to the presence of carboxylate-binding loop containing the 
conserved motif R/K-X-X-X-G-L-G-F. The peptide C-terminal carboxylate is 
coordinated by a network of hydrogen bonds with main chain amide group of this 
loop. The carboxylate group forms hydrogen bonds with conserved Arg or Lys 
mediated through an ordered water molecule. A mutational study in PSD-95 and 
syntrophin PDZ domains has revealed the importance of the identity of 
conserved but interchangeable Arg or Lys in peptide recognition [125]. The result 
also indicates that the identity of the residues at this position in the carboxylate- 
binding loop is critical for the interaction of one PDZ domain with another PDZ 
domain. PDZ domains with Lys at this position (PDZ2 of PSD-95, PDZ domains 
of both α- and β-syntrophins) dimerize with the PDZ domain of nNOS (neuronal 
nitric oxide synthase) while PDZ with Arg at this position (PDZ1 and 3 of PSD-95, 
PDZ of γ1-syntrophin) restricts the dimerization with PDZ of nNOS [125]. 
N-methyl amide scanning of the peptide backbone shows that hydrogen 
bonding plays an important role in the PDZ ligand interaction [126]. The order of 
affinity of the N-methyl amide peptides suggests that amide hydrogens at the “0” 
and “-2” positions are more important than at other positions, consistent with the 
hydrogen bonding inferred from the structural information of peptide-bound PDZ3 
of PSD-95 [88]. Replacing the carboxylate group with neutral alcohol and 
hydroxamide group shows that electrostatic interaction of carboxylate group 
andconserved Lys (in MAGI-3 PDZ2) is more important than preserving the size 
of the “0” residue.68 This study also points out that the interaction between the “-
2” Ser/Thr hydroxyl group and the His side chain (from αB1 of the PDZ domain) 
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is strictly regulated by the approximate size of binding pocket as peptide side 
chain modifications at “-2” position. Such modifications include inversion of chiral 
center, branching, and elongation; all lead to abolition of binding. 
Requirement of a free terminal carboxylate group for the ligand led to the 
belief that electrostatic interaction of the C-terminus with the domain plays an 
important role in recognition. But examining the salt dependence of both terminal 
and internal ligands and the effect of mutation of a conserved basic residue 
(thought to be important in electrostatic recognition) in syntrophin PDZ showed 
that direct electrostatic interaction with the terminal peptide do not play a 
significant part in binding specificity [127]. Binding analysis of a series of 
chemically modified C-terminal peptides with syntrophin PDZ demonstrates that 
steric features and hydrogen bonding complementarity are vital for recognition of 
the free carboxy group.  
One of the major projects in our laboratory is based on the design of 
macrocyclic ligands for PDZ domain using structure-based information [128, 
129]. Cyclic peptides show higher stability to proteolytic cleavage in in vivo 
studies, along with significant improvement in entropic contribution to the binding 
affinity[130]. Another approach utilized a peptide library containing nonstandard 
amino residues at position “0” was used to improve the ligand affinity by 
optimizing the size of hydrophobic group at this position to best fit the binding 
cavity [131]. 
2.6 Affinity of PDZ domain-mediated interactions. Binding affinities for the 
PDZ-mediated interactions have been reported in studies that used both solution-
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based methods (fluorescence [105, 132-135] and ITC [128, 129, 136, 137]) and 
solid-phase methods (surface plasmon resonance [116, 138, 139] and ELISA 
based assay [140]). Predominantly, solution methods are gaining lower values of 
affinity values (in the micromolar range) as opposed to the values from solid 
phase methods (in the nanomolar range). Such findings are attributed to solid 
phase methods possessing artifacts that lead to overestimation of binding 
affinity[141, 142]. PDZ domains are involved in transient, reversible interactions 
with other macromolecular targets, these low micromolar interactions are 
consistent with their regulatory function [143]. However, it is worth noting that 
actual in vivo values may be affected by local concentration in the subcellular 
compartments or the cellular enviroment (molecular crowding phenomenon).  
2.7 Regulation of PDZ domain interactions. Regulation of protein-protein 
interaction involving modular domains and their binding partners is often critical 
for cell signaling [80]. Several mechanisms have been proposed for the 
regulation of PDZ domain interactions. One is phosphorylation and 
dephosphorylation of Ser and Thr at the “-2” position in class I PDZ domains 
[144]. Specific phosphorylation at the “-2” position of β2 adrenergic receptor with 
GRK-5 (G-protein coupled receptor kinase 5) abolishes its interaction with PDZ 
of NHERF (Na+/H+ exchanger regulatory factor) [145]. Similarly, serine 
phosphorylation at the “-2” position in the inward rectifier K+ channel Kir2.3 by 
protein kinase A (PKA) disrupts Kir2.3 binding to the PDZ2 domain of PSD-95 
[146] In another example, phosphorylation of the “-3” residue of the AMPA 
66 
 
receptor subunit GluR2 C-terminus by another kinase PKC prevents GluR2 
binding to the GRIP PDZ domain [143]. 
Another mechanism proposed is allosteric regulation, as seen in the case 
of the Par6 PDZ domain. The binding of Cdc42 to CRIB (Cdc42/Rac interactive 
binding) domain of Par6 induces conformational changes in the Par6 PDZ 
domain, leading to enhanced affinity for the ligand [147, 148]. A NMR binding 
analysis of the hPTP1E (human protein tyrosine phosphatase 1E) PDZ2 domain 
with RA- GEF2 (Ras-associated guanine nucleotide exchange factor 2) peptide 
indicates a significant change in PDZ2 dynamics upon ligand binding, and the 
distal surface in PDZ2 are shown dynamically linked to the ligand binding site 
[149]. 
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2.8 Materials and Methods. 
This section describes all the materials and experimental procedures employed 
in conducting the research presented in this dissertation. 
2.8.1 Materials. Difco laboratories Bacto® Lennox LB Broth and granulated agar 
were used to prepare the LB/amp50 plates and LB/amp50 Media. Corning® 100 
mm/tissue culture dishes were used for the LB/amp50 plates. The ampicillin 
sodium salt was acquired from Fisher Biotech and a 20 mg/mL stock solution 
was prepared by dissolving ampicillin sodium salt (2%) in water. The ampicillin 
stock solution was filtered with a Star LB™ 0.22 µm filter. Corning® 0.22 µm 
polyethersulfone filters were used to sterilize the LB/amp50 media. The 
incubators used for bacterial culturing were the Fisher Isotemp® 200 series and 
the Lab-line® Incubator-Shaker incubators. Handling and plate streaking with 
glycerol stock, as well as transfer of the liquid cultures, were performed within a 
Laconco purifier class II biosafety cabinet. The 10 mL and 20 mL LB 
broth/amp50 cultures were grown in Falcon® Blue Max™ 50 mL conical tubes. 
The electrophoresis chamber used for the agarose gels was the Small 
Horizontal Gel System FB MSU-1 by Fisher Biotech and the gels were visualized 
on the Transilluminator FB TIV-88 UV Box by Fisher Biotech. The E-C Apparatus 
Corporation EC 105 electrophoresis power source was utilized. Ethidium bromide 
was obtained from LKB Instruments Incorporated. The QIAquick PCR Purification 
Kit and QIAprep Spin Miniprep kit were acquired from Qiagen. Invitrogen® DNA 
Dipsticks™ were used for quantitation of DNA samples. Eppendorf Centrifuge 
5810 R and Centrifuge 5417 C were utilized for centrifugation steps. 
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DNA primers were prepared by Sigma-Genosys and Invitrogen. The 
VentR® DNA Polymerase, T4 DNA ligase, and Buffer B were purchased from 
New England Biolabs. The Wizard® Plus Maxipreps DNA Purification System, 
PCR Nucleotide Mix, Buffer D, Buffer H, acetylated BSA, 1 kb DNA ladder, and 
the Bam HI, and Sal I restriction endonucleases were acquired from Promega 
Corporation. Ampliwax PCR Gem 100 was obtained from Perkin Elmer. The PCR 
thermocycler used was the Ericomp Inc. Twinblock™ System Easycycler Series. 
VWR Scientific Products Standard Heatblock and Model 1162 water bath were 
used. The E. coli cells were Epicurian Coli BL21-Gold competent cells by 
Stratagene. The BL21(DE3)RIL/pRK793 cells were obtained from Science 
Reagents. 
All biochemical reagents were purchased from Sigma, Fischer Scientific, 
and VWR. Molecular Weight Standard Mixture was obtained from Sigma. 
Coomassie® Plus-200 Protein Assay Reagent and TPCK Trypsin were obtained 
from Pierce. Advanced Protein Assay Reagent was obtained from Cytoskeleton. 
Glutathione agarose beads were purchased from Sigma. DTT and IPTG were 
obtained from Inalco Spa. SnakeSkin™ Pleated Dialysis Tubing and Slide-A-
Lyzer™ Dialysis Cassettes were obtained from Pierce. Amicon™ Ultra-15 
Centrifugal Filter Devices were obtained from Millipore. Mini-Protean® III 
Electrophoresis Cell from BioRad was used for PAGE analysis. HiTrap™ QHP 
column was obtained from Pharmacia Biotech. The liquid samples were loaded 
into the chromatographic columns (both for isolation and purification) with the 
help of Dynamix® peristaltic pump. OLIS-CD spectropolarimeter was used for 
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CD measurements. Beckman Coulter™ DU® 530 UV/VIS spectrophotometer was 
used to read the absorbance. Corning PH meter 430 and VWR symPHony 
electrode were used for pH measurements. Hamilton Gastight Syringes from 
Hamilton were used for ITC experiments. ThermoVac and VP-ITC 
Microcalorimeter from MicroCal™ Incorporated were used for ITC experiments. 
Wizard® plus maxiprep DNA purification kit (Promega) was used for the 
purification of plasmid DNA. 
2.8.1.1 Preparation of solid and liquid media. The agar plates were prepared 
by dissolving Lenox LB (Difco) broth (2%), agar (1.5%) and deionized water. The 
mixture was autoclaved for 30 min at 121-124 ºC. Once the temperature of the 
media reached 50 ºC, ampicillin stock solution (20 mg/mL) was added to obtain a 
final ampicillin concentration of 50µg/mL. Ampicillin stock solution was prepare 
by dissolving ampicillin sodium salt (2%) in deionized water followed by filtering 
through Star LBTM 0.22 µm filter to remove any potential contaminants.  
The agar solution was then pipetted into Corning® 100 mm tissue culture 
dishes and allowed to solidify at room temperature. Once solidified plates were 
inverted, labeled and stored at 4 ºC. 
TB (Terrific Broth)/amp50 media was prepared by dissolving Bacto Terrific 
Broth (4.76%), glycerol (0.4%) in deionized water. To this solution 20 mg/mL 
ampicillin stock was added to yield a final ampicillin concentration of 50 µg/mL. 
Finally, media was sterilized by filtering through Corning® 0.22 µm 
polyethersulfone filters and stored in autoclaved bottles at room temperature. 
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2.8.2 Methods 
2.8.2.1 Expression of fusion protein. A glycerol stock solution of E .coli BLR-
Gold cells, containing the gene that encodes for the desired GST fusion, was 
used to streak LB/amp50 plates and incubated for 12 h at 37 ºC. An isolated 
colony of moderate size was picked out and used to inoculate 10 mL of 
TB/amp50 broth in 50 mL Falcon tube, and left to grow with shaking for 
approximately 8 h. This culture was then placed in an autoclaved 1 L flask 
containing 90 mL of fresh TB/amp50 nutrient media, and incubated in the same 
manner for 2 h. The culture was then split in half, and 450 mL of the fresh 
TB/amp50 media was added to each. These cultures were incubated in 2x2 L 
flasks, with shaking at 37 ºC for approximately 3 h, until the optical density at 600 
nm (OD600) value reached 1.2. At this point the expression of fusion protein was 
induced by IPTG (isopropyl-1-thio-β-D-galalctoside), used at a final concentration 
0.8 mM. The incubation was allowed to continue at 30 ºC with shaking for an 
additional 5 h.  The culture was transferred into 250 mL centrifuge tubes and 
spun down at 3220xg for 20 min at 4 ºC. The supernatant was decanted and the 
harvested bacterial pellets were stored at -80ºC. 
2.8.2.3 Bacterial cell resuspension and lysis. The bacterial cell pellets were 
resuspended in ice-cold PBS buffer (Phosphate Buffered Saline) containing 1% 
Triton-X and 10mM β-mercaptoethanol. The Branson 250 Sonifier (Branson 
Ultrasonics Corporation) was used to lyse the cells by sonication. During 
sonication (3.2 mm probe, instrument set at 50% duty cycle and output control 5) 
that lasted for 55 s, cells were kept on ice. The sample was then centrifuged at 
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10,000xg for 20 min at 4 ºC to pellet the cell debris. The supernatant was 
decanted into a 50 mL Falcon tube. A clear cell lysate was obtained, and kept at 
4 ºC.  
2.8.2.4 Glutathione agarose beads (GST-affinity) column preparation. 
Approximately 0.75 mL of glutathione agarose beads (Sigma) were placed in a 
50 mL Falcon tube and allowed to swell in 10 volumes of 1xPBS ice-cold buffer 
for 1 h. The beads were than centrifuged at 10,000xg for 10 min, the supernatant 
discarded, and 5 mL of 1xPBS added to the bead slurry. Pre-swelled beads were 
then transferred to a glass column (20 mm diameter, 150 mm length). The 
glutathione bead column was then washed with ten times the volume of 1xPBS 
and stored in 10 mL of the same buffer (4 ºC). 
2.8.2.5 Isolation of fusion protein. Prepared glutathione-bound agarose beads 
column was washed with 10 volumes of ice-cold PBS buffer. Cell lysate was 
loaded onto the column at a rate of 5 mL/min, using Dynamix Peristaltic pump, 
followed by repeated washing with 10 volumes of PBS. The fusion protein was 
eluted with 50mM Tris-HCl, 5 mM reduced glutathione, pH 8.0. This extraction 
procedure was repeated till all the fusion protein was isolated from the cell lysate 
(determined by Coomassie plus-200 protein assay and SDS-PAGE analysis). 
2.8.2.6 SDS-PAGE analysis. In order to determine the effectiveness of the 
fusion protein extraction, protein samples were analyzed by 20% SDS-PAGE. 20 
µL aliquots were combined with 10 µL of sample buffer (12.5% Tris-HCl (pH 6.8), 
10% glycerol, 10%(w/w) sodium dodecylsulfate (SDS), 5% β-mercaptoethanol, 
15%(w/v) bromophenol blue and 47.5% deionized water). Molecular weight 
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marker (MW) was prepared by taking 20 µL of molecular weight standard 
(Sigma) and 5 µL of sample buffer. All samples were placed in a boiling water 
bath for 3 min (except for the MW; this period was 2 min). The samples were 
loaded on the gel, and run in the mini Protean III Electrophoresis Cell (BioRad) 
for approximately 50 min. at 200 V. The gel was then stained in Coomassie blue 
stain (50% methanol, 0.05% Coomassie brilliant blue, 10% acetic acid, 40% 
deionized water) for 15 min. The gel was then left overnight in destaining solution 
(5% acetic acid, 0.5% methanol, 85% deionized water). The gel was scanned 
using a CanoScan D1250 U2F scanner. 
2.8.2.7 Determination of fusion protein concentration. The Coomassie plus-
200 protein assay was used to determine GST fusion protein concentration. The 
spectrophotometer was auto-zeroed and measurements taken with deionized 
water as reference. According to the protocol provided (Pierce), a 50 µL aliquot 
of each fusion protein sample was added to 1.5 mL of Coomassie Plus-200 
protein reagent in a 2.0 mL microtube. A blank was prepared by mixing 50 µL of 
elution buffer with reagent. Contents of the tubes were gently mixed by inverting, 
and the absorbance measured at 595 nm. The results obtained were compared 
against a standard curve prepared by performing the Coomassie plus 200 
Protein assay on diluted samples of 200 50 µg/mg Bovine Serum Albumin (BSA) 
stock. 
2.8.2.8 Trypsin cleavage of fusion protein. Different trypsin to protein ratios 
were used for different fusion protein samples. For GST-PDZ1 and GST-PDZ2, 
the ratio used was 1:1400(w/w), and for GST-PDZ1-2 it was 1:7000 (w/w) of 
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trypsin (TPKC-trypsin, Pierce) to fusion protein. Trypsin working buffer (20 mM 
Tris-HCl, 200 mM NaCl, 1 mM EDTA, pH 7.4) was added, if required, to bring the 
final trypsin concentration to 1 µg/mL (from 1 mg/mL trypsin stock solution). The 
cleavage reactions were allowed to proceed for 2 h and 2.5 h for PDZ1 and 
PDZ1-2, respectively. 
In order to stop the trypsin cleavage reaction, immobilized Soybean 
Trypsin Inhibitor on beaded agarose (Pierce) was added. The inhibitor was made 
into a 50:50 v/v slurry according to the Pierce protocol. One milligram of the 
trypsin inhibitor in a slurry can stop 4.5 mg of trypsin. Twice the theoretical 
amount was added. The contents of the tube were mixed by inverting for 2 min at 
room temperature, and then left for 5 min on ice. The procedure was repeated 
two more times. The cleaved product was then filtered through a 0.45 µm nylon 
Bio Express syringe filter to remove the immobilized inhibitor. The cleaved 
sample was placed in Snake Skin 3500 MWCO dialysis bag (Pierce) and 
dialyzed into 1 L of 20 mM MES, 10 mM NaCl, 1 mM DTT, pH 6.0. Thr dialysis 
buffer was changed twice. 
2.8.2.9 GST removal. A GST affinity column was used to remove GST from 
dialyzed cleavage mixture. GST was bound to the glutathione agarose beads, 
while PDZ proteins were collected in the flow-through. The column was pre-
washed with 10 column volumes of ice cold PBS, and trypsin cleavage samples 
were loaded at the rate of 5mL/min, collecting the flow in 50 mL Falcon tubes on 
ice. The column was washed and the bound GST eluted with 50 mM Tris-HCl, 5 
mM reduced glutathione pH 8.0. The GST removal procedure was repeated 
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twice. The efficiency of GST removal after a second passage through the column 
was visualized by SDS-PAGE. The samples were further dialyzed in MES buffer 
(20 mM MES, 10 mM NaCl, 1 mM DTT, pH 6.0) for PDZ1 and MES buffer (20 
mM MES, 10 mM NaCl, 1 mM DTT, pH 5.9) for PDZ1-2. 
2.8.2.10 Purification of protein with ion exchange chromatography. Dialyzed 
protein samples were purified by ion exchange chromatography. The Hi-trap Q 
column (Amersham Pharmacia) was pre-washed with 5 column volumes of start 
buffer (20 mM MES, 10 mM NaCl, 1 mM DTT), followed by 5 volumes of 
regeneration buffer (20 mM MES, 1 M NaCl, 1 mM DTT), and then again 5 
column volumes of start buffer. Previously dialyzed protein samples were then 
loaded into the Q column at a rate of 5 mL/min, using the Dynamax  peristaltic 
pump. The column was washed with 5 column volumes of start buffer, and the 
bound protein was then eluted with 20 mM MES, 10 mM NaCl, 1 mM DTT, pH 
6.0 or pH 5.9 (depending on the protein of interest) with varying ionic strength 
buffer. The elutions were conducted with an overall volume of 3 column volumes 
(15mL) of 25, 35, 45, 50, 55, 60, 65, 70, 75, and 80 mM NaCl for PDZ1, and 25, 
40, 50, 70, 80, 90, 100, 110, 120, 140, 150, 200, and 250 mM NaCl for PDZ1-2. 
The column was then regenerated by washing with 5 column volumes of 
regeneration buffer, and 10 column volumes of start buffer. All the elutions were 
collected in 50 mL Falcon tubes on ice. 20 µL aliquots of all the elution fractions 
were analyzed by 20% SDS-PAGE. The elution fractions that contained protein 
of interest were dialyzed into final MES buffer (20 mM MES, 10 mM NaCl, pH 
6.0) for PDZ1 and PDZ2 and (10 mM sodium phosphate, pH 6.0) for PDZ1-2. 
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2.8.3 Concentrating sample and determining protein concentration. 
Dialyzed protein samples (dialysis buffer changed three times) were 
concentrated using Millipore Ultrafree-15 Centrifugal Filter Device MWCO 5000. 
The filter was rinsed with dialysis buffer, used for the sample for 10 min at 
2000xg, at 4 °C. The samples were added in 50 mL portions, and then 
concentrated by centrifuging at the same speed until a satisfactory concentration 
for ITC experiments was obtained. 
A final protein concentration was defined by UV measurements at λ = 280 
nm. Extinction coefficients for individual PDZ domains were obtained from 
calculations based on the protein sequence. Two quartz cuvettes (path length of 
1 cm) were used for the measurements. Sample dialysis buffer was used as a 
reference in the measurements and to auto-zero the instrument. 
2.8.3.1 Advanced Protein Assay. The absorbance was measured at 590 nm for 
this assay. Advanced Protein Assay Reagent (ADV01) was used as a reference 
and to auto-zero the instrument. The samples were gently mixed, transferred to 
disposable cuvettes, and the absorbance was measured with a UV-VIS 
spectrophotometer. Each 15 µL of protein sample was added to 1.5 mL ADV01, 
and the absorbance was read and concentration calculated based on correlation 
1.0 OD590 = 30 µg/mL of reagent, per cm of path length.  
2.8.3.2 Coomassie plus-200 protein assay. For the final protein sample, the 
Coomassie plus-200 Protein Assay was used. The same protocol described in 
2.3.2.7 was employed, with the only difference being that the dialysis buffer was 
used instead of reduced glutathione solution.  
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2.8.4 Characterization of PDZ1, PDZ2 and PDZ1-2 proteins of PSD-95. 
2.8.4.1 ESI mass spectroscopy. PDZ1, PDZ2 and PDZ1-2 tandem protein 
samples, whose purity were assessed by SDS-PAGE, were placed in 0.5 mL 
Slide-A-Lyzer dialysis cassettes (3500 MWCO) and dialyzed in 0.1 % 
trifluroacetic acid (TFA) in deionized water, volume of buffer 600 mL. The dialysis 
buffer was changed twice. The sample was taken out of the dialysis cassette and 
submitted for electrospray ionization mass spectroscopy (ESI-MS) analysis 
(Central Instrumentation Facility, WSU). 
2.8.4.2 Plasmid DNA preparation for sequencing. Glycerol stocks of E. coli 
bearing the individual GST fusion were used to streak a single LB/amp50 plate, 
which was then incubated at 37 °C overnight. One colony was chosen to 
inoculate 10 mL of TB/amp50 media in a 50 mL falcon tube incubated with 
shaking for 10 h at 37 °C. Only 2 mL of the prepared culture was centrifuged at 
20,800xg for 5 min to pellet the cells. The supernatant was removed, and a 
Qiagen Spin Miniprep Kit was used to extract the plasmid. 
2.8.4.3. Quantitation of GST-PDZ plasmids and DNA sequencing. The DNA 
DipStick Kit was used to determine DNA concentration in the sample. Plasmid 
preparation sample dilutions (1:1; 1:10; and 1:100) were spotted on the DNA 
DipStick membrane and developed accordingly. Based on comparison of the 
color intensities to the standard chart on the DNA DipStick Quick Reference 
Card, the concentration was estimated to be >500 ng/µL, sufficient for analysis. 
The result showed the DNA concentration to be 100 ng/mL or more. 20 µL of the 
77 
 
plasmid DNA sample and 10 µL of PGEX5 primer (1 µM) were sent to the 
sequencing facility in the Biological Sciences Department of WSU. 
2.8.5 Subcloning PDZ4 of MUPP-1.  
2.8.5.1 Isolation of donor plasmid. The template DNA for MUPP-1 PDZ4 was 
isolated from cells containing plasmid pcDNA-MUPP1. The gene that encodes 
for the whole rat MUPP-1 protein was constructed into plasmid DNA of the host 
cells. Glycerol stock of E. coli was used to streak a single LB/amp50 plate, which 
was then incubated at 37 °C overnight. One colony was chosen to inoculate 10 
mL of TB/amp50 media in a 50 mL falcon tube, incubated with shaking for 10 h at 
37 °C. Only 2 mL of the prepared culture was centrifuged at 20,800xg for 5 min 
to pellet the cells. The supernatant was removed, and a Qiagen Spin Miniprep Kit 
was used to extract the plasmid.  
2.8.5.2 Quantification of the MUPP-1 donor plasmid. The DNA DipStick Kit 
was used to determine the DNA concentration in the sample. Plasmid 
preparation sample dilutions (1:1; 1:10; and 1:100) were spotted on DNA 
DipStick membrane and developed accordingly. Based on comparison of the 
color intensities to the standard chart on the DNA DipStick Quick Reference 
Card, the concentration was estimated to be >500 ng/µL. 
2.8.5.3 Polymerase chain reaction of the MUPP-1 plasmid. 
Primers were designed to hybridize to sequences flanking the PDZ4 encoding 
region for amplification. The lyophilized forward (4.6 nmol) and reverse primer 
(4.8 nmol) (obtained from Invitrogen) were resuspended in sterile TE buffer (pH 
8.0) to make a 100 µM stock. From these stocks, working solutions (20 µM) were 
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prepared by dilution. Two separate reaction mixtures were prepared and Hot 
Start PCR was used. 
 
Solution 1 Solution 2 
Sterile deionized water (63 
µL) 
Sterile deionized water (6 
µL) 
Forward primer (5 µL) 10 x Thermo buffer (1 µL) 
Reverse primer (5 µL) Vent Polymerase (1 µL) 
10 x Thermo buffer (9 µL) Plasmid DNA (2 µL) 
nucleotide bases (8 µL)  
Total volume (90 µL) Total volume (10 µL) 
Table 2.2 PCR reaction conditions 
Each component of the Solution1 was added to a PCR microtube (50 µL) 
and an Ampliwax PCR Gem 100 wax bead was placed on the top of the liquid. 
The wax was melted by placing the PCR microtube in a 80 °C heat block for 5 
min, and then it was transferred on ice to allow the wax layer to solidify. On the 
top of the layer, Solution2 was carefully pipetted, and the tube was then placed in 
the Thermocycler. A second reaction was prepared exactly as the previous one, 
but with an increased concentration of MgSO4 (from 2 µM to 4 µM), while 
keeping the overall volume constant.  
The thermocycler was programmed for 3 cycles. Cycle 1-5 min at 94 °C 
for 1 repetition, cycle 2-10 seconds at 94 °C, 30 seconds at 45 °C, and 1 min at 
72 °C for 25 repetitions, cycle 3 was set for 10 min at 72 °C for one repetition. 
2.8.5.4 Agarose gel analysis of PCR product. A 1% agarose gel was prepared 
by mixing 0.5 g agarose powder with 50 mL 1xTBE buffer (prepared by dilution 
from 5 mL of 10xTBE buffer: 0.9M Tris base, 0.9M Boric acid, 0.025M EDTA (pH 
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8.0) and 45 mL of deionized water). The mixture was heated in a water bath for 
approximately 20 min, until the agarose was completely dissolved (solution 
became clear). After cooling for a few minutes, 2.5 µL of ethidium bromide (10 
mg/mL) was added to yield a final concentration of 0.5 µg/mL, and then the 
mixture was poured into a gel casting frame, with a comb inserted in it. After the 
gel solidified (15-20 min), the comb was removed and the gel placed into the 
electrophoresis apparatus and covered in 300 mL of 1xTBE buffer with 15 µL 
same ethidium bromide stock solution, final concentration being 0.5 µg/mL. 
Samles were prepared as follows using 10 X Loading buffer-(20% w/v) Ficoll 
400, 0.1M Na2EDTA (pH 8), 1.0% (w/v) SDS, 0.25% (w/v) Bromophenol blue, 
0.25% (w/v) Xylene cyanol and 1 X TBE buffer. 
  sample 1X TBE 10X Loading 
buffer 
LANE1 Promega 1kB DNA 
ladder 
8 µL 1 µL 
LANE2 PCR reaction (2 µM 
MgSO4) 
8 µL 1 µL 
LANE3 PCR reaction (4 µM 
MgSO4) 
8 µL 1 µL 
Table 2.3 Gel analysis of PCR products 
The samples (10 µL) of each were loaded into the wells and the gel was 
run at 82 V for 1 h. Lane 2 showed a band at approximately 300 bp, as expected. 
The increased concentration of MgSO4 didn’t result in any band at lane 3. The 
calculated size of the PCR product was 303 bp, which corresponds to the band 
visualized under the UV light. 
2.8.5.5 Purification and quantification of the PCR product sample. Qiagen 
PCR Purification Kit was used to purify the PCR product. The DNA DipStickTM Kit 
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was used to quantitate the purified sample. PCR product samples that were 
undiluted, (1:5), (1:10) diluted were spotted on a DipStickTM membrane and 
developed accordingly. Concentration estimated to be10 ng/µL. 
2.8.5.6 Double restriction enzyme digest of PCR product sample. The PDZ4 
PCR product was cleaved using Bam HI and Sal I restriction enzymes to form 
complementary ends for ligation into the GST plasmid. Double digest reaction set 
up was as follows: purified PCR product (20 µL), 10 X Buffer D (4 µL), acetylated 
BSA (0.4 µL), sterile deionized water (13.6 µL), Bam HI (1 µL) and Sal I. The 
reaction was mixed in a microtube and incubated for 2 hours at 37 °C. 
2.8.5.7 Preparatory agarose gel of the restriction digest (PCR of PDZ4). A 
1% agarose gel was prepared as described previously (2.1.3) except different 
comb with larger wells was used to accommodate the increased sample volume. 
After the gel was solidified, comb was removed and the gel placed into the 
electrophoresis apparatus and covered with 300 mL of 1 X TBE buffer, Ethidium 
bromide final conc. 0.5 µg/mL.  To the overall volume of 40 µL of restriction 
digest 5 µL of 10 X Loading buffer and 5 µL of 1 X TBE were added. The sample 
was run on the gel along with molecular weight marker (2 µL 1 kb DNA ladder, 2 
µL of 10 X Loading buffer, 16 µL 1 X TBE buffer) at 82 V for approximately  1 
hour. Gel was then taken out from the chamber and placed on the UV 
illumination box. The band containing PDZ4 DNA was cut out and weighted. 
2.8.5.8 Preparation of PDZ4 DNA for ligation. The Geneclean II kit Bio 101 
was used with the TBE modifier to dissolve the gel slice and remove 
contaminants. 
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2.8.5.9 Quantification of the purified, digested PDZ4 DNA sample. Once 
again DNA DipStickTM Kit was used to determine DNA concentration in the 
sample. Purified, digested samples that were undiluted and (1:10) were spotted 
on DNA DipStickTM membrane and developed according to the protocol. When 
the membrane dried, color intensities were compared to the standard chart. 
Concentration was estimated to be 100 ng/µL. 
2.8.5.10 Plasmid prep of GST/PDZ3 vector. A plate LB/amp50 was streaked 
with glycerol stock of E. coli cells which contained GST/PDZ3 vector and the 
plate was incubated overnight. Single, isolated colony was picked out and used 
to inoculate 10 mL of TB/amp50 media, followed by incubation at 37 °C with 
shaking for 8 h. Then 500 µL of the culture was used to inoculate 500mL of fresh 
TB/amp50, and the growth was continued overnight (37 °C, shaking).  
The culture was spun down in 250 mL centrifuge tube at 3220 x g for 20 
min, to pellet the cells. Supernatant was discarded and Wizard® Plus Maxiprep 
purification system from Promega was used to extract the plasmid from cells.  
2.8.5.11 Restriction digest of the GST/PDZ3 plasmid. GST/PDZ3 plasmid has 
also unique restriction sites Bam HI and Sal I (as previously 1.5). Therefore, 
double restriction digest was performed on GST/PDZ3 to remove PDZ3 insert 
and create complementary ends for the ligation of the PDZ4 (MUPP-1) into GST 
plasmid. Double restriction digest reaction was set up in the following order: 
sterile deionized water (5 µL) 10 X Buffer D (10 µL), acetylated BSA (1 µL),), at 
this point everything was mixed thoroughly by pipetting, and then enzymes were 
added Bam HI (2 µL) and Sal I (2 µL). 1.5mL microcentrifuge tube containing 
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reaction mixture was incubated at 37 °C, for 2 hours, and then it was immediately 
analyzed by agarose gel. 
2.8.5.12 Preparatory agarose gel of the restriction digest product-GST 
vector. Again 1% agarose gel was prepared with large wells as previously 
described (section 2.1.6) and to the restriction digest sample 10 x Loading buffer 
(5 µL) and 1 x TBE (5 µL) were added. The sample was run on the gel along with 
a molecular weight marker (2 µL of 1kb DNA ladder, 2 µL 10 x Loading buffer, 
16µL 1 x TBE buffer) at 82 V for 55 min. The gel was placed on the UV 
illumination box, under minimum UV exposure and least possible time to 
minimize DNA damage. Using sharp razor agarose piece (digested plasmid) was 
cut out and placed into 2 x 1.5 mL microcentrifuge tubes.  
2.8.5.13 Preparation of plasmid for ligation and quantification of the 
purified plasmid. For the extraction and purification of DNA sample, again 
QIAquick Gel Extraction Kit was used (according to the protocol). The DNA 
DipStickTM Kit was used to determine the concentration of the DNA in the 
sample. Purified, digested plasmid samples that were undiluted, 1:1, 1:5 diluted 
were spotted on the DipStickTM membrane and developed. After comparing the 
color intensities on the membrane to the standard chart, results showed DNA 
concentration of 100 ng/µL. 
2.8.5.14 Ligation reaction of the GST-plasmid with the PDZ4 DNA using 
FAST-LINK DNA Ligation Kit. The formula shown below was used to determine 
the amounts of PDZ4 DNA and GST plasmid DNA for the ligation reaction.  



=
 vectormoles
insert moles
 vectorof size kb
insert) of size (kb x  vector)(nginsert ng       
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According to the Fast-Link protocol, insert to vector ratios (2:1), (5:1) and 
(10:1) are most likely to give positive results, that’s why three different ligation 
reactions were prepared at the time.  
Fast-Link DNA Ligation Kit from Epicentre® was used containing Fast-Link 
DNA Ligase, 10 X Fast-Link ligation buffer and ATP. Based on protocol, final 
ligation reactions were set up according to Table 2.4. 
component (2:1) (5:1) (10:1) 
10 x Fast-
Link ligation 
buffer 
1.5 µL 1.5 µL 1.5 µL 
10mM ATP 1.5 µL 1.5 µL 1.5 µL 
Vector DNA 2.0 µL 2.0 µL 2.0 µL 
Insert DNA 0.4 µL 1.0 µL 2.0 µL 
Sterile 
deionized 
water 
8.6 µL 8.0 µL 7.0 µL 
Fast-Link 
DNA ligase 
1.0 µL 1.0 µL 1.0 µL 
Total 
volume 
15.0 µL 15.0 µL 15.0 µL 
 
Table 2.4 Fast-Link ligation conditions 
Actual incubation time at room temperature was 20 min instead of the 
suggested 5 min, since length of incubation can be extended with no deleterious 
effects. All three different ligation reactions were then transferred into heat block 
at 70 °C for 15 min to inactivate the Fast-Link DNA ligase, a very important step, 
since failure to inactivate ligase may decrease transformation efficiencies. 
2.8.5.15 Chemical transformation of E. coli cells. The Epicurian Coli BL-21 
Gold competent cells were transformed with DNA plasmid from ligation reactions 
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previously described. The protocol followed was the one provided in the 
Instruction Manual for the transformation of BL-21 Gold competent cells, from 
Stratagene®. After thawing the competent cells on ice, three aliquots 3 x 100 µL 
were placed in 3x15 mL pre-chilled falcon tubes. The whole amount of each 
ligation reaction mixture (15 µL) was added to the falcon tubes accordingly. The 
tubes were then incubated on ice for 30 min. The transformation reactions were 
then heat-pulsed in a 42 ° C water bath for 20 seconds. Since duration of the 
heat pulse is critical for optimal transformation efficiencies, an optimum was 
observed in the 20-25 s range. Reactions were then incubated on ice again for 2 
min. 0.9 mL of SOC media (stored at -80 ° C and allowed to thaw on ice prior to 
use) were added to all three samples, and then they were incubated at 37 °C, 
with shaking for 1 h 15 min. Transformed cells were concentrated by centrifuging 
at 10,000xg for 10 min. 750 µL of media was removed, and the cells were 
resuspended in 250 µL of the media that was left. Aliquots (3 x 15 µL) of each 
transformed cells were spread evenly onto LB/amp50 plates using sterile 
spreaders. The plates were placed upside-down in the incubator for 30-45 min, 
until the media was dried and then flipped and incubated for 37 °C overnight. 
2.8.6 Isothermal titration calorimetry (ITC) experiments. Calorimetry 
experiments were performed with a VP-ITC titration calorimeter (Microcal, Inc., 
Northampton, MA). The protein samples were extensively dialyzed for at least 24 
hours in the experimental buffer prior to experiments. The peptides used in the 
study were dissolved into the same dialysis buffer as that of the protein samples 
in each experiment. The pH of both solutions was measured at room temperature 
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using the pH-meter. The instrument was calibrated using three standard 
solutions of pH 4.0, 7.0 and 10.0 before measurements. The pH of peptide 
sample was corrected to perfectly match that of the protein sample. Differences 
of less than 0.02 pH units were considered a perfect match. The standard buffer 
for the calorimetry experiments was 10 mM sodium phosphate, pH 7.0 in case of 
PDZ1-2. Different buffer conditions were also tried for PDZ1-2 (20 mM MOPS, 10 
mM NaCl, pH 7 or 20 mM HEPES, 10 mM NaCl, pH 7).  For the different proteins 
tested in this study various buffer conditions were used 20 mM MES, 10 mM 
NaCl, pH 6.0 for PDZ1, PDZ2 and PDZ3 titrations. The standard experimental 
temperature was 25 °C. Solutions were degassed for 15-45 minutes under 
vacuum, without stirring, at a temperature a few degrees less than that of the 
experiment using the ThermoVac instrument. 
For a typical titration, 65−150 µM samples of the PDZ protein were placed 
in the 1.4 mL reaction cell while 1.0−4.0 mM peptides were loaded into the 290 
µL injection syringe. The c value, defined by Wiseman et. al. to be the product of 
the association constant for the reaction, K, and the macromolecule 
concentration, M, varied from 1 to 500. Each titration experiment consisted of a 
first (1 or 2 µL) injection (which was not used in data fitting) followed by 5 or 10 
µL injections performed at 3 minutes intervals. The stirring speed used was 270 
rpm and the reference power 10 µcal/sec. Heats of dilution were measured in 
blank titrations by injecting the peptides into the buffer used in the particular 
experiment. These results were used to correct the binding heats. This correction 
could sometimes be performed by taking the average of the last 5 microinjections 
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at the end of titration.  Also, control experiments were performed by injecting the 
buffer into the buffer and the PDZ protein into the buffer. 
2.8.6.1 Analysis of the ITC Data The data from each titration experiment were 
collected by the ORIGIN software (version 5.0, MicroCal Inc.). Thermodynamic 
parameters were determined by non-linear least-squares fitting for One Set of 
Sites, Two Set of Sites and Sequential Binding Sites model (all being standard 
model analysis in the Origin software used).  
2.9 Results. 
2.9.1 Subcloning of PDZ4 domain MUPP-1 into pGEX-2T vector. Primers for 
the PCR reaction were designed according to the known sequence of MUPP-1 in 
the pcDNA plasmid. This plasmid was used as a template for the polymerase 
chain reaction. Primers were designed to hybridize the sequences flanking the 
PDZ4 encoding region, in order for it to be isolated and amplified. The PDZ4 
product from PCR was then ligated into the GST/PDZ4-containing plasmid in 
which the PDZ3 domain of PSD-95 was removed by restriction digest. Bam HI 
and Sal I restriction sites in the PDZ3 sequence were utilized for the removal of 
the PDZ3 domain from the plasmid. Recognition sites for these two enzymes 
therefore must be engineered into the PCR primers, so complementary ends 
could be created for ligation of the PDZ4 (MUPP-1) fragment into the donor 
plasmid. 
When designing PCR primers, two other issues were taken into account. 
First, before the actual restriction, endonuclease recognition site series of short 
oligonucleotides were added in order to increase cleavage efficiency. Second, 
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primer lengths were increased by 9 extra oligonucleotides on both the forward 
and reverse PCR primers, outside the actual gene for PDZ4 (MUPP1), in order to 
ensure the accuracy of the obtained sequence. The DNA sequences for both 
forward and reverse primer are shown below. Primers were obtained from 
Invitrogen. 
PDZ4FOR     5’- CGC GGA TCC ATG GGA ATT AAC TAT GAA ATA G -3’ 
PDZ4REV     5’- A CGC GTC GAC TCA GGT GGG TGG CAC AG – 3’ 
The PCR was run using the “hot start“ protocol, in which the primers and 
the nucleotide bases were separated from the polymerase and the template by a 
thin wax layer. The actual composition of the reactions and the set up of the 
thermocycler are described in detail in the experimental section (section 2.2.5). 
Both the PCR product (calculated length 303 bp) and the GST vector 
(approximately 5 kb length), were digested using restriction enzymes. Bam HI 
and Sal I cut the sequence in such way that it leaves ‘sticky ends’ and facilitates 
insertion of the desired fragment. 
The Fast-Link DNA Ligation Kit (Epicentre) was used as described in 
detail in the experimental section (2.2.5.14). After chemical transformation of 
competent cells, 15 µL aliquots of each of transformed cells were spread evenly 
onto LB/amp50 plates and left for overnight growth. Only a single colony was 
spotted on a plate that had (5:1) ratio of ligated transformants. The colony was 
used to inoculate 10 mL of TB/amp50 media. After incubation and subsequent 
extraction of the plasmid, it was sent for DNA sequencing. Results confirmed that 
it had the right insert (PDZ4), and that the subcloning was successful. 
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2.9.1.2 GST-PDZ4 expression and purification. This was a rather challenging 
task of expressing and characterizing PDZ domain of MUPP-1 (Multi PDZ-
domain Protein), a structurally uncharacterized protein consisting of 13 PDZ 
domains, with no obvious catalytic activity, for which no binding studies had been 
performed. The protein domain chosen (PDZ4 of MUPP-1) needed to be 
produced in higher quantities, and to do so the well-established glutathione-S-
transferase (GST) Gene Fusion System (Amersham Pharmacia) was selected. 
The GST tag from Schistosoma japonicum has been successfully used to 
express a significant number of proteins [150]. It has the advantage of relatively 
easy isolation from the other proteins expressed in the cells by using its 
glutathione substrate in the affinity column. The high affinity of GST for 
glutathione is important in the purification of this protein (and those fused to it) 
from the mixture of proteins expressed in the bacterial cells.  
Expression of PDZ4 in the E. coli cells in the form of a GST fusion showed 
that it was mostly present in the insoluble inclusion bodies of the bacterial isolate. 
In an attempt to generate soluble protein, chemical lysis of the cells containing 
GST-PDZ4 fusion protein (using B-PER® bacterial protein extraction reagent 
from Pierce) was employed. The approach was intended as a milder way to 
break the bacterial cell membranes, in order to avoid any ‘precipitating’ 
processes and to access a higher concentration of the protein in the soluble 
form. Unfortunately, no soluble protein was harvested. However, the results are 
not surprising; in a comparative study done in the lab for a known protein 
expressed in high yield when sonication was used to rupture the cells, B-PER® 
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bacterial protein extraction gave poor results (Dorina Saro Ph.D. dissertation, 
WSU). A possible explanation lies in the composition of the reagent that contains 
a mild, nonionic detergent in 20 mM Tris-HCl (pH 7.5) buffer. 
A refolding procedure was also applied to the GST-PDZ4 from the 
inclusion bodies, but was not successful in isolating the protein in a properly 
folded form. The reason for this is likely related to the fact that the mixture of 
reduced and oxidized glutathione (which is considered a redox shuffling agent for 
disulfide bond formation [151]) is also a substrate for the GST tag of the fusion 
protein, so it cannot produce the correctly folded protein. 
2.9.2 Expression and purification of recombinant PDZ1-2 of PSD-95 
Although considerable effort was spent on expressing and characterizing 
individual PDZ domains (constructs PDZ1 and PDZ2), the main focus of this 
research study is the tandem PDZ1-2 domain. To the best of our knowledge this 
dual domain was never expressed in this fusion vector. Previous attempts made 
in the group resulted in the fragmented polypeptide, not a fully functional protein.   
The E. coli bacterial cells that were chemically transformed with pGEX-2T 
vector encoding the GST-PDZ (PDZ1, PDZ2 or PDZ1-2) fusion protein were 
used for overexpression of this protein. The vector is constructed in such a way 
that the gene that encodes for the GST enzyme (26 kDa protein) is fused to the 
N-terminal of PDZ protein. There is an engineered thrombin cleavage site in 
between the GST and the PDZ sequence that is used for proteolytic separation 
of these proteins. pGEX-2T vector contains an ampicillin resistance gene that 
allows the growth of the transformed bacterial cells in ampicillin containing 
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media. The protein expression from a pGEX plasmid is under the control of the 
tac promoter, which is induced using the lactose analog isopropyl β-D-
thiogalactoside (IPTG).  
The expression and purification of PSD-95 PDZ proteins (PDZ1, PDZ2 
and PDZ1-2 tandem) were successful and provided high purity samples as 
determined by SDS-PAGE analysis. However, in terms of final protein amounts 
and stability, considerable differences were observed. In particular, in the case of 
PDZ2 by itself, the required concentration of the protein for binding studies by 
ITC couldn’t be achieved. 
The plasmid PGEX-2T, used for the expression of GST-fusions, was 
engineered with the thrombin cleavage site LVPRGS on the C-terminal of GST. 
This serine protease cleaves after Arg or Lys residues in the sequence P4-P3-
Pro-Arg ↓ P1’-P2’ where P3 and P4 are hydrophobic amino acids and P1’ and 
P2’ are nonacidic amino acids. In the experiment, however, trypsin (a less 
specific protease) was used for cleavage reaction. Assuming that trypsin would 
have cleaved the fusion after any arginine or lysine residue, different results for 
mass spectra analysis of individual PDZ domains were expected. 
2.9.2.1. Expression and characterization of individual PDZ1 and PDZ2 and 
PDZ1-2 dual domain. For PDZ1 the yield of the fusion protein was 
approximately 120 mg/mL of bacterial culture, as determined by Coomassie® 
plus-200 Protein Assay (Bradford assay). After cleavage and further purification 
as described in detail in the experimental part, approximately 15 mg of protein 
91 
 
was isolated (value obtained based on three assays UV measurements (λ = 
280nm), Advanced Protein Assay and Coomassie plus-200 Protein Assay). 
The determined molecular weight for trypsin-cleaved PDZ1 by ESI-MS 
was 10,067±1.55 Da, which was 109 units less than calculated value of 10,176 
Da based on thrombin cleavage (95 amino acid residues). 
PDZ2 fusion protein yields for GST-PDZ2 were slightly lower than for 
GST-PDZ1, approximately 100 mg of protein per liter of bacterial culture 
(Coomassie® plus-200 Protein Assay). However, final purification provided a very 
low yield of pure PDZ2 (high purity sample as confirmed by SDS-PAGE) of only 
approximately 4.5 mg. Even an attempted concentrating of the sample still gave 
a very low concentration. When such samples were utilized for ITC binding 
studies against several of the high affinity peptides, the obtained data could not 
be processed. Saturation of the protein was reached within a few microinjections 
of a highly concentrated ligand. Therefore, the obtained results could not be 
interpreted. Further studies should focus on stability of the PDZ2 under the 
conditions tested. 
The determined molecular weight for trypsin cleaved PDZ2 by ESI-MS 
was 10,111.98±2.71 Da, which was the same as the calculated value based on 
thrombin cleavage (97 aa). 
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MW MW Yield fusion Final protein   amino acid 
residues (calculated) (mass. 
spec) 
(mg/L 
culture) 
(mg/L 
culture) 
PDZ1 95 10,176 10,067 120 15 
PDZ2 97 10,111.96 10,111.98 100 4.5 
 
Table 2.5 Protein yield and mass for PDZ1 and PDZ2. 
Expression and purification of the PDZ1-2 dual domain actually provided 
the highest quantities when compared to results from single PDZ domain 
expression attempts. As determined by the Bradford assay, approximate  yields 
were 200 mg from 1 L of cell culture. 
 
 
 
 
 
 
 
Figure 2.5 Separation steps for isolation of fusion protein, approximately 46 kDa 
from soluble cell lysate. Lanes: 1, molecular weight marker; 2, soluble cell lysate; 
3, cell pellet after lysis; 4-6, fusion protein extractions I, II, III, respectively; 7, last 
load. 
A major concern of the PDZ1-2 dual domain, with regard to the five amino 
acid linker region between PDZ1 and PDZ2, was that the attempted cleavage 
with trypsin (protease of choice) would result in ‘over-cleaving’ and separate the 
two domains. This was based on the previous results obtained in the laboratory. 
However, optimization of the cleavage reaction finally resulted in a protocol 
1     2     3     4    5    6     7 
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utilizing 1:7000 trypsin to protein ratio, and a reaction time of 2.5 h at room 
temperature. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Showing trypsin cleavage, reaction for 2,5h, (1:7000) trypsin to 
protein ratio used. Lanes: 1, molecular weight marker; 2, fusion protein; 3-6, 
reaction aliquots taken out after 1 h,1.5 h, 2 h, 2.5 h, respectively. 
In the Figure 2.6 shown above are the results from trypsin cleavage 
reaction (1:7000), determined after series of analytical scale cleavages with 
varying enzyme to protein ratios and incubation times.  
              
Figure 2.7 Final purification of PDZ1-2. MW- Molecular weight markers.  Final 
PDZ1-2 purified samples in lanes marked f1 and f2, which corresponds to ion 
exchange fractions of 100mM and 150 mM of NaCl. 
 
1     2     3     4     5      6 
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Final separation is shown in Figure 2.7. Gels in this figure contain the 
elutions from the ion exchange column. The GST portion, approximately 27 kDa, 
began eluting with the start buffer, at an ionic strength of 10 mM. The PDZ1-2 
dual domain eluted in later fractions at higher ionic strengths of 100 and 150 mM 
NaCl. The isolated PDZ1-2 domain is shown in lane labeled f1 and f2. 
2.9.3. Energetics of binding of separate PDZ1 and PDZ2 with peptides 
derived from their natural ligands. The initial design of peptides mimicking 
natural binding partners for the first two PDZ domains, was mainly focused on 
already reported results for protein-protein interactions of PSD-95. 
The first in hand was PDZ1 and peptides based on binding sequences of 
best known binders were tested by ITC in 20 mM MES, 10 mM NaCl, pH 6 
buffer. Figure 2.8 shows a typical isotherm (top panel) of titration of a peptide into 
a solution of PSD-95 PDZ1. The binding reactions are exothermic, and integrated 
heats of reaction for the data in Figure 2.8 (top panel) are shown as a binding 
curve in Figure 2.8 (bottom panel).  
A non-linear least-square fit of the binding curve gives the stoichiometry 
(n), equilibrium dissociation constant (Kd), and the change in enthalpy (ΔH) for 
binding interaction. These parameters (ΔH and Kd) were used to calculate the 
free energy of binding, ΔG, and change in entropy, ΔS, using equations (1) and 
(2). The solid line shown in the Figure 2.8 (bottom panel) is the best fit for one of 
the reaction performed at 25 °C. Three different peptide sequences 
corresponding to C-terminus of natural binding partners were tested against the 
PDZ1.The ITC results are summarized in the Table 2.6 and Table 2.7. 
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Figure 2.8 A representative thermogram of binding of PDZ1 with the 
AKAVETDV peptide in MES buffer pH 6 at 25 °C.  
 
Among the natural binders of PDZ1 of PSD- 95, the first series of peptides 
studied by ITC were synthesized based on C-terminal sequence of K+ channels 
of the Shaker type Kv1 family. The first two peptides, comprising 8 amino acid 
residues, were designed to probe the molecular recognition of binding. The C-
terminal ends with Thr-Asp-Val; having Thr at -2 and Val at position 0 is 
consistent with the Class I PDZ domain binding preferences. The last two 
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ligands, an octapeptide and a hexapeptide, are derived from the NMDA receptor 
NR2b subunit. This is one of the most well studied interactions of PSD-95 and is 
critical for a number of neuronal functions, such as synaptic transmission and 
synaptic plasticity. The best binder was proven to be that possessing the Kv1.4 
sequence, with a Kd of 5.93 µM, and which was slightly enthropically driven with 
ΔH of -4.42 kcal/mol. The potassium ion channel Kv1.3-derived sequence 
exhibited almost two times less binding affinity for PDZ1, with a Kd of 13.9 µM, 
with favorable enthalpy and similar contributing entropy. 
Association with the octameric C-terminal NR2b subunit peptide was 
weaker than expected, with Kd = 11.2 µM, and the interaction is primarily driven 
by a favorable change in entropy, TΔS = 3.88 kca/mol. Surprisingly, the 
hexapeptide had diminished signal, and no thermodynamic parameters could be 
calculated. 
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Kd ∆H -TΔS ΔG Peptide 
(µM) (kcal/mol) (kcal/mol) (kcal/mol) 
n c* 
AKAVETDV 5.93 ± 0.02 -4.42 ± 0.14 -2.71 ± 0.14 -7.13 ± 0.01 1.09 ± 0.03 17 
IKKIFTDV 13.9 ± 0.5 -3.51 ± 0.12 -3.11 ± 0.14 -6.62 ± 0.02 1.25 ± 0.01 7 
LSSIESDV 11.2 ± 0.7 -2.87 ± 0.04 -3.88 ± 0.01 -6.75 ± 0.04 0.84 ± 0.13 9 
SIESDV no detectable binding 
Table 2.6 Thermodynamic parameters for peptides based on potassium channel proteins (Kv1.x) 
Kv1.4 and Kv1.3 and on NMDA receptor (NR2a subunit). 
 
Kd ∆H -TΔS ΔG Peptide 
(µM) (kcal/mol) (kcal/mol) (kcal/mol) 
n c* 
KKKETEV 10.9 -3.02 -3.75 -6.77 1.63 9 
Table 2.7 Thermodynamic parameters for peptides based on consensus sequence for PDZ3. 
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Of all the three protein domains, PDZ2 was proven to be the least stable. 
The quantities of isolated pure protein were too low, and insufficient for ITC 
studies. Protein was dialyzed into 20 mM MES, 10 mM NaCl, pH 6, conditions 
that were observed to stabilize the PDZ1. In numerous attempts, during ITC 
titrations protein sample would precipitate in the cell. A huge shift in baseline 
could be observed, and it was impossible to integrate the data. Randomly, it was 
possible to collect a whole data set and thermogram of a single experiment was 
shown below (Figure 2.9).  
 
Figure 2.9 Thermogram of PDZ2 titration with AKAVETDV peptide. 
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When treated with a Single Binding Site model from Origin software this 
data set gave an n value of 0.5. Normally this would point to a binding 
stoichiometry wherein two peptides associate to each equivalent of protein. This 
in itself would be unlikely based on what is presumed about the binding behavior 
of individual PDDZ domains. In this case, however, there are experimental 
concerns such that this value is more likely attributable to an inadequate protein 
concentration estimate, or is indicative of the protein sample not being entirely in 
its native, folded state. 
PDZ2 was not pursued in further experiments; this was due to such poor 
yields at the end of the long purification, which could not be improved through 
optimization efforts, and because of its poor stability (protein precipitates after 2 
days at 4 °C).  
2.9.4. Energetics of binding of the PDZ1-2 dual domain. 
PDZ1-2 data was collected in 10 mM sodium-phosphate buffer, pH 7 at 25 °C. 
For data processing all three models provided by Origin software were used 
(One Set of Sites, Two Set of Sites and Sequential Binding Sites). The best 
model fitting, as judged by the χ2 value, was achieved using the Single Site 
binding model. This provided a stoichiometry of n = 1 (Table 2.8). This was not 
expected, based on the presence of two binding sites in the PDZ1-2 dual 
domain. Consequently, the thermodynamic data was hard to interpret from a 
biochemical perspective, and further studies were focus on obtaining the 
structure of tandem PDZ1-2 of PSD-95.
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Table 2.8 Tables thermodynamic parameters for peptides based on natural binding sequences of Kv1.4.
Kd  ∆H  -TΔS  ΔG  Peptide 
(µM) (kcal/mol) (kcal/mol) (kcal/mol) 
n c* 
AKAVETDV 3.86 ± 0.08 -4.25 ± 0.33 - 3.13 ± 0.31   -7.38 ± 0.01 1.12 ± 0.01 14 
KAVETDV 4.81 ± 1.93 -4.41 ± 0.09 -2.88 ± 0.18  -7.29 ± 0.27 1.03 ± 0.05 21 
AVETDV 2.81 ± 0.21 -4.60 ± 1.08 -2.57 ± 1.12 -7.56± 0.04 1.11 ± 0.14 41 
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2.9.5 Binding of PDZ1-2 to modified cyclic peptide ligands.  
CN2180 is one of several modified peptides designed to bind to PDZ3 of 
PSD-95, part of a larger program to develop novel cellular probes to investigate 
the in vivo roles of various PDZ domain-mediated interactions. CN2180 is a 
nontraditional form of cyclic peptide in which the ring bridges two side chains 
residues via a β-alanine linkage (Figure 2.10), and the sequence based on that of 
the CRIPT protein (KNYKQTSV), a known binder of PDZ3. Based on a simpler 
cyclic peptide structure that itself had been shown to exhibit good binding to 
PDZ3 [128], CN2180 contains two additional N-terminal residues and a myristic 
acid moiety to promote membrane permeability (Figure 2.10). 
 
 
 
 
    Figure 2.10 Chemical structure of the N-myristylated cyclic peptide CN2180. 
Although CN2180 was originally designed to bind PDZ3, screening (with a 
N-biotinylated version of CN2180) against a membrane-bound array of 96 
different PDZ domain constructs demonstrated that significant binding also 
occurred with PDZ1-2 (Dr. C. Rupasinghe, Ph.D. dissertation). This screen was 
based on the binding of ligand to solid-phase immobilized protein, and thus might 
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not have represented a true solution interaction. With the prospects of identifying 
a new binding ligand for PDZ1-2, as well as the newly discovered 
neuroprotective activities that CN2180 has exhibited (unpublished results, DJ 
Goebel, CN Rupasinghe and MR Spaller), there were compelling reasons to 
conduct a calorimeteric binding study of the system. 
Experimentally, these studies proved more onerous than the earlier ones 
utilizing linear peptide. The previous ITC data for the PDZ1-2 dual domain was 
collected using final dialysis buffer conditions of sodium phosphate (10 mM, pH 
7), which was proven to stabilize the protein. Numerous attempts were made to 
dissolve CN2180 under these conditions. ITC experiments were carried out 
varying the concentration of peptide, even at very low values (0.5 mM), only to 
observe diminished signal and precipitate at the end of the titration. Different 
buffer compositions were also tried (10 mM MOPS; 10 mM HEPES) at pH 7, and 
for all of them CN2180 was insoluble. In an attempt to match the conditions of 
previously obtained data for PDZ3 of PSD-95 binding to the same ligand (where 
Kd = 8µM), following purification PDZ1-2 sample was dialyzed against the same 
final buffer (20 mM, 10 mM NaCl, pH 6). These final conditions yielded titration 
curves suitable for subsequent analysis (Figure 2.11). 
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Figure 2.11 ITC thermogram and integrated data with fitted curve for 
PDZ1-2 titration with CN2180. 
 
Calorimetric binding analysis was performed in the same manner with the 
previously described work. Data was treated with all three models: One Set of 
Sites, Two Set of Sites and Sequential Binding Sites. After applying the Single 
Binding Model, it became clear that the stoichiometric n value is 2, meaning that 
both binding sites on the tandem PDZ1-2 are fully occupied. However, fitting of 
the data improved significantly if Sequential Binding Sites model was 
implemented, as judged by χ2 values. Therefore, it is clear that the Sequential 
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binding Sites Model gives the best description of the experimental data (Table 
2.8). 
Thermodynamics of the  
first binding site 
Thermodynamics of the  
second binding site 
Kd  
(µM) 
ΔH 
(kcal/mol) 
-TΔS 
(kcal/mol) 
ΔG 
(kcal/mol) 
Kd          
(µM) 
ΔH 
(kcal/mol) 
-TΔS 
(kcal/mol) 
ΔG 
(kcal/mol) 
6.09 
±3.13 
-0.37 
±0.09 
-6.83 
±0.25 
-7.20 
±0.34 
9.00 
±0.95 
-1.16 
±0.21 
-5.73 
±0.27 
-6.89 
±0.48 
 
Table 2.8 Thermodynamics for CN2180 binding to PDZ1-2. 
 
The data reflect the outcomes of three independent measurements. It is 
apparent that CN2180 populates both binding sites in PDZ1-2 tandem with the 
fairly good binding affinity for each domain (Kd1 = 6 µM and Kd2 = 9 µM). Although 
two different values are obtained, the model fitting does not allow a specific 
assignment to be made as to which is that of PDZ1 or PDZ2. These values are 
comparable to the previously obtained result for PDZ3 (Kd1 = 8 µM), and thus 
make this compound a reasonably effective inhibitor of the PSD-95 interaction 
with the NMDA receptor (NMDAR). 
2.9.5.1 CN2180 and PDZ1-2. A key organizing protein in the postsynaptic 
density of the excitatory synapses is PSD-95. Especially important is the role it 
plays in coupling NMDAR to intracellular proteins and signaling enzymes [152, 
153]. It has been known that through its second PDZ domain (PDZ2), PSD-95 
binds the COOH-terminus, tSXV motif of NMDAR NR2 subunits as well as 
neuronal nitric oxide synthase (nNOS) [91, 153] This binding couples NMDAR 
activity to the production of nitric oxide (NO), a signaling molecule that mediates 
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NMDAR-dependent excitotoxicity [154]. Previous studies have shown that 
NMDAR activity is not suppressed by genetically disrupting PSD-95 in vivo [155] 
or by suppressing its expression in vitro [156]. Complete PSD-95 deletion 
dissociates NMDAR activity from production of NO and suppresses excitotoxicity 
[156].   
NMDARs mediate ischemic brain injury [157], but targeting them has been 
proven deleterious in humans and animals [158-160] Targeting PSD-95, which is 
downstream of the NMDAR and would not be expected to impact other NMDA-
induced pathways, therefore represents an alternative therapeutic approach for 
diseases that involve excitotoxicity. Genetic mutation or reducing expression 
levels of PSD-95 is therapeutically impractical; therefore an attractive alternative 
approach would be perturbing its interaction with NMDARs in order to suppress 
excitotoxicity and ischemic brain damage. This might be achieved by intracellular 
introduction of ligands that bind to PDZ2 of PSD-95. In this case, CN2180 has 
proven to be a strong lead compound, based on its potential inhibiting of all three 
PDZ domains of PSD-95. Because CN2180 is myristylated, it is more 
bioavailable than a non-modified peptide, and its diffusion and uptake capacity by 
neurons in intact tissues should be enhanced.   
In a follow up study, CN2180 was tagged with fluorescein (FITC) to yield 
CN3205, and administered via intravitreal injection at the maximal effective dose 
to monitor its rate of diffusion of the retinal ganglion cells (unpublished results, 
CN Rupasinghe, DJ Goebel, MR Spaller). This is a common approach since 
NMDA-induced neuronal cell death has been extensively studied in the retina. 
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Results showed that as early as 1 hr following injection, uniform fluorescent 
staining was noted in the inner half of the retina, and that by 2 hrs, intensely 
stained vacuoles could be seen within select cells in the ganglion cell layer 
(GCL). Although further testing needs to be done in order to determine to what 
extent these cells express PSD-95, the fact that diffusion and localization of the 
modified peptide into putative NMDA-receptive cells occurs within a 2 hour time 
frame indicates that this preincubation period is sufficient for testing the 
neuroprotective properties of these compounds against NMDA-receptor 
mediated cell death. 
With the impressive biological properties of CN2180 now documented, the 
calorimetric results serve as an absolutely essential step towards fully 
characterizing this compound. The solution data make it clear that CN2180 is 
capable of binding both PDZ1 and PDZ2, and in so doing provide evidence for a 
mechanism by which the observed activity takes place. Although other possible 
cellular binding sites cannot be absolutely ruled yet, the combination of the ITC 
data, in conjunction with the absence of binding to other non-PSD-95 PDZ 
domains on the 96 domain array, strongly suggest that PSD-95 is indeed the in 
vivo target. 
2.9.5.2 In vivo retinal cell death model. NMDA-induced neuronal cell death has 
been extensively studied in the retina [161, 162]. Our laboratory conducted 
studies in collaboration with Dr. Goebel, WSU. Relying on previously published 
data [161] it was proven that following a moderate insult (20 nmol NMDA injected 
intravitreally) only 70-85% of the retinal ganglion cells and a significant number of 
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amacrine cells are lost.  Extensive research in the past few years in the Goebel 
laboratory improved this in vivo NMDA-toxicity model and also led to 
development of several quantitative assays to monitor biochemical, physical and 
energy dependent/independent pathways that are believed to be linked to the cell 
death pathway [163]. This includes measuring PARP-1 activation (believed to be 
linked to the process of necrosis), loss of plasma membrane selectivity (a 
process directly linked to necrosis), DNA cleavage using TUNEL labeling, 
endogenous ATP pools as well as ganglion cell survival.  This system offers 
several advantages to in vitro systems, with the most significant of them being 
that we can monitor the cell death process in an intact, living animal.  
In their previous work, Goebel et al have established a baseline for all of 
the above assays using NMDA-treated and control eyes; they have been able to 
assess putative neuroprotective compounds using this model and have recently 
reported that inhibition of PARP-1 activity, using the potent inhibitor PJ-34, 
abolished NMDA-induced PARP-1 activation in the retina, blocked NMDA-
induced loss of endogenous ATP and provided some neuroprotection to retinal 
ganglion cells.  However, this blockade did not attenuate NMDA-induced loss of 
membrane selectivity or prevent TUNEL labeling [163]. 
A different set of experiments has shown that blockade of CaMKII-αB 
completely abolishes NMDA-induced TUNEL labeling and did provide significant 
neuroprotection of retinal ganglion cells; however, this treatment had no effect in 
blocking PARP-1 activation nor loss of membrane selectivity of neurons in the 
ganglion cell and Inner nuclear layers of the retina (Goebel et al, manuscript in 
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preparation). Collectively, these studies clearly indicate that the pathway leading 
to cell death is complex and that it can no longer be confined to the classification 
of being necrotic or apoptotic.  
All the results presented in the following (chapter 2.3.6.2) represent the in 
vivo work done in Dr. Goebel’s laboratory. Only finalized data representations 
were outlined as a strong indication of CN2180 biological potential. 
2.9.5.2.1 CN2180 and CN2097 reduce NMDA-induced poly(ADP-ribosyl)ation 
(PAR) in a dose-dependent manner. Two compounds were tested in this study; 
myristylated peptide CN2180 (detailed description given in paragraph 2.3.6. of 
this dissertation) and its poly-Arg derivative (CN2097), designed to enhance its 
diffusion and uptake capacity by neurons in intact tissues. These two compounds 
were individually administered into the vitreal chamber of the left eye of male 
Spague-Dawley rats at designated doses 2 hours prior to the retina being 
exposed to a second injection containing an excitotoxic dose (20 nmol) of the 
glutamate agonist N-methyl-D-aspartate (NMDA) in the presence of the 
corresponding dose of the peptide (CN2180 or CN2097).  The companion eye 
(right eye of each animal) served as either the positive or negative control.   
Four hours following NMDA insult, the animals were decapitated (to 
eliminate any potential anesthetic influence on the results of the assay) and 
retinas were individually homogenized and processed for the detection of 
poly(ADP-ribosy)lation (an indicator of enhanced PARP-1 activity) as previously 
described [163].  
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Results show that both CN2080 and CN2097 reduce NMDA-induced 
poly(ADP-ribosy)lation (PAR) of large molecular weight proteins. Dose-response 
data shows that although both compounds did lower PAR-formation, the poly-Arg 
derived peptide (CN2097) was roughly 10 times more effective than the 
myristylated compound (CN2180).  Interestingly, a myristylated randomized-
cyclic peptide (of the same size; CN3500) administered at the optimal effective 
dose determined for CN2180 and CN2097, showed no significant decline in 
NMDA-induced PAR-formation. 
The obtained data is a clear indication that the decline in NMDA-induced 
PAR-formation is KNYKKTEV peptide-dependent, and that competitive binding to 
the PDZ domain of PSD-95 (or related proteins) containing this domain, aids in 
diminishing NMDA-induced PARP-1 activation.  This is consistent with the 
understanding that PSD-95 is linked to nNOS (neuronal nitric oxide synthetase), 
which generates nitrous oxide (NO) within the neuron.  It has been hypothesized 
that NO hyperstimulates PARP-1 activation in response to NO-free radical 
induced DNA-strand breaks [164] and that this response leads to the loss of 
plasma membrane permeability properties (i.e. necrosis) [163, 165].  
2.9.5.2.2 CN2180 and CN2097 attenuate NMDA-induced loss of plasma 
membrane selectivity. Same method as described in the previous chapter was 
employed to assess NMDA-induced loss of plasma membrane selectivity (LPMS) 
following NMDA insult in the presence of CN2180 or CN2097 and compared with 
NMDA-treatment alone or with retinas treated with the non-specific peptide 
CN3500 followed by NMDA insult as a control. LPMS is visualized by the ability 
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of ethidium bromide to pass through the affected neuron’s plasma membrane 
and stain the cell. This process has been shown to be an NMDA-dependent 
process, as retinas treated with buffer alone, or those that were untreated are not 
responsive to neuronal ethidium bromide staining [163].  
Retinas pre-exposed to CN2180 or CN2097 subsequently were subjected 
to NMDA insult. These samples showed a significant reduction in the density of 
ethidium bromide-stained cells in the ganglion cell layer (GCL), as compared with 
retinas treated with NMDA alone. This decrease in ethidium bromide staining 
density was shown to be dose dependent, and peptide-specific as the 
myristylated randomized cyclic peptide (CN3500), given at the same dose, had 
no effect in blocking NMDA-induced LPMS. Consistent with the PAR data above, 
the poly-Arg peptide (CN2097) provided almost complete blockade of ethidium 
bromide staining in the GCL and inner nuclear layers, whereas the myristylated 
peptide given at its maximum dose only partially attenuated LPMS.  
Presented data support the hypothesis that NMDA-induced cell death is 
mediated by the NMDA-receptor’s linkage to PSD-95 and shows, for the first 
time, that disconnection of the NMDA-receptor from PSD-95, through competitive 
binding of the peptide-ligand(s) with the PDZ-domain of PSD-95 (or similar 
protein), renders the NMDA-receptive neurons insensitive to NMDA-induced 
LPMS (necrosis). 
2.9.5.2.3 CN3205-FITC localizes to select subpopulations of retinal neurons 
that reside in the ganglion cell layer (GCL) and inner nuclear layer of the 
retina. Another cellular probe was developed by tagging the myristylated peptide 
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CN2180 with fluorescein (FITC: CN3205) and administered via intravitreal 
injection at the maximal effective dose (6 nmol/eye) to monitor its rate of diffusion 
into the retina.  Results showed 1 hr following injection and after 4 hrs, numerous 
cells showed preferential accumulation of the tagged peptide and were intensely 
stained in both the GCL and inner nuclear layer (INL) of the retina (Fig 2.12). 
Interestingly, this intense staining of the cells (in both layers) appears to be 
selective, as there were neighboring cells in both layers that did not fluoresce 
above tissue background levels (Fig 2.12).  Furthermore, the staining and density 
patterns of the cells that accumulated CN3205 showed strong similarities to 
those neurons that are susceptible to NMDA-induced LPMS. 
In the Figure 2.12 panel (a) 4 hrs following intravitreal injection of 12 nmol 
of CN3205 shows specific uptake into cells located in the ganglion cell layer and 
by 6 hrs (b) the staining density of labeled cells appears to parallel the staining of 
cells that are susceptible to NMDA-induced excitotoxcity as detected by ethidium 
bromide.  (c) Detection of CN3205 in ganglion cells was noted as early as 2 hrs 
following treatment and shows that the compound is localized to the cytoplasm. 
Panel (d) depicts the ability of the peptide to penetrate the retina radial sectioning 
of the retina shows that there is extensive staining in cells located in the ganglion 
cell layer (GCL) as well as in cells located in the inner portion of the inner nuclear 
layer (INL) (arrows).  
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Figure 2.12. Uptake of FITC-labeled KNYKKTEV peptide (CN3205) in the retina 
Although these findings are preliminary and will require further 
investigation to determine whether the stained cells are NMDA-receptive, and 
more importantly express PSD-95, the fact that diffusion and localization of the 
modified peptide into putative NMDA-receptive cells occurs within a 2 hour time 
frame indicates that this preincubation period is sufficient for testing the 
neuroprotective properties of these compounds against NMDA-receptor 
mediated cell death.  
2.9.5.2.4 CN2097 attenuates NMDA-induced loss of retinal ganglion cells. 
Based on the data presented, there is a strong indication that disruption of the 
PDZ binding disconnects NMDA-receptor activation from initiating the cell death 
signal for the short term (up to 4 hours following insult). However, it was still not 
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clear whether this short-term protection was transient or if it does provide long-
term neuroprotection.  To assess this, a series of animals were treated in such a 
way that the left eye received the optimal dose (3 nmol) of CN2097 followed by 
NMDA treatment 2 hours later and the right eye received NMDA alone or left 
untreated. Two weeks following insult each animal was surgically administered 
the retrograde tracer fluorogold. Retinas were harvested and photographed. 
Fluorogold (FG)-labeled cells densities were then determined at each eccentricity 
and then compared with the densities obtained from the companion eye (for full 
methodology [163]). 
  
   
Figure 2.13. Representative fluorogold labeling of retinal ganglion cells sampled 
from the same region of the retina at 1-2 mm from the optic nerve head are 
shown.   
 
First panel (Fig. 2.13) shows the NMDA treated retina (20 nmol) and a 
dramatic reduction in ganglion cell density of surviving ganglion cells is visible.  In 
the second panel retinas were pretreated with 3 nmol CN2097 for 2 hrs followed 
by 20 nmol NMDA w/ 3 nmol CN2097 (3nmol CN2097/NMDA) and show a 
dramatic increase in ganglion cell density which was essentially indistinguishable 
from the regional density of the untreated retina (Untreated labeled) third panel 
on Fig 2.13. 
114 
 
 
Preliminary results from 2 retinal pairings show that CN2097 provides 
significant neuro-protection against NMDA-induced ganglion cell loss (Fig. 2.13 
and 2.14).  In comparing cell densities from the CN2097/NMDA-treated retinas 
with those obtained from retinas that were untreated little differences at each 
eccentricity were observed between the two treatment conditions (Fig. 2.13 and 
2.14).   
 
      
Figure 2.14 Effect on CN2097 pre and post insult was induced (NMDA) 
 
Figure 2.14 represents retinal pairings (n=2), where one eye was 
pretreated with 3 nmol CN2097 and 2 hrs later treated with 20 nmol /NMDA were 
compared with companion retinas treated with NMDA-alone show that CN2097 
offers almost full protection against NMDA-induced ganglion cell loss when 
compared with the densities found in untreated retinas (n=4).   
Although the full analysis of these experiments are still forthcoming, 
indications from the two retina pairs analyzed here indicate that the competitive 
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binding of CN2097 to the PDZ-binding domain does offer almost complete 
protection against NMDA-induced ganglion cell loss and indicates that the 
interaction of the NMDA receptor subunits to a PDZ containing protein (PSD-95) 
is the initiator of the cell death signal that mediates both necrosis and apoptotic-
like pathways. 
2.10 Discussion  
The primary focus of this dissertation is exploring the nature of PDZ 
interactions, with the special interest in domain organization and multiplicity. As 
stated before, although modular in design, PDZ domains are often linked in 
groups within a multi-PDZ protein. Our work has confirmed previously reported 
data that the first two PDZ domains in the PSD-95 of the MAGUKs subfamily are 
immediately adjacent to each other and form a protease-resistant unit. The 
functional significance of such linkages is still uncertain, although it has been 
studied extensively lately. 
2.10.1 PDZ1 and PDZ2 domain binding characteristics Our first aim was 
examining the postulated ability of the combined PDZ1-2 of PSD-95 to show 
significantly different binding specificity for C-terminal sequences than did the 
individual PDZ1 and PDZ2 domains [166]. We possessed both domains (rat 
ortholog sequence) expressed in E. coli and purified. PDZ1 and PDZ2 belong to 
Class I based on their preferred binding partner, and we recognized that there 
may be similar recognition properties based on this fact alone when testing the 
binding of our peptide ligands. 
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To evaluate binding to the short peptide ligands, we employed isothermal 
titration calorimetry (ITC). ITC has been successfully used to characterize the 
binding interactions in the case of protein domains like Src homology 2 (SH2) 
and Src homology 3 (SH3). ITC presents great advantages over other methods 
(see Chapter I), as it characterizes the molecular interactions with the native, 
unmodified form of macromolecules in solution. It allows the measurement of 
thermodynamic parameters; namely, the change in enthalpy (ΔH), binding 
constant (Kd), and stoichiometry (n) from a single experiment. The change in 
Gibbs free energy (ΔG) and change in entropy (ΔS) can be calculated using 
equations (1) and (2) respectively. ITC is a method of choice extensively used for 
binding studies of PDZ3 of PSD-95 and published in our lab, Saro et al.[136, 167] 
Lacking structural information for our PDZ1/PDZ2 system, which is 
abundant for PDZ3, we have relied on yeast two-hybrid results published earlier 
and well-described interactions with the NMDA receptor. A series of short peptide 
ligands, corresponding to the C-termini of endogenous binding partner proteins, 
were designed and tested against each individual domain. PDZ1 showed 
characteristic binding parameters, similar to PDZ3 reported for its natural binding 
partners [167]. Among the natural binders of PDZ1 of PSD-95, the first series of 
peptides studied by ITC were synthesized based on C-terminal sequence of K+ 
channels of the Shaker type Kv.1 family. The first two peptides (8 amino acid 
residues) were designed to probe the molecular recognition of binding. The C-
terminal ends with Thr-Asp-Val ; and having Thr at -2 and Val at position 0 is 
consistent with the Class I PDZ preferences. The last two peptides (8-mer and 6-
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mer) are derived from the NMDA receptor NR2b subunit. This is one of the most 
well-studied interactions of PSD-95, and is critical for a number of neuronal 
functions such as synaptic transmission and synaptic plasticity. The best binder 
proved to be that derived from the Kv1.4 sequence, with Kd of 5.93 µM, and with 
a slightly enthropically driven of -4.42 kcal/mol. Potassium ion channel Kv1.3 had 
almost two times reduced binding preference for PDZ1, Kd of 13.89 µM, with 
favorable enthalpy and similar contributing entropy (Table 2.6 and 2.7). 
Interaction with the octapeptide derived from the C-terminus of the NR2b 
subunit was weaker than expected at Kd of 11.2 µM, and the interaction is 
primarily entropic at 3.88 kcal/mol. Surprisingly, the hexapeptide sequence 
exhibited a diminished signal, and no thermodynamic parameters could be 
calculated. Results for all the natural PDZ1 binders show the changes in the 
enthalpy (∆H) and in the entropy (∆S) for the binding of the peptides to the PDZ3 
protein were favorable, reflected in an enhanced, i.e., negative change, in Gibbs 
free energy (∆G) for the interaction. These findings are consistent with binding 
affinities for PSD-95, and comparable to the extensively studied PDZ3 [168] 
interactions with its natural binding partners. 
PDZ2, on the other hand, was unstable during titration and would 
precipitate in the cell. After extensive trials, only a few complete datasets were 
collected due to these problems. These showed a binding stoichiometry of 0.5, 
which clearly denotes a problem with the samples; we hypothesized that the 
protein is poorly folded and all binding sites are not fully functional (Fig. 2.9). 
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Since our primary focus was on PDZ1-2 we have discussed individual domain 
data merely in a context of control experiments. 
2.10.2. PDZ1-2 dual domain binding characteristics. The PDZ1-2 dual domain 
had expressed well and demonstrated an increased stability as compared to the 
single domains. Binding thermodynamics of the peptide ligands based on the 
potassium ion channel Kv1.4 sequence provided some interesting functional 
insight.  
Sequence truncation of peptide binders (from 8 to 6 residues) did not 
diminish binding affinity, which would indicate that the maximum contribution of 
binding is found in the residues of the hexapeptide. Results (Table 2.8) were 
comparable to data for the single PDZ1 domain. The dual domain showed an 
increased affinity of Kd = 3.86 µM for the AKAVETDV peptide, as opposed to Kd 
= 5.93 µM for PDZ1. Changes in ∆H and in ∆S for the association of the peptides 
with the domain had roughly similar values, although binding entropy was very 
unfavorable (TΔS = -3.13 kcal/mol) indicating a substantial loss of degrees of 
freedom upon binding (Fig. 2.15). 
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Figure 2.15. Binding energetic of PDZ1-2 domain to its natural derived peptides. 
When integrating the ITC data, each of three models were applied (the 
One Set of Sites (OSS), the Sequential Binding Sites (SBS), and the Two Sets of 
Sites (TSS) models, each as implemented in the Origin program). In addition to 
assessing whether the assumptions of each model made biochemical sense, the 
chi-squared (χ2) value was used as the primary criterion for the data fit. OSS 
yielded the best fitting of the binding isotherm, which appeared contradictory at 
first, since there are two binding sites in the domain. Taking into account all our 
data presented, we can only conclude that these two binding sites are not equally 
exposed or properly folded. Our results are in good agreement with published 
work by Cierpicki et al.[169] investigating the dual PDZ domain of syntenin. Their 
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crystallographic data showed that peptide binds to a single binding pocket. No 
electron density was observed for the lower affinity domain. Their NMR titration, 
however, showed that peptides bind to both PDZ1 and PDZ2, although the 
magnitudes of the associated chemical shift changes differ significantly. The data 
are consistent with fast exchange kinetics and relatively weak affinities [169].  
At this point, it is worth mentioning that although ITC represents a very 
powerful technique with all its numerous advantages (outlined in Chapter 1) it is 
often hard to deconvolute the heat signal. Therefore, any interaction beyond the 
simplified 1:1 binding stoichiometry is challenging, especially since the relevant 
literature is very scarce. Work presented on dual domain binding, such as 
presented in this dissertation, is unique in the field. At the same time it was clear 
that without the proper structural information on PDZ1-2 tandem of PSD-95, it 
would be extremely difficult to progress with binding studies. Our efforts toward 
solving the structure of the dual domain are discussed in detail in Chapter 3 of 
this dissertation. 
 2.10.3. PDZ1-2 dual domain binding to modified cyclic peptide ligand 
(CN2180). In an ongoing effort to develop new cellular probes for in vivo 
investigations on the nature of protein-protein interactions, our lab has chosen 
PSD-95 as a target of interest. This is due to the extensive biological information 
available, and especially due to its important roles in the functioning of the post-
synaptic density of neuronal cells.  Initially designed to bind PDZ3, modified 
ligand CN2180 was developed and synthesized by Chamila Rupasinghe in the 
Spaller lab. CN2180 is a cyclic peptide based upon KNYKQTSV, in which the 
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ring bridges two side chains residues via β-alanine linkage (Figure 2.7). An 
elaboration of a simpler cyclic peptide structure that itself had been shown to 
exhibit good binding to PDZ3 [128], CN2180 contains two additional N-terminal 
residues and a myristic acid moiety to promote membrane permeability. 
However, screening (with a N-biotinylated version of CN2180) against a 
membrane-bound array of 96 different PDZ domain constructs demonstrated that 
comparable or enhanced binding occurred with the PDZ1-2 dual domain of PSD-
95. 
In light of the exquisite results that we were observing for the biological 
activity of CN2180 and its derivatives (in collaboration with Dr. Goebel, WSU), in 
parallel we have tested in vitro binding to the dual domain PDZ1-2 by ITC. After 
applying the OSS curve fitting, it became clear that the stoichiometric n value is 
2, meaning that both binding sites on the tandem PDZ1-2 are fully occupied. 
However, fitting of the data improved significantly if SBS model was implemented 
(details Appendix C), as judged by χ2 values. Therefore, it is clear that the 
Sequential binding Sites Model gives the best description of the experimental 
data. 
CN2180 populates both binding sites in the PDZ1-2 tandem, with fairly 
good binding affinity for each domain (Kd1 = 6 µM and Kd2 = 9 µM). Although two 
different values are obtained, the model fitting does not differentiate between the 
binding sites. These values are comparable to the previously obtained result for 
PDZ3 (Kd1 = 8 µM), and thus make this compound a reasonably effective inhibitor 
of the PSD-95 interaction with the NMDA receptor (NMDAR). 
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2.10.3.1. In vivo validation of CN2180 activity. Thermodynamic validation of 
CN2180 binding to PDZ1-2 represents a strong support of the in vivo tests 
carried out in rat retinal model. CN2180 peptide and its polyArg counterpart 
(CN2097) showed strong activity in the NMDA-induced stressed neurons. 
Decline in NMDA-induced PAR-formation is KNYKKTEV peptide-dependent, and 
that competitive binding to the PDZ domain of PSD-95 (or related proteins) 
containing this domain, aids in diminishing NMDA-induced PARP-1 activation.  
This is consistent with the understanding that PSD-95 is linked to nNOS 
(neuronal nitric oxide synthetase), which produces NO within the neuron. Also, 
results shown indicate that NMDA-induced cell death is mediated by the NMDA-
receptor’s linkage to PSD-95 and connect this finding, for the first time, that 
disconnection of the NMDA-receptor from PSD-95, through competitive binding 
of the peptide-ligand(s) with the PDZ-domain of PSD-95 (or similar protein), 
renders the NMDA-receptive neurons insensitive to NMDA-induced necrosis. 
More extensive analysis of these experiments is still forthcoming, although 
indications from the two retina pairs analyzed here clearly point out that the 
competitive binding of CN2097 to the PDZ domain-binding domain does offer 
almost complete protection against NMDA-induced ganglion cell loss and 
indicates that the interaction of the NMDA receptor subunits to a PDZ containing 
protein (PSD-95) is the initiator of the cell death signal that mediates both 
necrosis and apoptotic-like pathways. 
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2.11 Conclusions  
The central purpose of this dissertation research was to investigate 
multiplicity in PDZ domain binding, and our system of choice was a biologically 
critical and abundant protein in the cytoplasm of neuronal cells, PSD-95. Since 
the broader goal of our laboratory was exploring the nature of PDZ interactions, 
both monovalent and multivalent, we had independently expressed three 
separate constructs: PDZ1, PDZ2 and PDZ1-2. A series of peptide ligands 
derived from the C-terminus of natural binding partners were synthesized and 
tested against all three proteins. In the case of PDZ1, association of these 
peptide ligands is driven by dominant favorable enthalpic contributions to the 
binding free energy. The interactions are usually entropically favorable. The 
reported assoiciation constant are in good agreement with the previously 
published fluorescence data [170].  
PDZ2 did not express well in recombinant form from bacteria, and it was 
likely misfolded, and therefore the resulting ITC binding data with peptide ligands 
was inconclusive. Future efforts in this area should perhaps focus on using the 
full-length (uncut) GST-PDZ fusion for binding studies. Although GST fusion 
proteins can dimerize, the alternative would be the preparation of other types of 
fusion protein, such as with maltose-binding protein (MPB) or NusA and use 
these for the binding studies. 
The dual domain PDZ1-2 showed strong binding preferences toward the 
same ligands, although a stoichiometry of n=1 clearly points out that only one 
binding pocket equivalent is occupied. In the case of a very strong binding to 
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modified peptide CN2180, the stoichiometry of n=2 indicated favorable 
orientation and occupancy of both binding sites of the domains. We should not 
rule out, however, the possibility of CN2180 binding to a remote site on the 
surface of tandem domain, although there is no biochemical evidence in the 
literature relating to PDZ domains that would suggest this. A lack of structural 
information for the intact dual domain in complex with ligands encouraged our 
efforts to crystallize and solve PDZ1-2 tandem structure, further discussed in 
detail (Chapter 3). CN2180 showed very promising biological activity and efforts 
are ongoing in this direction. 
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CHAPTER 3 
 
PRELIMINARY STRUCTURAL STUDIES OF THE TANDEM PDZ1-2 DOMAIN 
PROTEIN OF PSD-95  
PSD-95 is one of the key proteins in the postsynaptic density. Although, its 
individual domains have been structurally characterized, PDB deposition for dual 
PDZ1-2 is only modeled. Also, ITC data was very difficult to interpret without true 
structural insight. In this Chapter we report for the first time successful 
crystallization of dual PDZ1-2 of PSD-95. This study was carried out in 
collaboration with Dr. Ladislau Kovari, WSU. The work is featured in a 
manuscript that is in preparation. 
3.1. PDZ domain protein crystallography 
X-ray crystallography represents a very powerful method used to 
determine the three dimensional structures of the major biomacromolecules, 
namely, proteins, DNA and RNA and their complexes. The information provided 
by a crystal structure is fundamental in explaining the biological function of 
macromolecules.  Obtaining detailed pictures of large molecules at the molecular 
and atomic level was practically impossible before employing the technique of 
single-crystal X-ray crystallography [55, 171, 172]. This method utilizes diffraction 
of X-rays from many identical molecules in an ordered array of a crystal. It is 
important to point out that proteins mostly retain their fold, and therefore their 
function, in the crystal form, therefore obtaining high resolution structures helps 
in our understanding of proteins’ biological functions in terms of their binding 
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properties and thermodynamics. A detailed explanation of the technique is 
provided in Chapter 1 of this dissertation.  
3.1.1. PDZ domain structures. There have been a considerable number of PDZ 
domain structures, currently on the order of 200, deposited in the Protein Data 
Bank (PDB). This includes those solved by either X-ray crystallography or NMR; 
at least 120 of them were obtained by the former technique. The vast majority of 
these are structures of just the PDZ domain substructure subcloned from their 
larger parent protein, which indicates that this class of domain is relatively stable 
under laboratory conditions and well suited for structural studies. It also indicates 
that even though they might possess a similar three-dimensional fold, there exist 
many differences in each particular PDZ domain in both the free or complexed 
forms as revealed by these structures. Most importantly, these structures have 
contributed tremendously to our understanding of the biological role of these 
relatively small protein modules.   
3.1.1.1 The general structural form of the PDZ domain. The numerous entries 
in the PDB databank illustrate vast interest in these PDZ proteins, but also 
underlie the importance of understanding protein domain organization in general. 
Most importantly, these studies helped in formulating the rules of peptide (protein 
binding partner) recognition, which is essential for their biological function. One of 
the first studies that revealed the molecular recognition events taking place in the 
PDZ mediated complex formation involved solving the X-ray crystallographic 
structure of PDZ3 of PSD-95 complexed with a nonapeptide ligand derived from 
the PDZ3 binding partner, CRIPT protein [88].  
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The crystal structure (Figure 3.1) of PDZ3 comprises six β strands (βA-βF) 
and two α-helices (αA and αB), which fold in an overall six-stranded β sandwich. 
Four residues of the ligand’s C-terminal region have been shown to interact with 
the peptide-binding groove between the βB strand and αB helix as an antiparallel 
β strand extending one of the β sheet. The C-terminal hydrophobic residue valine 
at the “0” position of the peptide binds to the hydrophobic pocket created in the 
PDZ domain by several hydrophobic residues, which are Leu323, Phe325, 
Ile327, and Leu379 [88]. The tight contact of the side chain of valine with the 
hydrophobic pocket explains the preference for the sequence having a 
hydrophobic residue at the “0” position. Another critical interaction is the 
hydrogen-bonding interaction of the hydroxyl group of the “-2” threonine with N3 
of His372 (first residue of the αB helix). The side chain of the “-1” Ser residue is 
shown pointing away from the interacting surface. 
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 Figure 3.1 Stereo view of the peptide binding site demonstating protein –
peptide interactions [88]. 
 
The peptide (yellow) inserts between the β strand and β helix and forms 
an antiparallel sheet with βB. The connecting loop between αB and βB is 
involved in binding the peptide C-terminus and therefore is designated the 
carboxylate-binding loop.˚ 
More recently, crystal structure of the same protein at higher resolution 
was solved by Dorina Saro in Spaller lab. Two different structures of PDZ3 
complexed with hexapeptides KKETWV and KKETPV were deposited, with PDB 
codes 1TP5 and 1TP3, respectively. The method employed in both cases was 
that of molecular replacement (details in Chapter 1). Figure 3.2 depicts the 
domain in association with KKETWV (shown in dark blue) and its position 
between β strand and β helix. 
Molecular Basis of Peptide Recognition by PDZ
1071
Figure 4. Chemical Interactions Involved in Peptide Binding
(A) Stereo view of the peptide-binding site demonstrating protein–
peptide interactions via hydrogen bonds (dashed white lines) and
the location of the Val 0 side chain in the hydrophobic pocket.
Oxygen atoms are shown in red and nitrogen atoms in blue. The
green sphere shows a well-ordered water molecule linking the car-
boxylate group to Arg-318. The picturewas drawn with MOLSCRIPT
and Raster3D.
(B) Schematic view of the contacts identified in the crystal structure
of the complex. Dashed lines represent hydrogen bonds, and the
two closest atom-to-atom distances between the Val 0 side chain
and all atoms in the hydrophobic pocket of the PDZ domain are
drawn as solid black lines. The Val 0 side chain makes numerous
other Van der Waals contacts within the range of 3.9 to 4.3 A˚;
however, for clarity they are not indicated in this diagram. The fixed
orientation of the arginine guanidinium head group via hydrogen
bonds with backbone carbonyl groups is also shown.
sequence Glu-Thr-Asp-Val-COO!) with PDZ-2 from peptide residue at position !1, on the other hand, has
been shown to be functionally unimportant and is poorlyPSD-95 in which the histidine residue (corresponding
to position 372) is conserved (Kim et al., 1995). The conserved among the C-termini of membrane proteins
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Figure 3.2 Ribbon diagram showing PDZ3 complexed with KKETWV, 
PDB code 1TP5. Ligand shown in dark blue. Image generated by Protein 
Workshop. 
 
Crystals of PDZ3 soaked with KKETWV peptide diffracted at high 
resolution, 1.54 Å. The structure of the PDZ3/KKETWV complex represents the 
highest resolution structure of the PDZ3 of PSD-95 available, and one of the 
highest resolution structures of all PDZ domains solved to date. These structures 
reveal the specific interactions that play an important role in the PDZ3 recognition 
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of these ligands. Even though these peptides have similar sequences and 
identical residues at the critical “0” and “-2” positions, they still bind to PDZ3 
domain with different thermodynamic properties and this is a result of the 
structural differences in each complex formation.  
Structural studies have also discovered important biological functions of 
these domains. The differences in C-terminal peptide recognition between class I 
and II PDZ domains became clear with the information from the complex 
structures of PDZ domains of each class [88, 120, 173, 174]. The recognition of 
internal sequences by some PDZ domains were also revealed from structural 
data [121, 122]. The effect of chaperoning and intermolecular interaction of PDZ 
domains with each other [122, 174-176] is one aspect of PDZ function known 
from the structural data. Novel structural features of PDZ domains, like the 
presence of alternative binding pocket [177], or novel mode of peptide 
recognition by a PDZ domain [178], have also become clear from analysis of 
crystallographic and NMR structural information. Diverse biological functions of 
PDZ domains were discovered from structural studies as well. One example of 
this is the study of DegS stress sensor PDZ domain that recognizes misfolded 
proteins and activates the proteolytic activity of this enzyme [179]. To further 
explain this behavior, the function of PDZ domains in DegP (or also known as 
HtrA) protease might be very similar, as described by Krojer et al. [180], 
indicating a possible general mechanism of recognition and binding of misfolded 
proteins by PDZ domains. 
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Interestingly, the most precise crystal structure of a protein known so far is 
the PDZ2 domain of syntenin protein. This structure is defined at ultra-high 
resolution of 0.87 Å with crystallographic refinement values of R = 7.5% and Rfree 
= 8.7% [181]. These refinement values are typically much higher for protein 
structures (in the range of 20 to 25% for well-refined structures)[182] and closer 
to the small molecule refinement, “bridging the gap” [181] between the two fields. 
Being an ultra-high resolution structure, the model of PDZ2 of syntenin also 
shows important features of protein structures like the flexibility of the peptide 
bond, and the presence and stereochemistry of weak C−H---O hydrogen bonds 
[181].  
3.1.1.2 Dual or tandem PDZ domains. An important question for which the 
answer remains largely unknown and that we have tried to address is the manner 
of binding action for multiple PDZ domains. Specifically, this entails the form 
involving two vicinal PDZ domains, which are referred to as tandem or dual 
domains. Such tandem forms may be critical for the biological activity of the 
protein in which they are found. Examples include neuronal nitric oxide synthase 
(nNOS) [183] and the cystic fibrosis transmembrane conductance regulator 
(CFTR) protein [110, 184, 185].  
In the case of PDZ1-2 from PSD-95, which is a focus of this dissertation 
research, isothermal titration calorimetry data yielded results that were difficult to 
interpret. Using different experimental conditions, it appeared that only one 
peptide ligand was binding to the dual PDZ1-2 domain. These finding were 
discussed in detail in Chapter I. Also, thermodynamic experiments have their 
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own limitations and could not answer some important questions: how do tandem 
domains bind to similar targets, and where does the difference in specificity come 
from? These questions are best answered by structural methods using a tandem 
PDZ1-2 domain as a target to crystallize in both the free and ligand bound forms. 
Postsynaptic density protein-95 (PSD-95; also known as synapse 
associated protein 90(SAP 90))[85] found in high concentrations at the post 
synaptic densities of dendritic spines. All the members of this family consist of 
three PDZ domains, followed by one SH3 domain and one guanylate kinase 
homology (GK) domain Figure 3.3. 
 
 
 
Figure 3.3 Domain organization of PSD-95 protein.  
 
Interestingly enough, a NMR structure of tandem PDZ1-2 domain of PSD-
95 was previously published [186]. However, this was not a true solution 
structure, but the result of modeling the two domains together, each of which had 
been solved independently. The PDZ1 domain NMR structure was also 
previously solved and deposited in the PDB (codes 1iu0 and 1iu2). Relying on 
other experimental results, PDZ2 domain was modeled. A mechanism of binding 
was hypothesized, and modeled as well. This study is the first to characterize the 
three-dimensional structure of a tandem (supramodular) array of PDZ domains.  
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Previously, the same group has solved the free structure of PDZ2 and deposited 
in the PDB (PDB code 1qlc) [187]. 
Although these modeled results are intriguing, it is unclear why an effort 
was not made to solve a true NMR structure of dual domain? One can only 
speculate that it was attempted, but for unreported reasons was not successful. 
In the absence of an explanation from the reporting group, it is not unreasonable 
to suppose that the NMR methodology did not yield solvable information on the 
actual tandem construct. Thus, there remains a large hole in our understanding 
of how the PDZ12 dual domain of PSD-95 is truly structured. The availability of 
this structure would add considerably to our understanding of the endogenous 
binding interactions that PDZ12 engages in. Besides helping to shed light on this 
fundamental character of PDZ12, it would also greatly aid efforts to design novel 
inhibitors that could specifically and simultaneously target both domains. As 
described in Chapter 2 there are profound biological—and potentially 
therapeutic—effects associated with small peptides that target PDZ1 and PDZ2. 
Therefore, a significant effort was expended in attempts to solve the structure of 
the first two PDZ domains of PSD-95 protein by X-ray crystallography. 
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3.2 Materials and Methods  
3.2.1 Materials Crystallization plates were obtained from Nextal Biotechnologies 
Inc. (Qiagen). For fast setup of crystallization conditions screw-in, greaseless 
crystallization supports were used that also provide easier setup and crystal 
recovery. The EasyXtal Tool is supplied as an empty 24 well plate with a capacity 
of 1 mL of solution per well and 24 EasyXtal CrystalSupports. For initial 
screening of crystallization conditions the Wizard™ I&II (Emerald Biosystems) 
was used. Wizard™ I&II screens provided full 96 unique formulations of the 
random sparse matrix for the crystallization of biological macromolecules. A 
Leica GZ7 microscope was used to check the plates after set up and to observe 
the crystallization process. Diffraction data were collected from several crystals 
on a Rigaku/MSC FRD generator/R-AXIS HTC image plate system. Silicon 
Graphics and Monarch Computer Systems Unix box were used for computer 
calculations. 
3.2.2 Methods 
3.2.2.1 PDZ1-2 protein expression and purification The PDZ1-2 dual domain 
of PSD-95 was expressed and purified as described in section 2.3.2.1 of Chapter 
2. 
3.2.2.2 Crystallization of dual PDZ1-2 protein The PDZ1-2 samples were 
dialyzed into the final dialysis buffer (10 mM sodium phosphate, pH 8.0). The 
sample was then concentrated up to 15 mg/mL using Amicon centrifugal filter 
devices 3000 MWCO (Millipore) and stored at 4 °C until needed. Preliminary 
crystallization trials were performed using Wizard™ I&II. The hanging-drop 
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vapor-diffusion technique was utilized. For initial screening, concentrated PDZ1-2 
protein (1 µL) was mixed with an aqueous buffer containing precipitant (1 µL). 
The cover slip with the prepared droplet was inverted over the same precipitant 
aqueous solution (0.7 mL) in the well, and after the set up the plates were 
incubated in the dark under controlled temperature (22 ºC) and humidity 
conditions. After 1-2 weeks micro crystals were observed in three out of 96 
conditions; these were from Wizard™II crystallization screens listed below: 
 
Solution 1: 10% (w/v) PEG-3000 , 100mM acetate( pH 4.5) , 200mM Zn(OAc)2  
Solution 19:  1.6 M NaH2PO4/0.4 M K2HPO4, 100mM phosphate-citrate (pH 4.2)      
Solution 40: 20% (w/v) PEG-3000, 100mM imidazole (pH 8.0) ,200mM Zn(OAc)2 
 
These conditions were repeated, but now with varying protein to 
precipitant ratios (1:1, 1:2, 1:3, 1:4) and with the same ratios for precipitant to 
protein. Chemicals were purchased from following vendors: PEG-3000 (Fluka), 
Zn(OAc)2, NaH2PO4, K2HPO4, imidazole, acetic acid, sodium acetate, citric acid 
(Sigma).  Controls were run alongside with final dialysis buffer.  
Microcrystals were observed only in the drops formed with 10% (w/v) 
PEG-3000, 100 mM acetate (pH 4.5), 200mM Zn(OAc)2. These were further 
optimized resulting in good size crystals (0.2-0.4) mm obtained by mixing 4 µL of 
high purity protein sample (15 mg/mL) with 1 µL of precipitant. Crystals formed 
within one week. Hexagonal PDZ1-2 crystals were stable for approximately three 
months in mother liquor, but started to degrade afterwards. These crystals were 
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directly flash-frozen in liquid nitrogen and preliminary test showed very good 
diffraction. Therefore, it was concluded that the presence of PEG-3000 was 
sufficient and no additional cryoprotectant was needed.  
3.2.2.3 PDZ1-2 data collection Diffraction data were collected from a single 
crystal on a Rigaku/MSC FRD generator/R-AXIS HTC image plate system at 
WSU Medical School. The temperature during data collection was -180 °C due to 
continuous liquid nitrogen stream over the crystal. The crystal-to-detector 
distance was 150 mm. Copper radiation (1.5418 Å) was used. For a complete 
data set, 360 frames with 0.5° oscillation were collected. The exposure time was 
3 minutes for each frame. Diffraction data were collected and processed using 
Rigaku/MSC CrystalClear software. 
3.3 Results 
3.3.1 Crystallization properties of the free PDZ1-2 dual domain The 
conjoined first two PDZ domains (PDZ1-2) from PSD-95 were overexpressed as 
a GST fusion protein and purified using a slightly altered purification protocol. 
The 190-amino acid long tandem domain was separated from the GST affinity 
tag by trypsin cleavage.  After further purification the isolated PDZ1-2 protein 
appeared very stable when stored at 4 ºC, even though it was highly 
concentrated (up to 15 mg/mL).  
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The crystallization setup using optimized conditions (10% (w/v) PEG-
3000, 100mM acetate (pH 4.5), 200mM Zn(OAc)2) as explained in detail in 
(3.2.2.2), provided for well shaped crystals as shown in Figures 3.4 and 3.5. 
                
           Figure 3.4 PDZ1-2 dual domain crystals in a 5 µL hanging drop (crystal 
diameter 0.4 mm). 
 
Figure 3.4 is a photograph of a one week old crystals in the 5 µL drop. Nicely 
shaped hexagonal crystals, well dispersed in mother liquor can be easily 
separated. No skin formation on the drop also made the process of mounting the 
crystal much easier. Crystals were flash-frozen without the additional 
cryoprotectant. 
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Figure 3.5 Single PDZ1-2 crystal. Hexagonal crystals grew in a week in 10% 
(w/v) PEG-3000, 100 mM acetate (pH 4.5), 200 mM Zn(OAc)2. (crystals 0.4 mm). 
 
 
3.3.2 Data collection. The crystals formed were of very good quality and stable 
while flash-freezing in liquid nitrogen. Upon assessing crystal diffraction quality 
by collecting initial frames, obtained diffraction pattern was very good and 
estimated a resolution was high. Therefore, the same crystal was left in the X-ray 
beam for the complete data set collection (360 frames, 0.5º oscillation and 3 
minutes exposure time per frame). A typical diffraction pattern of PDZ1-2 dual 
domain protein is shown in Figure 3.6. 
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 Figure 3.6 Diffraction pattern-single frame of free tandem PDZ1-2. Exposure 
time 3 minutes. 
 
3.3.3 Data reduction. The crystal of PDZ1-2 dual domain protein diffracted at 
good resolution (2.6 Å). A complete data set of 360 frames were collected, 0.5º 
oscillation angle and exposure time of 3 minutes per frame.  This data set was 
collected using a Rigaku/MSC FRD generator/R-AXIS HTC image plate system. 
Data collection and initial processing were conducted using CrystalClear for 
Rigaku. CrystalClear incorporates the concept that data acquisition and data 
processing should be combined. Further data reduction was performed utilizing 
MOSFLM software. MOSFLM processes diffraction images and gives a MTZ file 
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as an output, which contains reflection indices with their intensities and standard 
deviations. This MTZ file is then used by other programs of the CCP4 program 
suite for data reduction, scaling and merging. Table 3.1 lists the parameter 
values after processing data with SCALA from the CCP4 package. These results 
indicate that PDZ1-2 dual domain form cubic crystals that belong to the P23 
space group. This is a high symmetry space group, which, unfortunately, has 
historically proven to be a problem when attempting to solve the structure using 
the molecular replacement method. 
 
Table 3.1 Data collection statistics for the dual PDZ1-2 protein domain 
 
Resolution range (Å)                     29.09 – 2.60         (2.74 – 2.60) 
 
Unit –cell parameters (Å)             a = b = c = 87.2667 Å 
                                                           
                                                     α = β = γ = 90°  
 
Space group                                 P23 
 
Rmerge                                            0.112                     (0.630) 
 
No. of total reflections                  149876  
 
No. of unique reflections              7052  
 
Completeness (%)                        99.9                      (100.0) 
 
Average I/σ(I)                                29.0                      (5.1) 
 
Multiplicity                                     21.3                      (21.4) 
 
Values in () are for the last resolution shell 
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3.4 Discussion 
A PDZ1-2 dual domain protein that was expressed and purified as 
discussed, was successfully crystallized. Purification protocol for this protein was 
altered and explained in detail in Chapter I of this report. This modified 
purification scheme resulted in a highly pure and stable protein. Crystallization 
set-up experiments using optimized conditions (10% (w/v) PEG-3000, 100 mM 
acetate (pH 4.5), 200 mM Zn(OAc)2) explained in detail in (section 2.2.2), 
provided for well-shaped hexagonal crystals. PDZ1-2 crystallizes in cubic P23 
group. Data reduction gave a Rmerge value of 11.2 %, which proves that this was 
a high quality data set.  
We tried to solve the PDZ1-2 dual domain protein structure using the 
molecular replacement method. The rationale for this was that structures of 
several PDZ domains are known and can be used as a model for this technique. 
The first model used was that of the crystal structure of PDZ3 domain of PSD-95 
protein [88], complexed with a peptide ligand. This attempt failed to yield an 
acceptable solution, as this model represents only a single PDZ domain and we 
are looking for the structure of a dual PDZ domain containing protein. The 
structure of another dual PDZ domain protein syntenin was also used in 
molecular replacement calculations, but likewise did not result in a clear solution. 
[188] 
The 1n99.pdb file of PDZ tandem of human syntenin was downloaded 
from the PDB and used as the model (Fig 3.7). The file was modified by 
removing solvent molecules, and used as a model during calculations. In order to 
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ensure that these changes to the template model really occurred, the structure 
was inspected using PyMol display software, and in fact it was confirmed to be a 
single polypeptide chain.  
 
     
Figure 3.7 PDZ 1-2 of synthenin. PDB code: 1N99. Image generated with PyMol. 
The programs utilized for solving the structure were from the CCP4 
package; Refmac 5 was used. The template file was modified with rigid body 
refinement at 4 Å. After the first round of Refmac 5 was successful, a rigid body 
refinement at 3 Å was performed, followed by restrained refinement at 3 Å. This 
round was followed by restrained refinement to the limited resolution. In our case 
that was 2.6 Å. The Mtz output file was created, followed by twenty cycles of 
ARP/wARP and adding water molecules to the structure resulted in file 
10_solvent.pdb. An image from this file is reproduced below in Figure 3.8. 
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Figure 3.8 Image of the 10_solvent.pdb. Image generated with PyMol. 
This image represents mostly a random coiled structure, but it can be 
clearly seen that there are some structured regions. However, this does not 
represent a true solution of the PDZ1-2 tandem domain structure, since R = 47.7 
and Rfree = 52.8. As these values were very high (more than 50%), this indicates 
that the experimental data are not in good agreement with the model. A good 
starting point for R/Rfree values is around 40%, and further structure refinement 
can bring those values down to acceptable values of 20 – 30%.   
Another view of the hypothetical structure denoted 10_solvent.pdb is 
depicted in Figure 3.9. The characteristic fold of PDZ domains of six β-strands 
and two α-helices can be easily visualized in both domains, although for the 
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reasons explained above, this rendering cannot be accepted with confidence as 
a true solution structure. 
 
Figure 3.9 Image of the 10_solvent.pdb. Image generated with PyMol. 
The reason the molecular replacement calculations failed relate to the 
different space groups of the model and our molecule. An alternative way to 
solve this problem would be to use AMoRe [189], another molecular replacement 
program that has the advantage of transforming both the model and the new 
structure into a hypothetical space group and then performing the searches. If 
the molecular replacement methods do not work, then the structure can still be 
solved by another method, like heavy atom derivative or MAD (multiwavelength 
anomalous diffraction). 
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The problem with molecular replacement methods not being able to solve 
the PDZ1-2 structure, despite the fact that there is good quality diffraction data 
available, might be that the PDZ1-2 dual domain crystallizes in a different way 
than the previously known structures. So even though structures of separate 
PDZ domains are known, their relative orientation in the PDZ1-2 dual domain 
might be different and that accounts for significant changes between the model 
and the experimental data that the molecular replacement method cannot 
resolve. 
Since PDZ12 of PSD-95 is a novel unsolved protein, never crystallized 
before, further efforts to solve the structure should focus on using methods other 
then molecular replacement. One way is producing heavy metal derivatives. 
Anomalous scattering methods can be used to calculate phases based on the 
advantage that a heavy-atom can absorb X-rays of specified wavelengths. Also, 
multiwavelength anomalous dispersion (MAD) phasing can be used as an 
alternative to solving the phase problem in crystallography. For this purpose 
selenomethionine derivatives can be used. In this strategy, the protein is 
expressed in media that contains selenomethionine as the only source for amino 
acid methionine.  
GSEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRL
RVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIK
LIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAV
NSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNA 
 
     Figure 3.10. Sequence of PDZ1-2 with highlighted methionines. 
As a result selenium is incorporated as a heavy atom containing amino 
acid in the protein that can be further purified and crystallized as the wild type. If 
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that is successful, than data collection using synchrotron radiation with multiple 
wavelengths can result is solving the phase problem and the crystal structure of 
the protein. 
3.5 Conclusions 
In this thesis chapter, crystallization of a new protein construct, PDZ1-2 of PSD-
95 is reported. Identifying the conditions required to grow crystals is a major step 
forward in efforts to solve this tandem domain by X-ray methods. Significant 
efforts were made to solve the structure using the molecular replacement 
method, but due to specific space group that protein crystallizes in, thus far 
solved models of similar proteins could not be implemented. However, producing 
a seleno-methionine derivative would gain a diffractable crystal and would enable 
to solve the structure of the protein. 
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CHAPTER 4 
 
CHARACTERIZING BINDING PROPERTIES OF Fe(II) BINDING TO 
FRATAXIN  
Further exploring the idea of multivalency and applying ITC as a true 
solution method for assessing affinity of protein–mediated interactions; another 
project was carried out in collaboration with Dr. Timothy Stemmler’s lab at WSU 
Medical School. The study provided greater in depth understanding of cellular 
processes, this time on the example of metal binding to the iron chaperone-
Frataxin. The work presented in this chapter has been published in Biochemisty, 
2006. 
Friedreich’s ataxia (FRDA) is caused by deficiency in the protein frataxin. 
FRDA is as an autosomal recessive cardio and neurodegenerative disorder that 
affects approximately 1 in 50 000 people, as reported by independent studies 
[190-192]. At this rate, it is believed to be the most common autosomal-recessive 
neurodegenerative disease of Caucasians [193]. Frataxin is nuclear-encoded 
protein subsequently localized in mitochondria at the matrix side of the inner 
membrane [194, 195]. Cells depleted of frataxin will have progressive 
mitochondrial accumulation of iron. However, iron deposits are biologically 
unavailable, which leads to further decrease of metal activities – its role in iron-
sulfur cluster enzymes, oxidative damage to mitochondria [196, 197]. Clinical 
picture of iron deficiency in humans manifests through hypertrophic 
cardiomyopathy, degeneration of sensory neurons in the dorsal root ganglia, and 
diabetes mellitus [195].  
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4.1 Mitochondrial iron metabolism Transition metals play a key role in 
regulatory, structural and catalytic properties of the cell [198]. Metal content in 
prokaryotic cells of iron, zinc and calcium is very similar and ranges around 0.1 
mM [198]. The concentration of iron in mitochondria of yeast cells is the same as 
for prokaryotes, which is consistent with its role within the organelle. Iron is 
required for two major pathways in the mitochondria: iron-sulfur (Fe-S) cluster 
and heme assembly. These cofactors are found in key proteins like aconitase 
(Krebs cycle), complex I of the respiratory chain (electron transport) that require 
Fe-S clusters [199] or cytochromes, membrane proteins that utilize heme. 
However, redox ability of the transition metals, iron and copper in particular can 
generate toxic organic and oxide based radicals [200]. Maintaining iron 
concentration within the mitochondria is crucial for cell survival.  
Iron is found ubiquitously in all living systems, although both metal 
deficiency and metal overload are destructive to cells. Through its protein 
controlled mechanisms organisms have evolved, so that iron import can be 
quickly enhanced or suppressed, or finally stored for the future use [201]. In 
humans, Fe obtained from diet is reduced and acidified by the low pH 
environment of the stomach and potion is transported for production of heme and 
Fe-S clusters. More than 2/3 of Fe found in the body is incorporated into 
hemoglobin in developing erythroid precursor cells or in mature red blood cells 
[202]. Such an abundance of heme prosthetic group is absolutely necessary for 
controlling O2 concentration, availability and reactivity. As previously outlined, Fe-
s clusters are another Fe containing prosthetic groups that help control cell 
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viability by taking part in electron transfer events, substrate binding and 
activation, iron and sulfur storage, regulation of gene expression and enzyme 
activity [203]. 
4.2 Heme bisynthesis. Heme is an iron-containing tetra-pyrrole ring system. The 
heme biosynthetic pathway was described in detail during 1950’s and 60’s [204]. 
Heme biosynthesis consists of eight sequential steps [205], four of which (step 1 
and steps 6-8) occur in mitochondria, while the other steps occur in the 
cytoplasm. The final step is the insertion of ferrous ion into porphyrin ring by 
enzyme ferrochelatase to yield a functional heme prosthetic group [206]. In 
prokaryotes, ferrochelatase is found within the cytoplasm or embedded in the 
cytoplasmic membrane [207], as in eukaryotes enzyme is part of the inner 
mitochondrial membrane. In was revealed that ferrochelatase can chelate divers 
divalent metal ions, most prominently Zn2+ [208].  
4.3 Iron-sulfur cluster biosynthesis Fe-S clusters are ancient and complex 
prosthetic group. They are absolutely crucial in electron transport, catalysis, gene 
regulation and iron uptake [209]. In the recent studies various steps of their 
biosynthetic pathways have been revealed, but surprisingly research is still 
ongoing for in depth understanding of particular processes. 
Iron sulfur cluster (ISC) assembly in yeast begins with the liberation of 
sulfur by the cysteine desulfurase, Nfs1 [210]. Nfs1 is an enzyme that contains 
pyridoxal phosphate (PLP) as cofactor, through which it forms Schiff base with 
free cysteine. This is followed by a nucleophilic attack on the cysteine-PLP 
complexby the active site thiolate, releasing alanine [211]. Most recently a small 
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protein Isd11 is identified, believed to act as an adaptor between Nfs1 and 
scaffold proteins thus helping stabilize the complex and promote sulfur release 
[212-214]. In the next step, sulfur is transferred to the cluster assembly scaffold 
proteins, ~ 28 kDa protein dimer constructed of Isu1 (and/or) 2, usually through 
heterotetrameric complexes of the scaffold and the desulfurase [211, 215-217] 
This protein–controlled mechanism prevents toxic effect of iron while enabling 
bioavailability for delivery to the Isu. 
4.4 Disruption of iron homeostasis and Friedreich’s ataxia Friedreich’s ataxia 
(FRDA) is a disease related to the disruption of cellular iron homeostasis [201]. 
First described by a physician Nicholaus Friedreich, FRDA is an autosomal 
cardio and neurodegenerative disorder, and it is the most prevalent inherited 
ataxia. FRDA affects 1 in 50,000 people and is caused by deficiency of the 
protein frataxin (Ftx). The void of Ftx leads to progressive iron accumulation and 
a deficiency in heme and Fe-S clusters, resulting in loss of cell viability and 
eventually patient death. The patients with FRDA (96%) have extensive 
trinucleotide repeat expansions in the first intron of the gene encoding Ftx, while 
small some patients have frataxin point mutations [218]. The expanded GAA 
repeat adopts abnormal DNA structures that impair Ftx transcription; longer the 
repeat, the more profound is the frataxin deficiency and the earlier the onset and 
greater the intensity of the disease [219-221].  
Early symptoms of the disease like loss of coordination, muscle weakness 
and scoliosis usually begin between ages 5 to 15 years. About 20% of patients 
develop diabetes mellitus. Disease is progressive and death occurs during early 
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thirties and mostly (91%) involves cardiomyopathy. At present, there is no cure 
for Friedreich’s ataxia. The treatment is limited to 3 possible approaches [222]. 
One strategy involves antioxidants targeted to mitochondria and recent trials 
include idebenone (proven to delay cardiac dysfunction in mice) and drugs like 
VitQ and MitoQ. Second approach uses iron chelators to protect from peroxide 
induced toxicity (deferoxamine). At last, third approach uses DNA sequence 
specific polyamides and histone deacetylase inhibitors that reverse gene 
silencing [222].  
4.5 Role of frataxin in the mitochondria Frataxin is a nuclear encoded protein 
localized in the mitochondria. This protein is highly conserved from prokaryotes 
to eukaryotes and amino acid sequence identity of yeast frataxin (Yfh1) 
compared to bacterial (CyaY) is 28.1% and to human (Hftx) is 37.8%. Frataxin is 
abundant in tissues with high metabolic rate such as kidneys, liver, brown fat 
neurons and heart [195]. Initial studies of frataxin’s role in maintaining iron 
homeostasis were done on yeast homolog (Yfh1)[223]. Deletion of frataxin gene 
results in accumulation of mitochondrial Fe deposits [223], followed by aconitase 
and general Fe-S cluster protein deficiencies [196, 224]. The presence of zinc 
suppresses iron accumulation phenotypes in yeast [225]. Cells depleted of Yfh1 
were hypersensitive to H2O2, iron and copper levels [223, 224]. However, it was 
also noted that after reintroducing Yfh1 expression under depleted conditions, 
recovery and export of original mitochondrial iron deposits was promoted. 
Therefore, it was proposed that frataxin has a role of directly controlling 
mitochondrial iron efflux [226].  
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Frataxin’s ability to directly bind iron was first identified in the yeast system 
[227]. The same property has been confirmed for bacterial and human orthologs 
[228-233]. Initial hypothesis was that the iron binding in the yeast system induces 
frataxin to oligomerize under unique solution conditions. Numerous reports after 
that have proven that oligomerization is not essential when protein act as a 
chaperone, but it might be necessary when protein participates in helping control 
ROS production under iron overload conditions [234]. Metal to protein 
stoichiometries, measured for monomeric bacterial, yeast and N-terminally 
truncated human frataxin show these proteins will tightly bind 2, 2 and 7 Fe(II) 
atoms, respectively [230, 231, 233]. Iron dissociation constants, measured for 
bacterial (CyaY), yeast (Yfh1) and N-terminally truncated human frataxin (HsFtx) 
give average Kd values of 3.8, 3.0 and 55.0 µM, respectively [230, 233].  
However, the exact role of frataxin is still unclear. Initially, it was believed 
to be an iron regulator, since metal accumulation occurs as a result of its 
depletion [226]. It was also shown that frataxin is involved in energy conversion 
and ATP synthesis [235], also protecting aconitase [4Fe-4S]2+ clusters against 
disassembly and inactivation [236, 237]. Frataxin is involved in the in vivo 
production of heme [238-240] and Fe-S clusters [216, 241, 242].  
In order to characterize binding affinity of monomeric yeast frataxin to 
ferrous ion, isothermal titration calorimetry was used. The research conducted is 
a collaboration project with Dr.Stemmler’s group (WSU, Medical School). In order 
to better understand how frataxin binds iron, besides ITC measurements, nuclear 
magnetic resonance (NMR) spectroscopic analysis was used to further identify 
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amino acids affected by the presence of iron.  Finally, X-ray absorption 
spectroscopic (XAS) studies were used to determine the oxidation and spin-state 
of iron bound to frataxin, as well as help provide structural detail of the binding 
event [233].  
ITC experiments performed so far were done using yeast frataxin (Yfh1), 
wild type protein. Since, there is a high sequence homology and structural 
similarities between protein family members, these results provide additional 
direct insight into general properties that dictate how frataxin orthologs bind iron. 
Besides wild type protein, additional mutant proteins were used. Mutations were 
engineered in order to knock out the assumed binding points for ferrous ion.  
 This project was worth more than 80 ITC experiment. Unfortunately, for a 
lot of them good curve fitting was impossible to achieve.  Working under 
anaerobic conditions, with the presence of a reducing agent requires extreme 
caution; since iron solution readily oxidizes. Experiments were very lengthy due 
to a long equilibration period between injections. 
4.6 Structure of frataxin Human, yeast and bacterial frataxin orthologs have 
their structures deposited in PDB [243-248]. All frataxin variant share structural 
similarity, as expected based on the high sequence overlap. Frataxin structure is 
comprised of two terminal α-helices that make one plane, five antiparallel β-
strands that build a second plane of the protein and a sixth β-strand (even 
seventh in case of HsFtx) that intersects the planes to give an overall planer α-β 
sandwich structural motif (Fig. 4.1).  
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Figure 4.1. Top: ribbon diagram of yeast, human and bacterial frataxin. Middle: 
electropotential plots for proteins in same orientation. Bottom: electropotential 
plots for proteins rotated -90 degrees around the y-axis compared to top display. 
Structure figures made using solution structures of Yfh1 (PDB ID# 2GA5), HsFtx 
(PDB ID# 1LY7) and CyaY (PDB ID# 1SOY) frataxins. 
 
 
As a illustration of the structure similarities between orthologs, RMSDs of HsFtx 
versus CyaY and Yfh1 in regions of secondary structure are 1.34 and 0.65 
respctively [201]. Very interesting property of frataxin structure is a large number 
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of Asp and Glu residues in the N-terminal region. These residues are primarily 
located in the α1 and β1 regions of the protein [201]. In the electrostatic potential 
plots (Fig 4.1), these conserved acidic residues form negatively charged surface 
that covers almost a quarter of frataxin’s total accessible surface [244]. 
Carboxylate Asp and Glu serve as ligands for metal binding, so it is believed to 
be the case for frataxin as well.  
4.7 Mapping iron binding sites of yeast frataxin NMR spectroscopy was used 
to identify frataxin amino acids perturbed by the presence of ferrous iron under 
solution conditions that stabilize the monomeric protein. The goal was to locate 
the region of the monomeric protein affected by the presence of iron with the 
intent to determine which amino acids may be directly involved in iron binding 
[233]. Subsequently, these residues will be subjected to mutations in order to 
further investigate the nature of Fe binding. Ferrous iron titrations performed 
anaerobically with the 15N labeled frataxin orthologs show distinct alterations in 
α1 and β1 amino acid NMR resonances. General trends in amide resonance 
perturbations upon addition of iron can be divided into two categories: amide 
resonances that significantly line broaden (often beyond detection) and amide 
chemical shifts that are shifted in the presence of metal. Yfh1 resonances 
broadened by addition of up to 2 iron atoms include alpha-1 residues Asp28, 
Asp31, His32 and Asp35, the β1 residue Glu61 and the β2 residue Glu61 (Fig 
4.2). 
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Figure 4.2 Mapping binding sites on the frataxin. A) Apo-protein structure with 
helix-1 amino acid side chain atoms from line broadened amide resonances in the 
yeast frataxin NMR iron titration.  Expanded view to the right of arrows. B) Apo-
protein structure with β-sheet amino acid side chain atoms from line broadened 
amide resonances in the yeast frataxin NMR iron titration and D50.  PDB accession 
number 2GA5. 
 
Amide resonances for additional α1, β1 and β2 residues undergo chemical shift 
perturbations in the presence of iron [233, 245]. Ferric iron titrations were 
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performed on CyaY with similar results to those obtained from ferrous iron 
binding.  
Characterizing the metal-ligand coordination geometry and electronic 
properties of bound iron provide additional insight into the metal binding ability of 
the monomeric frataxin orthologs. X-ray absorption spectroscopy (XAS) provides 
a powerful tool for characterizing structural and electronic properties of metals 
bound to proteins in solution [249].This technique has been used to characterize 
iron bound to Yfh1. Analysis of the iron 1s→3d transitions in the X-ray absorption 
near edge structure (XANES) portion of the XAS spectrum are consistent with 
ferrous iron existing in the high-spin state and coordinated in a highly centro-
symmetric metal-ligand coordination geometry when bound to monomeric HsFtx 
and Yfh1 [201, 233]. Structural analysis of the Fe(II)-ligand coordination 
geometry for monomeric Yfh1 and HsFtx from the extended x-ray absorption fine 
structure (EXAFS) portion of the XAS spectrum are consistent with iron bound in 
a highly symmetric 6 coordinate ligand environment. Ligands coordinating Fe(II) 
are exclusively oxygen and/or nitrogen based, in agreement with α1 and β1 Asp, 
Glu and His residues identified in the multiple NMR titrations as residues that 
possibly interact with iron. Additional ligands to the protein bound metal surely 
also come from water or hydroxide ions. There is no evidence for any 
metal•••metal interaction for the ferrous iron bound to monomeric frataxin, even 
when up to 2 metals are bound to Yfh1. 
4.8 Results-ITC measurement of Fe binding to yeast frataxin ITC 
measurements were performed to determine the metal binding affinity and 
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maximum metal to protein stoichiometry of monomeric yeast frataxin.  
Experiments were performed at 30 °C on a VP-ITC titration microcalorimeter 
(Micro Cal Inc.).  Protein and aqueous ferrous ammonium sulfate solutions were 
prepared anaerobically in 20 mM HEPES (pH = 7.0) and 10 mM MgSO4.  
Experiments were designed to keep a ca. 20 fold excess of iron in the syringe 
and data were collected at three independent protein concentrations (100 µM, 70 
µM and 50 µM) corresponding to aqueous iron solutions of 2.5 mM, 1.4 mM and 
0.8 mM, respectively.  Protein samples were loaded anaerobically into the 
sample chamber and after an initial 2 µL iron solution injection, 29 additional 
injections of 10 µL each were titrated into the protein sample.  Spacing between 
injections was 10 minutes and the stirring speed of the syringe was held constant 
at 500 rpm.  All experiments were repeated in triplicate on independent protein 
and iron samples Isothermal titration calorimetry (ITC) measurements were 
performed to measure the to ensure data reproducibility.  The Origin 5.0 software 
package supplied by Micro Cal Inc. was used for data analysis.  Origin 5.0 uses 
non-linear least squares curve fitting algorithm to determine the stoichiometric 
ratio, dissociation constant and change in enthalpy of the reaction. 
4.8.1 Yeast Frataxin Binds Two Iron Atoms at Micro-Molar Affinity. ITC was 
used to provide insight into monomeric yeast frataxin’s iron binding affinity and 
the maximal number of ferrous iron atoms that the protein can bind.  ITC 
measurements were performed anaerobically under solution conditions that 
stabilized the monomeric iron loaded protein.  Changes in heat resulting from 
iron binding are displayed in µcal/sec on the raw ITC data (Figure 4.3A).  These 
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data show a single strong exothermic reaction that follows exponential behavior 
in the early injection points.  Heats at the end of the titration equal those obtained 
from Fe(II) alone, indicating metal binding is complete following the early titration 
points.  Initially, data sets were treated using a model with one set of binding 
sites (Origin 5.0).  The calculated stoichiometry from the fitted curve provided for 
an average of 1.4-1.6 iron atoms per monomeric frataxin.  However, upon 
analyzing the diagram, it was apparent that complete saturation is achieved for a 
2:1 Fe(II) to protein ratio.  Considering also the nature of binding sites in yeast 
frataxin, an advanced curve fitting of two sets of binding sites was employed.  
The theoretical curve for this model resulted in a better fit to the original data 
represented in the metal binding isotherm (Figure 4.3B), and used to determine 
the protein’s metal binding affinity.  After curve fitting analysis, binding affinities 
for both sites was determined to be in the micromolar range (Kd1 = 3.0 ± 0.4 µM 
and Kd2 = 2.0 ± 0.2 µM).  These results indicate the two metal binding sites are 
independent, although they have nearly identical binding affinities. 
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Figure 4.3. Raw isothermal titration calorimetry (A) and binding isotherm 
data (B) for ferrous iron to yeast frataxin. Grey line in panel (A) shows 
baseline and in panel (B) shows the simulated fit to the binding isotherm data.  
Data were collected anaerobically at 30 °C in 20 mM HEPES (pH 7.0) and 10 
mM MgSO4. These data were collected by injecting small aliquots of a 0.8 mM 
ferrous iron solution into a 50 µM Yfh1 sample. Spacing between injections was 
10 minutes. Syringe stirring speed was kept at 500 rpm [233]. 
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4.8.2 Binding Affinity of Mutated Yeast Frataxin Homologs In order to 
investigate the role of individual residues involved in iron binding, different 
mutations were made to the original sequence. Work on the double mutants was 
done in collaboration with Andrew Dancis group at University of Pennsylvania. N-
terminal double mutant (H32A/D35A), showed binding of two iron atoms, per 
molecule of protein.  Binding isotherm is shown in figure 4.4. 
 
          Figure 4.4 Binding of frataxin double –mutant to Fe(II). 
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These results are easily interpreted if the original NMR structure is 
examined [233]. There are a lot of residues in helix-1 being perturbed by the 
presence of iron (shown in red on Figure 4.4), which implies that there are more 
residues that can facilitate metal binding instead of H32 and D35.  
4.9 Discussion  
Frataxin has been hypothesized to play a variety of roles in helping 
maintain cellular iron homeostasis, most of which involve direct binding to iron. 
Frataxin facilitates in vivo heme and Fe-S cluster production and the monomeric 
protein binds to enzyme partners that complete the assembly of these iron-
containing cofactors, suggesting monomeric protein may play a direct role in both 
processes by acting as the iron chaperone [238, 239]. Since a single iron atom is 
transferred during heme and Fe-S cluster assembly, it seems further unlikely that 
frataxin oligomers would participate as the source of metal during delivery. Given 
this rationale, having a structural and biochemical understanding of iron bound to 
monomeric frataxin would help propel the general understanding of how frataxin 
functions towards controlling iron bioavailability in the cell. 
Frataxin's metal binding affinity is similar to those seen for the copper 
chaperones suggesting a common theme in cellular metal delivery if frataxin is in 
fact acting as an iron chaperone. The micromolar dissociation constants 
measured for yeast frataxin, with respect to ferrous iron (Kd's of 2.0 and 3.0 µM), 
resembles those obtained for the human and bacterial orthologs (Kd's of 55.0 and 
3.8 µM, respectively). Ferrous iron binding affinities measured for ferrochelatase 
are also within the micromolar range indicating frataxin's metal binding affinity is 
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closely matched by its protein partner that receives metal. It is therefore 
reasonable to suggest frataxin can act as an iron chaperone during Fe-cofactor 
production. 
4.9 Conclusions 
All three structurally characterized frataxin orthologs bind multiple iron 
atoms with a micromolar binding affinity when the protein exists in the monomeric 
state, which is consistent with a functional role of monomeric protein being 
involved in iron binding and delivery. The weak nature of the protein's metal 
binding affinity (Kd's of 2.0 and 3.0 µM) and the ligand environment utilized by the 
protein when binding metal would be consistent with frataxin acting as an iron 
chaperone; the protein must be able to form a favorable interface with its protein 
partners and also easily release the metal. Additional structural characterization 
will be critical to help elucidate how frataxin binds iron and docks with its protein 
partners to promote metal delivery. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
Our understanding of multivalent effects in biological molecular recognition 
has been extensively broadened by emerging new research involving 
biochemical studies that seek to address the topic. Whether this pertains to the 
binding of two or more peptide ligands to a single or dual domain protein, or the 
binding of multiple metal ions to a protein, there are common themes that unite 
the two. Conceptually, there are binding theories and data treatments that can be 
applicable to both. Operationally, what is also unfortunately in common is the 
degree of experimental difficulty that often accompanies studying such systems. 
But such investigations are necessary if we not only want to understand the 
fundamental molecular recognition properties of these types of systems, but also 
want to apply that knowledge to the discovery and development of cellular 
probes and therapeutic agents that take multivalency into account. This could 
yield ligands that have higher affinity, and improved selectivity, for a given 
biomolecular receptor. The projects outlined in this dissertation, encompassing 
the peptide-protein interactions of PDZ domains, and the iron-binding interactions 
of frataxin, are steps towards understanding multivalency for both fundamental 
knowledge and biomedical application. 
5.1 Protein-Peptide Interactions: PDZ Domains  
Regarding the first project area, PDZ domains have proven to be an ideal 
subject for exploring multivalency, given the incidence of the phenomenon as 
reported in the literature, especially in proteins involved in critical cellular 
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processes. This domain family often appears in proteins situated at neuronal 
synapses, and involved in organizing transduction complexes, clustering 
membrane receptors, and maintaining cell-polarities [96, 250-252]. These 
properties of PDZ domains have been extensively discussed in Chapter 1 of this 
dissertation. In these proteins, PDZ domains are usually present in multiple, but 
not identical, copies. The protein that we have centered our research upon, the 
tandem (PDZ1-2) domain of the N-terminal region of postsynaptic density 
protein-95 (PSD-95), is connected by a five-residue peptide linker between the 
two domains [186]. Our choice for such a spatially proximal domain may allow 
our studies to contribute to understanding other domain constructs so configured. 
For example, a four amino acid residue linker is observed in tandem repeats in 
mammalian syntenins [253] and also in X11s (also known as Mints) [254]. 
Besides these dual repeats, clustering of the first three (PDZ123) and second 
three (PDZ45) domains has been observed in GRIP (glutamate receptor-
interacting protein) and ABP (AMPA receptor-binding protein) [255-257]. 
Evidence is emerging which indicates that tandem PDZ repeats show distinct 
target-binding properties from the individual PDZ domains or from a simple sum 
of the two PDZ domains in the repeats [137, 185, 186, 258-260], although the 
molecular basis of such supramodular properties remains largely unclear.  
The research efforts in our laboratory yielded monovalent [136, 167] and 
cyclic [128] peptides that provided insight into nature of interaction of a single 
PDZ domain (PDZ3 of PSD-95). In brief, we found that relative short peptides, 
with exposed C-termini, are capable of binding to PDZ domains with dissociation 
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constants in the low micromolar range, provided they possess certain sequence 
motifs. Further on, this knowledge led us to validation of a PDZ domain-directed 
molecular probe that functions within human cells [130]. Based on this efforts 
homobivalent ligands were designed and probed against the PDZ3 [261] and 
proven was the formation of the ternary complex. 
The above-mentioned results provided us with the chemical tools to tackle 
the problem of the dual PDZ1-2 domain, although immediately it became clear 
that the nature of the questions we would ask were based on exactly how we 
constructure our bivalent participants; the possibilities for the two-binding site 
architecture is outlined in the schematic Fig 5.1. Our initial focus was to pursue 
studies that would correlate with cases (3) and (4) in that diagram. 
 
                   
             Fig 5.1 Protein domain-ligand combinations for bivalent interactions. 
Reprinted by permission. 
Based on the previous experience in the group, in the reported 
dissertation studies we continue to rely on the extensively used technique of ITC, 
which had been applied towards linear [131, 167] and macrocyclic [128, 129] 
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ligands for the third PDZ domain (PDZ3) of the PSD-95. These studies benefited 
greatly from the advantages of ITC, a pure solution method that provides for 
each of the thermodynamic binding parameters, as well as the stoichiometry of 
the interaction. We have employed the same approach to our protein domains 
PDZ1, PDZ2 and PDZ1-2 tandem.  
Challenging the individual PDZ1 and PDZ2 and dual domains with short 
peptides derived form the C-terminal region of the domains’ natural binding 
partners, we found that only one of the domains remains functional when 
expressed separately. Binding of PDZ1 and tandem PDZ1-2 we were able to 
characterize, whereas PDZ2, despite extensive efforts, could not be stabilized 
under solution conditions to yield a valid binding curve. The PDZ1-2 dual domain 
of PSD-95 therefore functions in the same manner as hypothesized for PDZ1-2 
of GRIP1 [262] or PDZ4-5 of the same protein [263]. We suggest that PDZ2 
induces the folding of PDZ1, stabilizing its structure. The two domains can pack 
closely to each other and form a compact supramodule, which is the case in 
GRIP1 [263]. Alternatively, they might be partially restrained to promote 
synergistic target binding, as in the case of syntenin [176]. Our ITC data for the 
binding of PDZ1-2 to natural binding partners supports the hypothesis that PDZ2 
binding groove is distorted and probably cannot bind C-terminal peptides, which 
is in good agreement with the published work for syntenin [169].  
At the same time, in an ongoing effort to develop new cellular probes for in 
vivo investigation of multiprotein assembly, we studied modified ligand CN2180 
(designed and synthesized by Dr. Chamila Rupansinghe) which targets the 
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tandem PDZ1-2 of PSD-95. This cyclic peptide showed striking biological activity, 
which was thoroughly described in section 2.9.5.1 of Chapter 2. Our in vitro 
testing by ITC of the same peptide after integrating the binding isoterm, yielded a 
stoichiometry of n=2, indicating that both binding sites are fully occupied. Affinity 
for the interaction is Kd1 = 6 µM and Kd2 = 9 µM, for each domain. These values 
are comparable to the previously obtained result for PDZ3 (Kd1 = 8 µM), and thus 
make this compound a reasonably effective inhibitor of the PSD-95 interaction 
with the NMDA receptor (NMDAR).  
Although two different values are obtained, the model fitting does not 
differentiate between the binding sites. Although ITC is a very powerful 
technique, it is often hard to deconvolute the heat signal. Therefore, based on 
this data we cannot make the final determination on the precise mode of PDZ1-2 
binding; this will have to await for more structural information to be obtained.  
In terms of progress on that structural front, we have successfully 
crystallized a new protein construct, PDZ1-2 of PSD-95. Identifying the 
conditions required to grow crystals is a major step toward the goal of solving the 
structure of this tandem domain by X-ray methods. Significant efforts were made 
to solve the structure using the molecular replacement method, but due to 
specific space group that protein crystallizes in, thus far solved models of similar 
proteins could not be implemented. We are confident that producing a seleno-
methionine derivative of PDZ1-2 would gain a diffractable crystal and would 
enable us to eventually solve the structure of the protein. Further on, these 
protein crystals should be co-crystallized with ligands already tested by ITC. 
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These results should be valuble in revealing the mode of protein-protein 
interactions mediated by PSD-95.  
5.2 Protein-Metal Interactions: Frataxin  
Exploring the phenomenon of mutivalency and its possible applications, 
we have looked into the nature of protein-metal interaction on the example of 
frataxin binding to ferrous ion. This project provided valuable knowledge on 
possibilities of ITC when analyzing more complexed interactions beyond 
standard 1:1 host-ligand titration.  
Iron deficiency still represents one of the medical concerns of the modern 
world. It has been speculated that nearly 9 milion people are iron deficient in the 
United States. Iron deficiency is associated with pregnancy problems and 
impaired cognitive development in the newborns. On the other side, excess iron 
(ca. ten times the nutritional need) causes severe mitochondrial dysfunction that 
is associated with several prominent neurodegenerative, hematological and other 
related disorder [222, 264]. Iron dysregulation is proposed to be important in the 
pathophysiology of human brain diseases during Parkinson’s, FRDA, and 
Alzheimer’s [222]. Another iron overload disorder, hemochromatosis leads to 
severe health consequences characterized by diabetes, cirrhosis of the liver and 
bronze pigmentation of the skin [222]. Therefore, a deeper understanding of iron 
metabolism and characterization of proteins involved in iron homeostasis is 
essential to tackle these diseases.  
It has been proposed that the cellular iron metabolism can be divided into 
three sequential steps. First is the synthesis of proteins that are modulated by 
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iron levels in the cell. Second is the regulation of the activities of the proteins that 
transport iron in and out of the cell, store cytoplasmic iron and direct iron to 
various cellular compartments. Third is the compartmental trafficking of soluble 
ionic iron for activation of essential cofactors. The protein that is the center of our 
research efforts is implicated in the third biochemical activity.  
Frataxin is a nuclear encoded protein targeted to the mitochondrial matrix. 
This protein is essential for the effective regulation of cellular iron homeostasis. 
Inability to produce frataxin leads to mitochondrial iron accumulation and loss of 
cell viability. This results in a severe neurodegenerative disease, Friedreich’s 
ataxia, that affects 1 in 50, 000 humans. Frataxin is essential for the cellular iron 
control and is believed to serve as an iron chaperone that delivers mitochondrial 
Fe(II) to the enzymes ferrochelatase and the ISU apparatus for completion of 
heme and Fe-S cluster biosynthesis.  
ITC measurements were performed to measure the metal binding affinity 
and maximum metal to protein stoichiometry of monomeric yeast frataxin. The 
micromolar dissociation constants measured for yeast frataxin, with respect to 
ferrous iron (Kd's of 2.0 and 3.0 µM) were obtained from ITC titrations. The weak 
interaction is consistent with the hypothesis of frataxin acting as an iron 
chaperone. Frataxin must be able to form a favorable interface with its protein 
partners and also easily release the metal. Additional structural characterization 
will be critical to help elucidate how frataxin binds iron and docks with its protein 
partners to promote metal delivery. 
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Frataxin has been suggested to play a variety of roles in helping to 
maintain cellular iron homeostasis, most of which involve direct binding to iron. 
Frataxin facilitates in vivo heme and Fe-S cluster production and the monomeric 
protein binds to enzyme partners that complete the assembly of these iron-
containing cofactors, suggesting monomeric protein may play a direct role in both 
processes by acting as the iron chaperone [238]. Fluctuations in mitochondrial 
iron or Fe-cofactor levels, and the differences in binding affinities between 
partners, have been proposed to serve as the trigger for which cofactor assembly 
system is delivered iron [231]. 
Metal binding site(s) on monomeric frataxin must accommodate the 
binding of multiple iron atoms. Additional structural characterization will be critical 
to help elucidate how frataxin binds iron and docks with its protein partners to 
promote metal delivery. 
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APPENDIX A 
SINGLE AND THREE LETTER CODES FOR AMINO ACIDS 
                                                     Codes 
Amino acids                           Single letter         Three letter 
Alanine     A      Ala 
Arginine      R      Arg 
Asparagine      N      Asn 
Aspartic acid     D      Asp 
Cysteine      C      Cys 
Glutamic acid     E      Glu 
Glutamine      Q      Gln 
Glycine      G      Gly 
Histidine      H      His 
Isoleucine      I      Ile 
Leucine     L      Leu 
Lysine      K      Lys 
Methionine      M      Met 
Phenylalanine     F      Phe 
Proline      P      Pro 
Serine      S      Ser 
Threonine      T      Thr 
Tryptophan     W      Trp 
Tyrosine      Y      Tyr 
Valine      V      Val 
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APPENDIX B 
GENERAL CHARACTERISTICS OF PDZ1-2 DUAL DOMAIN OF PSD-95 
 
PDZ1-2 sequence 
GSEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRV
NDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKG
PKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGL
EDVMHEDAVAALKNTYDVVYLKVAKPSNA 
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Protein-mediated interactions that involve multiple ligands in their binding 
mechanisms are critical for many cellular functions. The primary focus of this 
dissertation research was to investigate such interactions for two proteins, the 
PDZ domain and frataxin, involving peptide and metal binding ligands, 
respectively. The three component projects of this work comprised (1) 
thermodynamic analysis of PDZ domain binding using calorimetry; (2) X-ray 
crystallographic structural studies of a PDZ dual domain; and (3) thermodynamic 
analysis of frataxin binding to iron. The specific goal of the research conducted 
with the PDZ domains was to understand the mechanism of action of 
multiple/tandem protein domains. The protein chosen for study was the dual 
domain PDZ1-2 of postsynaptic density-95 kDa (PSD-95) protein, a mammalian 
neuronal protein. The individual constructs, PDZ1 and PDZ2, were also prepared 
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for comparative studies. Challenging the individual PDZ1 and PDZ2 and dual 
domains with short peptides derived form the C-terminal region of the domains’ 
natural binding partners (8-mer to 6-mer) sequences, it was found that only one 
of the domains remains functional when expressed separately. Binding of PDZ1 
and tandem PDZ1-2 could be characterized, whereas PDZ2 could not be 
stabilized under solution conditions to yield a valid binding curve. The use of 
bivalent peptides that would bind with 1:1 stoichiometry to the tandem PDZ1-2 
domain was problematic due to ligand insolubility. In an ongoing effort to develop 
new cellular probes for in vivo investigation of multiprotein assembly, we studied 
modified ligand CN2180 which targets the tandem PDZ1-2 of PSD-95. Our in 
vitro testing by ITC of the same peptide after integrating the binding isoterm, 
yielded a stoichiometry of n=2, indicating that both binding sites are fully 
occupied, and dissociation constants for each of the two interaction sites were in 
the single digit micromolar range. 
In terms of progress on that structural front, the dual PDZ domain protein 
construct PDZ1-2 of PSD-95 was successfully crystallized. Identifying the 
conditions required to grow crystals is a major step toward the goal of solving the 
structure of this tandem domain by X-ray methods. Optimization of the 
purification protocol resulted in high purity protein that allowed for increased 
volume of protein crystallization attempts. The optimized conditions yielded well-
shaped hexagonal crystals for PDZ1-2, which crystallizes in cubic P23 group. 
Data reduction resulted in a Rmerge value of 11.2 %. A final structure could not be 
200 
 
solved by molecular replacement methods, and additional work will be needed to 
accomplish this. 
In the last project, calorimetry was employed to investigate the binding of 
frataxin to iron ions. This protein is essential for the effective regulation of cellular 
iron homeostasis. Frataxin, is essential for cellular iron control and is believed to 
serve as an iron chaperone that delivers mitochondrial Fe(II) to the enzymes 
ferrochelatase and the ISU apparatus for completion of heme and Fe-S cluster 
biosynthesis. Monomeric frataxin protein has a high affinity for ferrous ion, 
completely saturating at 2:1 iron to protein ratio. The micromolar dissociation 
constants measured for yeast frataxin, with respect to ferrous iron (Kd's of 2.0 
and 3.0 µM) were obtained from calorimetric titrations. The weak interaction is 
consistent with the hypothesis of frataxin acting as an iron chaperone. Frataxin 
must be able to form a favorable interface with its protein partners and also easily 
release the metal. Although this thermodynamic binding study increases 
understanding of the underlying metal-binding behavior, additional structural 
characterization will be critical to help elucidate how frataxin binds iron and docks 
with its protein partners to promote metal delivery. 
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